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Scope and Outline of the Investigations
1. General objective
The objective of the research described in this thesis was to explore rotenone as a
toxin for inducing Parkinson's disease in rats as a new rat model of this disease,
and to use this rat model in pharmacokinetic(-pharmacodynamic) (PK-PD)
studies on antiparkinson drugs with special reference to blood-brain barrier (BBB)
functionality. 
2. Scope and outline
Parkinson's disease is a progressive neurodegenerative disease, characterised by
the loss of dopamine producing neurons in the striatum and substantia nigra pars
compacta (SNc). Dopamine controls a variety of functions including locomotor
activity, cognition, emotion, positive reinforcement, food intake, and endocrine
regulation. Pathological conditions such as Parkinson's disease are linked to a
dysregulation of dopaminergic transmission (Missale et al., 1998), resulting in
clinical symptoms like bradykinesia, resting tremors, rigidity and postural
instabilities (Thomas and Beal, 2007). Dopamine is formed from L-3,4-
dihydroxyphenylalanine (L-DOPA) and the treatment of Parkinson's disease
consists mainly of symptomatic treatment by replacing the lost dopamine with 
L-DOPA. L-DOPA is given  in combination with a peripheral aromatic amino acid
decarboxylase (AAADC) inhibitor, while at later stages other drugs (such as direct
dopamine receptor agonists, monoamine-oxidase (MAO) inhibitors, catechol-O-
methyltransferase (COMT) inhibitors) may be added. Unfortunately, treatment of
Parkinson's disease is not without complications as typically the effect of
symptomatic drug treatment wears off with progression of the disease and motor
complications arise. At present it is poorly understood which mechanisms
contribute to the loss of efficacy. Moreover there is an increasing interest in the
development of treatments aimed at impairing disease progression. An important
aspect in research on drug treatment of Parkinson's disease is its multifactorial
nature. For example there may be changes in the brain distribution of drugs, the
disposition of endogenous neurotransmitters, the expression and functionality of
receptors etc. This underscores the importance of a system's approach towards the
development of novel drug treatment paradigms. The investigations in this thesis




Overview of the pathophysiology of Parkinson's disease and the current
treatment modalities, emphasis on changes in the functionality of the BBB
In Chapter 2, a summary of Parkinson's disease characteristics, diagnosis and
etiopathogenesis is given. In Parkinson's disease, the functional imbalance in
dopaminergic transmission is thought to be responsible for the bradykinesia,
which may be temporarily normalised by dopamine replacement therapy. In the
treatment of Parkinson's disease, L-DOPA in combination with a peripheral
AAADC inhibitor like Carbidopa or Benserazide, is the golden standard. In a later
stage of the disease, L-DOPA is often administered in combination with a
dopamine agonist, a COMT inhibitor, or a MAO-B inhibitor to overcome any
motor complications associated with long-term L-DOPA treatment. However, the
further the progression of Parkinson's disease, the more effective drug treatment
fails and more complications occur.
In order to be able to answer the questions on the reasons behind this reduction
in effectiveness, one should consider the mechanisms that may affect the target
site distribution of the CNS drug and ultimately the drug response (e.g. plasma
protein binding, BBB transport, within brain distribution, target interaction). To
improve drug treatment (and drug development), detailed information on the
interrelationship between disease, pharmacokinetics and drug response is needed
as all individual mechanisms may vary among different physiological,
pathological, and chronic drug treatment conditions, and therewith their relative
importance in relation to the effect. Chapter 2 presents an overview of the
mechanisms involved in drug response and the factors which influence these
mechanisms. Special emphasis is on the contribution of the BBB on the drug
response, specifically under diseased conditions like Parkinson's disease. BBB
transport of a particular CNS drug into and out of the brain is the sum of all actual
BBB transport mechanisms applicable to that particular drug. Therefore, any
changes in BBB transport mechanisms may affect actual BBB transport and
therewith the effects of the drug. This may also apply for the drugs used in
treatment of Parkinson's disease, like L-DOPA as well as the co-administered
AAADC inhibitors. This may contribute to the motor complications that develop
after long-term treatment with L-DOPA in the more advanced stages of the
disease. This implies the need for  research on the role  of the BBB in the dose-
response relationships of the Parkinson's disease related drugs along with the
stage of the disease.  
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Overview of experimental animal models of Parkinson's disease
In Chapter 3, an overview of the most commonly used animal models in
Parkinson's disease research together with their main disease characteristics is
presented. Further information is provided on in vivo techniques to assess target
site distribution as well as on behavioural tests for pharmacodynamic
information. 
As Parkinson's disease is composed of many components -each caused by the
interplay of a number of genetic and nongenetic causes- a systems pharmacology
approach to the improvement of present drug treatments and the development of
novel drug treatments of Parkinson's disease is warranted. Animal-based models
combined with integrated research approaches that address the individual
mechanisms involved, including their time-dependencies, are needed to fully
understand these aspects.
The currently applied animal models for Parkinson's disease are presented as
toxin-induced and genetic animal models. The behavioural tests that can be used
in animal models include drug-induced rotometry, the staircase- and the rotorod
test, among others. Further emphasis has been put on in vivo techniques to assess
the BBB functionality on drug transport into and out of the brain, and the
distribution of drugs to the target site. To that end, intracerebral microdialysis is
very useful as it is able to measure kinetics of exogenous compounds. Moreover,
it also offers the possibility of monitoring endogenous compounds such as
neurotransmitters (e.g. dopamine) and its metabolites and any changes in their
kinetics as a consequence of disease and/or treatment. 
Taken together, information obtained experimentally by applying animal models
of Parkinson's disease in combination with intracerebral microdialysis and
behavioural testing can be used for the development of advanced mechanism-
based PK-PD models.
Experimental research on the 'rotenone model' of Parkinson's disease
Chapter 4 deals with experimental research on the 'rotenone model' of
Parkinson's disease. The aim was to find a suitable and applicable animal model
for Parkinson's disease resembling the characteristics of the disease, specifically
displaying slow and selective lesioning of dopaminergic neurons over time in
addition to the presence of Lewy Bodies (LB) in the remaining neurons and
detectable motor deficits. To that end, the neurotoxin rotenone was used for
inducing Parkinson's disease in rats, and a comparison was made between the
systemic and the intracerebral route of administration. 
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Previously, the administration of low-dose intravenous or subcutaneous rotenone
to rats has been shown to produce a slow, selective degeneration of nigrostriatal
dopaminergic neurons accompanied by α-synuclein-positive LB inclusions as
seen in Parkinson's disease (Betarbet et al., 2000; Sherer et al., 2003). Rotenone's
advantages of being able to create an animal model exhibiting a slow progression
of disease and the formation of LB-like structures outweighed the use of the well-
documented but more acute neurotoxins 6-OHDA and MPTP which did not show
any LB formation. 
Ultimately, for application of an animal model as a tool for the development of
systems PK-PD disease progression models, in which time-dependent changes in
the biological system-specific parameters of diseased animals can be obtained
(Post et al., 2005), induction of a progressive form of the disease is important. 
In the investigations described in Chapter 4 the subcutaneous route of
administration of rotenone was compared with intracerebral administration,
directly into the median forebrain bundle (MFB), on parameters such as
bodyweight and BBB permeability using sodium fluorescein as a marker and
intracerebral microdialysis to quantify flurescein brain distribution. In addition,
behavioural assessments were conducted using the rotorod for the subcutaneous
model and amphetamine-induced rotometry for the intracerebral model. Post-
mortem analysis consisted of assessing nigrostriatal damage based on
immunohistological staining with TH and α-synuclein inclusions and peripheral
organ pathology. 
The results indicated that rotenone infused intracerebrally at the highest dose
tested is able to create a progressive rat model for Parkinson's disease, which
makes this model useful for research on PK-PD relationships at different stages of
Parkinson's disease. The subcutaneous route of administration was found to be of
limited value due to the occurrence of peripheral organ toxicity, which indirectly
influenced the BBB permeability.
Research on the disposition and brain distribution of L-DOPA in the rotenone
model of Parkinson's disease
Chapter 5 describes the research on the disposition and brain distribution of 
L-DOPA in the Rotenone model of Parkinson's disease. 
Parkinson's disease treatment is still mainly focussed on symptomatic treatment
by replacing the striatal dopamine by drugs like L-DOPA (Factor, 2008; Nyholm,
2006; Schapira, 2008). L-DOPA is actively transported across the BBB to the brain
by the LAT-1 transporter and there are a number of indications on changes in BBB
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transport of L-DOPA in animals (Carvey et al., 2005) and in patients (Bartels et al.,
2008). In Chapter 5, we describe the investigation on potential changes in BBB
transport of L-DOPA in conjunction with its brain conversion to the dopamine
metabolites DOPAC and HVA, as a consequence of the disease using the
intracerebral rotenone model as the rat model for Parkinson's disease. At 14 days
after an unilateral injection of rotenone (5 µg) in Lewis rats, intracerebral
microdialysis was used to measure endogenous and exogenous brainECF
concentrations of L-DOPA and brainECF concentrations of DOPAC and HVA
following different dosages of L-DOPA (10, 25 or 50 mg/kg). These
measurements were used for the investigation of the relationship between plasma
and brainECF kinetics of L-DOPA, and the dopamine metabolites DOPAC and
HVA in the untreated as well as in the treated brain side. Post-mortem analysis
using striatal TH staining was used to determine "responders" to rotenone. Non-
linear Mixed Effects Modeling (NONMEM) was used to develop a population
based PK model of L-DOPA and metabolites. The results indicated that the
disease conditions at 2 weeks post-rotenone-injection in the MFB did not result in
any change in the kinetics (including the brain distribution) of L-DOPA. Merely,
a clear effect of disease on the concentrations and elimination rates of DOPAC and
HVA in brain was found, providing indirect information on decreased dopamine
concentrations at the diseased brain side based on "formation-rate limited
elimination" pharmacokinetic principles.
Summary, conclusions and perspectives
Finally, in Chapter 6 the results presented in this thesis are discussed and
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Abstract
Symptomatic treatment of the later stages of Parkinson's disease is far from
optimal, while drugs that halt disease progression are not, yet, available. To
improve drug treatment and drug development, detailed information on the
interrelationship between disease, pharmacokinetics and drug response is
needed. This review aims at the understanding of the mechanisms that govern
drug response in Parkinson's disease. Special emphasis is on the impact of the BBB
on drug response, specifically under diseased conditions like Parkinson's disease. 
It is concluded that systems pharmacology approaches are needed to investigate
and understand the various mechanisms that determine the drug response as well
as their interplay.
1. Introduction
Parkinson's disease is characterised by the loss of dopamine producing neurons in
the striatum and substantia nigra pars compacta (SNc), resulting in clinical
symptoms like bradykinesia, resting tremors, rigidity and postural instabilities
(Thomas and Beal, 2007). Treatment of these symptoms of Parkinson's disease is
still by replacing the lost brain dopamine. L-3,4-dihydroxyphenylalanine 
(L-DOPA) in combination with an aromatic amino acid decarboxylase (AAAD)
inhibitor is currently still the golden standard. At later stages of the disease, when
L-DOPA-related motor complications arise, dopamine agonists may be added to
the treatment (Mercuri and Bernardi, 2005). The future for new drug therapies in
Parkinson's disease is heading towards neuroprotection or neurorescue
(Bonuccelli and Del Dotto, 2006; Chen and Le, 2006; Schapira, 2008b) as L-DOPA
or dopamine agonists merely give relief to symptoms thereby increasing the
quality of life, but are not halting or reversing the progress of Parkinson's disease. 
In most neuropharmacological studies the effects of drugs in the CNS are still
related to the dose (Girgin et al., 2008; Homma et al., 2008; Kinon et al., 2008; LeWitt
et al., 2008; Mischoulon et al., 2008; Stern et al., 2004; Walsh et al., 2008). However,
a dose-effect relationship is not informative as there are many mechanisms (e.g.
plasma protein binding, blood-brain barrier (BBB) transport, within brain
distribution, target interaction) that affect the brain distribution kinetics of the
CNS drug and ultimately the drug response. Differences in factors such as
genetics, species, gender, age, environmental and pathological conditions can
influence these individual mechanisms and should therefore also be taken into
consideration when comparing or making predictions on drug response. This
Chapter 2
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review gives a summary of the mechanisms involved in CNS drug response and
the factors that may influence them and thereby the drug response. Special
emphasis is on the BBB as a keyplayer in CNS drug response, and how the BBB
functionality may change under diseased conditions like Parkinson's disease.
2. Parkinson’s Disease
Disease characteristics
Parkinson's disease is the second most common progressive movement disorder
(Dauer and Przedborski, 2003). The disorder affects several regions of the brain.
One of these areas is the SNc that controls balance and movement. Clinical
manifestations are a result of the loss of 50-80% of neuromelanin containing
dopaminergic neurons in the SNc (and striatum) and include motor impairments
such as resting tremor, bradykinesia, rigidity, gait difficulty and postural
instability as well as non-motor symptoms (Dauer and Przedborski, 2003; Forno,
1996; Thomas and Beal, 2007). Non-motor symptoms include depression,
constipation, pain, genitourinary problems, and sleep disorders and dominate the
clinical picture of advanced Parkinson's disease. They contribute to severe
disability, impaired quality of life, and shortened life expectancy (Chaudhuri et al.,
2006). Residual nigral neurones show characteristic, eosinophilic inclusions called
Lewy Bodies (LB) that are made up of neurofilaments and show ubiquitin
immunoreactivity (McNaught et al., 2001). Other affected brain areas include
regions of the brain that regulate involuntary functions such as blood pressure
and heart activity. A schematic overview of the neuronal interconnections in
Parkinson's disease as compared to the "healthy" situation is depicted in Figure 1.
Dopamine is the predominant catecholamine neurotransmitter in the mammalian
brain, where it controls a variety of functions including locomotor activity,
cognition, emotion, positive reinforcement, food intake, and endocrine regulation.
Pathological conditions such as Parkinson's disease are linked to a dysregulation
of dopaminergic transmission. (Missale et al., 1998). 
Dopamine is the primary endogenous ligand for the G-protein-coupled dopamine
receptors. These dopamine receptors can be divided into D1-like receptors (D1
and D5) and D2-like receptors (D2, D3 and D4). Through their different G-protein
coupling, D1-like and D2-like receptors have opposing effects on adenylyl cyclase
activity and cyclic AMP concentration. All five subtypes of dopamine receptors
are found in the striatum (Smith and Kieval, 2000). The highest expression of both
the D1 and D2 mRNAs are localised to the dorsal and ventral striatum as
measured in normal human post mortem brains. Cortical expression is moderate
Understanding Drug Response in Parkinson's Disease
21
for D1 mRNA and very low for D2 mRNA. The SNc expresses D2 but not D1
mRNA. The D3 receptor has a specific distribution to limbic-related ventral
striatum (Hurd et al., 2001; Smith and Kieval, 2000). Low levels of the D4 receptor
mRNA have been found in the basal ganglia. In contrast, this receptor appears to
be highly expressed in the frontal cortex, amygdala, hippocampus, hypothalamus,
and mesencephalon. The expression of the D5 receptor compared to the D1
receptor as measured in rat brain is very poor. The D5 receptor can be found in
the cerebral cortex, lateral thalamus, diagonal band area, striatum, and, to a lesser
extent, SNc, medial thalamus, and hippocampus (Hurd et al., 2001). 
The degree of forward locomotion is primarily controlled by the ventral striatum
through activation of D1, D2, and D3 receptors. Activation of D2 autoreceptors,
which results in decreased dopamine release, has been shown to decrease
locomotor activity, whereas activation of postsynaptic D2 receptors slightly
increases locomotion. Activation of D1 receptors has little or no effect on
locomotor activity. However, there is synergistic interaction between D1 and D2
receptors in determining forward locomotion so that concomitant stimulation of
D1 receptors is essential for D2 agonists to produce maximal locomotor
stimulation. The D3 receptor, which has been shown to be mainly
postsynaptically located in the nucleus accumbens, seems to play an inhibitory
role on locomotion (Missale et al., 1998). The synergistic interaction between D1
and D2 receptors is due to two main pathways in the nigrostratial tract. Both
pathways receive a glutamatergic corticostriatal input (Gerfen, 2003). One
pathway leads directly from the putamen to the Gpi (Figure 1, left panel). It has
dopamine D1 receptors, co-express the peptides substance-P, and dynorphin and
establish a monosynaptic inhibitory connection with GPi neurons. Neurons in the
indirect pathway express the dopamine D2 receptor, which is coupled to the
inhibitory Gi G-protein, as well as the A2A adenosine receptor, which is coupled
to the stimulatory Golf G-protein. These neurons also co-express enkephalin
(Gerfen, 2003). They project to the GPe which in turn influence the GPi by a
monosynaptic inhibitory connection and indirectly through the GPe-STN-GPi
projection (Obeso et al., 2008). Thus, the direct and indirect pathways have
opposing effects on the output function of the basal ganglia. Dopamine modulates
glutamatergic effects on corticostriatal inputs by exerting a dual effect on striatal
neurons: exciting Dl-receptor-expressing neurons in the direct pathway and




In Parkinson's disease, the direct striatal output tract from the striatum to the SNc
is less active, as a result of decreased dopaminergic inhibitory tone. A study in
MPTP (1-methyl-4-phenyl-1,2,3,6-tertahydropyridine)-lesioned mice also
indicated a hyperactivity of the glutamatergic cortico-striatal pathway as a
consequence of dopaminergic denervation resulting in an increase of striatal
GABA levels (Chassain et al., 2008). This leads to overactivity of the indirect
striatal GABAergic output from the striatum to the GPe (Chassain et al., 2008),
diminishing inhibitory signals from the GPe to the STN and consequently
resulting in excitatory projections to the GPi and SNc (Figure 1). These two basal
ganglia nuclei, in turn, send inhibitory projections to the thalamus. Inhibition of
the thalamus leads to decreased excitatory projections to the motor cortex,
resulting in Parkinsonism (Del Tredici et al., 2002). An increase in striatal
glutamine concentrations was also seen in MPTP-lesioned mice, which might be a
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Figure 1: Schematic overview of the neuronal interconnections involved in Parkinson's disease;
(left) is the case of  normal motor function and (right) is in the case of a dysfunctional motor
control as seen in Parkinson's disease. The solid arrows depict excitatory projections and the dotted
arrows depict inhibitory projections. The thickness of the arrows indicates the degree of activation
of each projection (right). The red boxes and projections are GABAergic, the green boxes and
projections are dopaminergic and the blue boxes and projections are glutamatergic. SNc:
substantia nigra pars compacta; SNr: substantia nigra pars reticulata; VTA: ventral tegmental
area; STN: subthalamic nucleus; GPe:globus pallidus, external segment; GPi: globus pallidus,
internal segment. For the purpose of clarity, the neuroanatomy and interconnections are
incomplete (Obeso et al., 2008; Smith et al., 2000; Smith et al., 2008)
strategy to protect neurons from glutamate excitotoxic injury after striatal
dopamine depletion (Chassain et al., 2008), although these results could not be
confirmed in a study in 6-hydroxydopamine-lesioned (6-OHDA) rats (Kickler et
al., 2009). Excitotoxicity will be discussed in more detail later in this review.
Degeneration of the dopamine input to the striatum results in opposing affects in
the direct and indirect pathways. The resulting functional imbalance is thought to
be responsible for the bradykinesia of Parkinson's disease, which may be
temporarily normalised by dopamine replacement therapy. However, direct
striatal projection neurons become irreversibly supersensitive to D1 dopamine
receptor activation, despite the fact that there is an actual decrease in receptor
number. Recent studies show that this D1-supersensitive response results from a
switch in D1-receptor-mediated regulation of protein kinase systems responsible
for neuronal plasticity and is suggested to underlie dyskinesia produced by 
L DOPA treatment of Parkinson's disease (Gerfen, 2003).
Diagnosis & Biomarkers
Currently, the diagnosis of Parkinson's disease is based on patient history and
physical examination alone as there is no simple and effective biomarker available
(Savitt et al., 2006). Using the current diagnostic criteria, 90% may be the highest
accuracy that can be expected (Hughes et al., 2001). Biomarkers might be used to
assist in the diagnosis of Parkinson's disease. The search for suitable biomarkers
has led to various studies using imaging techniques such as positron emission
tomography (PET) and single photon emission computed tomography (SPECT).
However, such studies provide markers of nerve terminal function rather than
cell density and thus, like clinical assessments, are potentially influenced by
compensatory mechanisms and direct effects of medication (Brooks, 2004). In
post-mortem investigations and in animal research, tyrosine hydroxylase (TH)
immunostaining is used as a golden standard to determine the degree of lesion in
the dopaminergic neurons in striatum or SNc. However, this analysis can only be
performed post-mortem. Availability of relevant biomarkers which could be
measured in vivo, could result in a more detailed and mechanistic description of
Parkinson’s disease progression and serve as useful tools in disease models. 
A combination of biomarkers might be needed to provide a complete
characterisation of treatment effects (beneficial and harmful) or disease
progression (Lesko and Atkinson, Jr., 2001). 
Other biomarkers for Parkinson's disease include clinical tests, blood tests,
cerebrospinal fluid (CSF) tests and genetic tests. An example of a clinical test is the
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pharmacological challenge in which the response to L-DOPA or a dopamine
agonists is examined to differentiate Parkinson's disease from other parkinsonian
syndromes (Dorsey et al., 2006). Blood and CSF tests mainly focus on markers of
oxidative stress such as the mitochondrial complex I level in blood or 8-hydroxy-
2'-deoxy-guanosine, which results from oxidised DNA among others in blood and
CSF (Michell et al., 2004). Alternative blood markers which are potential
biomarkers for Parkinson's disease are platelet α-synuclein, platelet monoamine-
oxidase-B (MAO-B) activity and dopamine transporter density on peripheral
lymphocytes  (Dorsey et al., 2006; Michell et al., 2004). For the purpose of early
clinical evaluation and effective patient management, diagnostic strategies based
on the usual screening panels for nigrostriatal somatomotor symptoms associated
with Parkinson's disease might be supplemented for persons at risk by tests
designed to elicit signs such as symptoms related to dysautonomia, signs
indicating subtle disruptions within the gain setting nuclei of the lower brainstem
or quantifiable deficits in olfactory acuity, differentiation, or memory of
substances smelled (Del Tredici et al., 2002). 
For the majority of the patients with Parkinson's disease, genetic factors do not
clearly play a role, however for individuals with a family history of the disease,
genetic testing can indicate the risk. Genetic testing can also be helpful in
diagnosis as many cases of 'genetic' Parkinson's disease have a different clinical
course than sporadic Parkinson's disease (Dorsey et al., 2006). 
Etiopathogenesis
Parkinson's Diseases often begins after the age of 50 (late onset), but may also
begin before the age of 50 (early onset) or even before the age of 20 (juvenile
onset). Parkinson's disease occurs in 1-2 % of individuals over 50 and in more than
3% of individuals above 75 years of age (Pankratz and Foroud, 2007). The
prevalence of Parkinson's disease is higher in men than women (Van Den Eeden
et al., 2003). Estrogen has an effect on dopamine neurotransmission i.e. inhibition
of dopamine reuptake, effect on dopamine synthesis and release and estrogen has
shown to protect nigrostriatal neurons from toxic influences (Shulman, 2007)
which might explain the gender difference in prevalence. An advancing age is
associated with a faster rate of motor progression, decreased L-DOPA
responsiveness, more severe gait and postural impairment, and more severe
cognitive impairment and the development of dementia in patients with PD
(Levy, 2007). 
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Risk factors
For Parkinson's disease, no single causative factor has been identified. Instead,
various mechanisms- including mitochondrial defects, oxidative stress,
excitotoxicity, genetic factors and apoptosis- seem to play a role. This suggests
that the etiopathogenesis of Parkinson's disease is most likely multi-factorial.
Certain risk and protective factors have been identified for Parkinson's disease.
Smoking and (moderate) consumption of coffee or tea (caffeine intake) have been
associated with a decreased risk for Parkinson's disease (Ascherio et al., 2001;
Hong et al., 2008; Kandinov et al., 2008; Morozova et al., 2008; Saaksjarvi et al.,
2008). Hydroquinone and nicotine, two components of cigarette smoke
apparently inhibit α-synuclein fibrillation and stabilize soluble oligomeric forms
(Hong et al., 2008). Caffeine or its metabolite paraxanthine might be
neuroprotective via antagonist action on the adenosine A2 (A2A) receptor
(Guerreiro et al., 2008). Animal studies suggest that caffeine may protect the BBB
against experimental parkinsonism (Chen et al., 2008). Animal studies (McGeer
and McGeer, 2004b) also suggest that nonsteroidal anti-inflammatory drugs
(NSAIDs) decrease the incidence of Parkinson's  disease, but epidemiologic
studies are inconclusive (Etminan and Suissa, 2006; Hancock et al., 2007; Hernan
et al., 2006; Powers et al., 2008; Ton et al., 2006; Wahner et al., 2007). Furthermore,
rural living, farming, gardening and drinking well water have been identified as
risk factors as these factors can be associated with exposure to pesticides (Chade
et al., 2006; Kamel et al., 2007). 
Toxic substances, in general, can cause neurological damage as was first
demonstrated by MPTP which is associated with parkinsonism in young drug
addicts (Langston et al., 1983). MPTP, which is a pro-toxin, rapidly crosses the BBB
and is converted to 1-methyl-4-phenylpyridinium (MPP+) which is transported
into dopamine neurons where it impairs mitochondrial respiration by inhibiting
complex I of the electron transport chain (Vila and Przedborski, 2003). Pesticides
and metals are also named as neurotoxins involved in Parkinson's disease. Metals
(eg iron and copper) have been investigated as potential risk factors on the basis
of their accumulation in the SNc and their participation in harmful oxidative
reactions such as the production of hydrogen peroxide during the oxidation of
dopamine and the conversion of hydrogen peroxide to hydroxyl radicals which is
catalysed by iron (Di Monte, 2003; Landrigan et al., 2005). Manganese has been
mentioned as potential risk factor (Landrigan et al., 2005), however, it damages the
globus pallidus and not the SNc. There is also an absence of nigral LBs and this is
inconsistant with the neurological symptoms of Parkinson's disease (Perl and
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Olanow, 2007). The widely used pesticide rotenone is, like MPTP, an inhibitor of
complex I and able to induce the major features of Parkinson's disease in rats
(Betarbet et al., 2000; Ravenstijn et al., 2008). Rotenone is able to cross cell
membranes and is therefore likely to affect all cells but mainly targets
dopaminergic neurons probably because dopamine metabolism is responsible for
high basal levels of oxidative stress in the SNc (Giasson and Lee, 2000; Jenner,
2003; Mandemakers et al., 2007). Epidemiological studies have revealed a
relationship between pesticide exposure and a high risk for Parkinson's disease
(Di Monte, 2003). 
Mitochondrial dysfuntion & Oxidative stress
Molecular studies in neurotoxin based and genetic-based animal models suggest
a major etiologic role for mitochondrial dysfunction in the pathogenesis of
Parkinson's disease. Neurons in general appear to be more sensitive than other
cells to mutations in genes, such as Opa1, Mfn1 and Dnm1l encoding
mitochondrial proteins involved in the dynamic morphological alterations and
subcellular trafficking of mitochondria (Mandemakers et al., 2007). Post-mortem
biochemical studies in patients have revealed mitochondrial defect (30-40% in
complex I activity) in specifically the SNc of the brain and in platelets and muscle
(Olanow and Tatton, 1999; Schapira, 2006) and animal studies in mice which have
a knockout of mitochondrial transcription factor A in dopaminergic cells, have
shown Parkinson-like symptoms (Onyango, 2008). Oxidative stress is linked to
mitochondrial dysfunction as well as other components of the degenerative
process such as excitotoxicity and inflammation (Schapira, 2008a). Oxidant stress
and consequent cell death could develop in the SNc under circumstances in which
there is (1) increased dopamine turnover, resulting in excess peroxide formation;
(2) a deficiency in glutathione (GSH), thereby diminishing the brain's capacity to
clear H2O2; or (3) an increase in active iron, which can promote OH. formation
(Olanow and Tatton, 1999). The evidence for oxidative stress in Parkinson's
disease has been summarised elsewhere (Jenner, 1991) and will not be repeated
here. Complex I deficiencies in SNc mitochondria evoke free radical generation,
which, in turn, impairs the function of the respiratory chain. Mitochondrial
abnormalities decrease the activity of the ubiquitin proteasomal system (UPS), a
process that is further exacerbated by the increased substrate load of oxidised
protein from oxidative stress. Abnormalities in protein phosphorylation might
influence the UPS and mitochondrial function. 
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Inflammation
Chronic inflammation may play an important role, if secondary, in the
pathogenesis of Parkinson's disease (Hirsch et al., 2005; McGeer and McGeer,
2004a). The proinflammatory cytokine tumor necrosis factor-α (TNF-α) kills
dopamine neurons in vitro and is elevated in the brains of patients with
Parkinson's disease (Logroscino, 2005). The TNF-308A allele was found
significantly more frequent in early onset patients compared to the controls and
might influence the risk for the development and/or onset of Parkinson's disease
(Bialecka et al., 2008a). Inflammation will enhance free-radical production
including nitric oxide and peroxynitrite. It has recently been proposed that
Parkinson's disease might be an autoimmune disease as a disruption of the BBB,
as explained later, might result in the entry of immune cells leading to a
progressive degenerative process (Monahan et al., 2008).
Excitotoxicity
Free radical species will also be enhanced by excitotoxicty, which leads to nitric-
oxide-mediated damage to the mitochondria (Schapira, 2008a). Excitotoxicity is an
established cause of neurodegeneration that has been implicated in Parkinson's
disease based on two possible mechanisms. The first is direct excitotoxicity
resulting from increased glutamate formation. SNc dopaminergic neurons are rich
in glutamate receptors and receive extensive glutamate innervation from the
subthalamic nucleus (STN; Figure 1). Dopamine lesions disinhibit the STN which
results in an increased firing rate of its output neurons leading to excessive
calcium influx into the cell and nitric oxide (NO) formation (Figure 2). The second
mechanism involves indirect excitotoxicity where a defect in mitochondrial
function results in the loss of the ATP-dependent Mg-blockade of N-methyl-D-
aspartate (NMDA) receptors leading to a calcium influx into the cell under
physiological glutamate levels (Figure 2) (Olanow and Tatton, 1999). NO reacts
with superoxide radical to form peroxynitrite and hydroxyl radical which are
both powerful oxidizing agents (Beckman et al., 1990). Also the mitochondrial
respiratory chain might, in turn, be damaged by sustained exposure to NO
(Bolanos et al., 1996). Next to NO formation, the formation of L-ornithine
decarboxylase (ODC) is increased due to excessive calcium influx. ODC is an
enzyme involved in the synthesis of polyamines (spermidine, spermine and
putrescine) (Williams, 1997). Polyamines may in turn stimulate the NMDA
receptor and result in a 'run-away-process'. Cell death in Parkinson's disease
occurs by way of apoptosis rather than necrosis (Olanow and Tatton, 1999).
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Neuronal apoptosis can be induced by low concentrations of toxins or substances
such as L-DOPA, dopamine, iron, MPTP among others (Tatton et al., 1997).
Genetics
Most cases of Parkinson's disease (>95%) are sporadic, although some genes
(associated with the PARK loci) have been identified and linked to rare forms of
Parkinson's disease. Among them are the SNCA or α-synuclein (PARK1), LRRK2
(PARK8), which result in autosomal dominant Parkinson's disease; PRKN or
Parkin (PARK2), DJ-1 (PARK7), PINK1(PARK6), which result in autosomal
recessive Parkinson's disease (Pankratz and Foroud, 2007); UCHL1 (PARK5),
which has been implicated but not confirmed and a link with the locus PARK3 has
been identified but no gene has been found. So there are only five clearly defined
genetic causes of Parkinson's disease. A more detailed description of the
consequences of these mutations are described elsewhere (Farrer, 2006; Pankratz
and Foroud, 2007; Thomas and Beal, 2007).
3. Current Drug Treatment of Parkinson's Disease
Symptomatic treatments
Treatment of the symptoms of Parkinson's disease is currently by replacing the
lost brain dopamine. Unfortately these therapies only provide temporary relief
from early symptoms and do not halt disease progression. Moreover, pathological
changes outside of the motor system leading to cognitive, autonomic, and
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Figure 2: Mechanisms of excitotoxicity STN: Subthalamic Nucleus; GLU: Glutamate; gly:
glycine; NMDA: N-methyl-D-aspartate
psychiatric symptoms are not sufficiently treated by current therapies (Savitt et al.,
2006). 
The most widely used drug in the treatment of Parkinson's disease is L-DOPA
(Kostrzewa et al., 2005; Mercuri and Bernardi, 2005). L-DOPA is metabolised by
AAAD to dopamine. AAAD is present in low concentrations in most body tissues
and in high concentrations in liver, kidney, intestinal mucosa and plasma
(Leppert et al., 1988). A second but less important biotransformation pathway is
the O-methylation of L-DOPA to 3-O-methyldopa (3-OMD) by COMT (Nutt and
Fellman, 1984). Carbidopa and benserazide are the two most commonly used
decarboxylase inhibitors used in combination with L-DOPA, increasing the
proportion of L-DOPA dose in plasma (increase of Cmax and AUC, decrease of
tmax) in such a manner that a 70 to 80% reduction in total daily dose of L-DOPA
is possible in order to obtain the same clinical benefits (Cedarbaum, 1987). The
rate of gastric emptying is the principle determinant in the disposition of 
L-DOPA. Absorption of L-DOPA in the small intestine occurs by means of an
active, saturable, large neutral amino acid carrier system (Deleu et al., 2002). 
L-DOPA reaches its effect site by crossing the BBB via an active transporter, the
large amino acid transporter (LAT) (del Amo et al., 2008). In brain tissue, L-DOPA
is metabolised for about 69% by AAAD and for about 10% by COMT (Nutt and
Fellman, 1984).
During early Parkinson's disease, the effect of L-DOPA is long lasting and stable.
However, at later stage of the disease and after long-term L-DOPA treatment,
motor complications may develop, starting with "wearing-off" which is the
progressive shortening of the effect of L-DOPA to 4 hours or less after
administration of the dose. In the more advanced stages of the disease, the "on-
off" phenomenon appears, in which the effect of L-DOPA can suddenly and
unpredictably disappear, resulting in a mobile ("on") patient to become immobile
("off") (Nyholm, 2006; Bhidayasiri and Truong, 2008). At the same time, patients
may develop dyskinesias (involuntary movements), which are considered to be
related to large and multiple doses of L-DOPA (Bhidayasiri and Truong, 2008;
Obeso et al., 2004). The underlying pathology of motor complications is believed
to be due to the progressive loss of dopaminergic neurons that results in a
decreased ability to buffer fluctuations in dopamine levels in the brain, coupled
with the short half-life of L-DOPA of approximately 1 hour (Deogaonkar and
Subramanian, 2005; Tse, 2006). Animal studies as well as a few human studies
have revealed that motor complications developed after intermittent
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administration of L-DOPA but did not develop when L-DOPA was given
continuously (Nyholm, 2006; Olanow et al., 2004; Stocchi, 2005). The high degree
of interindividual variability in absorption after oral administration is
significantly reduced when L-DOPA is given intraduodenally or intraperitoneally
(Bredberg et al., 1994). Consequently, to overcome these motor complications, 
L-DOPA can be given with a shorter dosing interval i.e. in a more continuous
manner (Stocchi, 2005), but also by administration of L-DOPA in combination
with a COMT inhibitor or a dopamine agonist. Also, L-DOPA may be
administered together with a MAO-B inhibitor, such as selegiline or rasagiline,
which inhibits dopamine metabolism (Bhidayasiri and Truong, 2008; Factor, 2008;
Nyholm, 2006; Nyholm, 2006; Stacy and Galbreath, 2008). The symptomatic
effects of selegiline were thought not only to relate to MAO inhibition but were
also thought to be associated with an amphetamine effect (enhancing release of
dopamine) as selegiline is metabolised to L-amphetamine via the first pass in the
liver (Factor, 2008).
Concomitant medication with a COMT inhibitor, such as entacapone or tolcapone
increases the amount of L-DOPA available for transport across the BBB as well as
reduces the amount of 3-OMD which is a competitor to L-DOPA in the uptake by
the LAT transporter at the BBB (Wade and Katzman, 1975). Entacapone is a
mainly peripherally acting COMT inhibitor and has a low BBB penetration.
Tolcapone, however, is able to cross the BBB and also act on central COMT
(Ceravolo et al., 2002; Kaakkola and Wurtman, 1992; Napolitano et al., 2003; Russ
et al., 1999), although it has not been investigated whether this further enhances
the efficacy of L-DOPA (Forsberg et al., 2003). Tolcapone increases the AUC and
Cmax of L-DOPA but does not influence its PK-PD relationship, making it a
suitable add-on to L-DOPA therapy (Baas et al., 2001). L-DOPA treatment has
been shown to increase plasma homocysteine levels in Parkinson's disease
patients as it is metabolised via O-methylation by COMT using S-adenosyl-L-
methionine (SAM) as the methyl donor which results in the subsequent formation
of homocysteine (L-DOPA induced hyperhomocysteinaemia). Increased levels of
homocysteine might lead to an increased risk for coronary arterial diseases. Based
on studies using rats and confirmed in human studies, entacapone may reduce 
L-DOPA-induced hyperhomocysteinaemia in patients with Parkinson's disease
(Nissinen et al., 2005; Valkovic et al., 2005) and thereby reducing the risk of
pathologies probably linked to it.
Dopamine agonists, such as ropinerole, apomorphine, bromocriptine, pergolide,
cabergoline, lisuride or pramipexole are less effective than L-DOPA in yielding
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symptomatic relief and almost all patients will require L-DOPA at some point.
Dopamine agonists are drugs acting directly to stimulate dopamine receptors,
classified as D1-like (D1, D5) and D2-like (D2, D3, D4). Postsynaptic D2 receptor
stimulation is closely associated with antiparkinsonian activity and presynaptic
D2 receptor stimulation may have neuroprotective effects. Optimal therapeutic
response is thought to require stimulation of both D1 and D2 receptors (Deleu et
al., 2002). Dopamine agonists have a reduced risk of the development of
dyskinesias which is probably related to the longer t1/2 relative to L-DOPA (Savitt
et al., 2006; Yamamoto and Schapira, 2008). 
Future symptomatic therapies which are currently being investigated for the
treatment of Parkinson's disease include non-dopaminergic agents such as the
adenosine A2A antagonists which are related to caffeine. The A2A receptors are
co localised with D2 receptors on striatal medium spiny GABAergic neurons of
the striatopallidal pathway, and antagonists of A2A receptors have been found to
enhance the effects of dopamine at the D2 receptors on striatopallidal neurons,
thus suppressing inhibitory GABAergic output and improving parkinsonian
symptoms (Petzer et al., 2009). Another way to counter the excessive excitatory
stimulation or to treat the glutamate excitotoxicity, as described earlier, is by
glutamate antagonist drugs such as amantadine and riluzole which are currently
under investigation for the treatment of patients with motor fluctuations and
dyskinesias (Factor, 2008; Wu and Frucht, 2005). Finally, noradrenergic drugs are
being examined, because this neurotransmitter appears to influence motor and
affective symptoms.
Neuroprotective treatments
The most important goal for drug development in Parkinson's disease is
neuroprotection or neurorescue (Bonuccelli and Del Dotto, 2006; Chen and Le,
2006; Schapira, 2008b). Some of the drugs already in use as treatment in
Parkinson's disease or currently under investigation seem to possess
neuroprotective properties 
Dopamine agonists such as bromocriptine, pergolide, ropinirole and pramipexole
have been shown to act as free radical scavengers against hydroxyl radicals, NO
radicals and to have antioxidant effect (Deleu et al., 2002). Pramipexole has been
shown to reduce nigrostriatal cell death in MPTP-treated non-human primates
(Iravani et al., 2006). Furthermore, MAO-B inhibitors (selegiline, rasagiline) may
also possess neuroprotective properties in part by reducing the damaging effect of
dopamine turnover in the brain. These effects of MAO-B inhibitors are especially
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relevant when considering that the brain shows an age-related increase in 
MAO-B activity (Petzer et al., 2009). Next, as mentioned previously, caffeine
consumption has been associated with a decreased risk for Parkinson's disease
and it has been thought that it might be neuroprotective via antagonist action on
the A2A receptor (Guerreiro et al., 2008). This is further substantiated in a study in
which caffeine was able to protect MPTP-induced BBB dysfunction in mice (Chen
et al., 2008). Another study revealed that caffeine and other A2A-antagonists were
able to attenuate MPTP-induced loss of striatal dopamine and dopamine
transporter binding sites in mice (Chen et al., 2001). 
Coenzyme Q10 is able to enhance mitochondrial function, increasing ATP
production, and also functions as an antioxidant. A study in patients with early
Parkinson's disease demonstrated that high doses of coenzyme Q10 were
associated with a reduced rate of deterioration in motor function (Bonuccelli and
Del Dotto, 2006). Diet supplement of creatine not only enhances mitochondrial
function but also reduces oxidative stress through stabilisation of mitochondrial
creatine kinase. Moreover, creatine supplementation may exert an anti-apoptotic
effect because creatine kinase acts to inhibit opening of the mitochondrial
transition pore and the consequent triggering of apoptosis. A few experimental
studies suggest a neuroprotective role of dietary intake of creatine in Parkinson's
disease models (Matthews et al., 1999). In the MPTP model of Parkinson's disease,
amantadine, a NMDA receptor antagonist, showed partial protection suggesting
beneficial effects not only on the clinical features but also on disease progression
(Rojas et al., 1992). Memantine is another aminoadamantane derivative with weak
NMDA receptor antagonistic properties. Preclinical data suggest that the
potential neuroprotective effect of memantine might be mediated by the increase
of endogenous production of brain cell-derived neurotropic factor (BDNF) in the
brain (Bonuccelli and Del Dotto, 2006). Minocycline is an antimicrobial
tetracycline compound which has shown in the MPTP and 6-OHDA rodent
models of Parkinson's disease an enhanced survival of dopaminergic nigral
neurons (McGeer and McGeer, 2007). This drug may act by inhibiting microglial
activation. Other experimental data suggest that minocycline is able to block
caspase 1 and 3 and to counteract apoptosis (Bonuccelli and Del Dotto, 2006). As
mentioned above, animal studies (McGeer and McGeer, 2004b) suggest that
NSAIDs decrease the incidence of Parkinson disease which gives it potential
neuroprotective relevance. A more detailed understanding of neuroinflammatory
mechanisms in Parkinson's disease will lead to new cellular and molecular
targets. Future treatment may involve combination therapies with drugs directed
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at both inflammatory and non-inflammatory mechanisms (Klegeris et al., 2007).
In general, for major progress to be made in the treatment of Parkinson's disease,
we need a paradigm shift away from focus on dopamine and dopaminergic
neurons. With current medications and surgical options designed to restore brain
dopaminergic function, we are close to going about as far as we can with this
avenue of treatment and investigation. It has become increasingly clear that clues
to the etiology of Parkinson's disease will not be found via studies of dopamine
metabolism, and major treatment advances lie beyond the dopaminergic
nigrostriatal system (Ahlskog, 2007). Understanding why and how susceptible
cells in motor and non-motor regions of the brain die in Parkinson's disease is the
first step toward preventing this cell death and curing or slowing the disease
(Savitt et al., 2006).
4. Mechanisms Involved in Target Site Distribution of CNS Drugs
In most neuropharmacological studies the effect of drugs in the CNS are still
related to the dose (Girgin et al., 2008; Homma et al., 2008; Kinon et al., 2008; LeWitt
et al., 2008; Mischoulon et al., 2008; Stern et al., 2004; Walsh et al., 2008). However,
a  single unique dose-CNS response relationship does not exist. CNS target site
distribution kinetics is determined by many mechanisms such as plasma protein
binding, BBB transport and within brain distribution. The ultimate kinetics of the
drug at the target will, combined with target interaction and signal transduction,
account for the CNS drug response profile. Here we discuss the main mechanisms
that play a role in target site distribution of CNS drugs, together with some
examples of conditions that influence the particular mechanism. 
Plasma protein binding
After administration, drugs will enter the plasma compartment and may circulate
either in the free form or associated with one or more binding sites, such as on
plasma proteins. Plasma has two major proteins: albumin and α1-acid
glycoprotein, with different capacities and characteristics for drug binding
(Kremer et al., 1988), and other plasma constituent like lipoproteins, erythrocytes
and α-, β-, γ-globulins (Wright et al., 1996). Albumin is the most important drug-
binding protein due to its high concentration in plasma. Albumin has several
high- and low-affinity binding sites and is mainly involved in the binding of
acidic drugs (Day and Myszka, 2003; Murai-Kushiya et al., 1993; Notarianni, 1990;
Piafsky, 1980). In contrast α1-acid glycoprotein is mainly involved in the binding
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of neutral and basic drugs (Kopecky, Jr. et al., 2003; Kremer et al., 1988). Especially
α1-acid glycoprotein is of interest as its levels are susceptible to changes. 
It is well-known that the extent and strength to which drugs are bound to plasma
components is important for the distribution of the drug over the body
compartments (Rowland and Tozer, 1995) and will determine the time-dependent
fraction of a drug that is available for transport into the brain (Fenstermacher et
al., 1995; Filippi and Rovaris, 2000). It has been suggested that only the free
(unbound, dissociated) drug in plasma (Robinson and Rapoport, 1986; Rowley et
al., 1997) is available for transport across the blood to brain barriers and
determines the intensity of the response for drugs such as benzodiazepines,
opiates and steroids (Cox et al., 1998; Kim et al., 1997; Mandema and Danhof, 1992;
Visser et al., 2003a). However, some plasma protein bound drugs seem to cross the
BBB (Cornford et al., 1992; Jolliet et al., 1997; Lin et al., 1987; Lolin et al., 1994; Urien
et al., 1987). For propanolol (Pardridge et al., 1983; Pardridge, 1988b) it has been
reported that the total rather than the free concentration determines the response,
indicating that the bound drug is available for transport into the brain.
Furthermore, it has been shown that drugs which bind fairly selectively to one of
the main binding sites of albumin, Sudlow II (e.g., benzodiazepines and
tryptophan) showed enhanced dissociation and a greater uptake into the brain
than could be accounted for by the Kety-Crone-Renkin equation which is
commonly used to analyse capillary transport (Fenerty and Lindup, 1989; Jones et
al., 1988; Lin and Lin, 1990; Tanaka and Mizojiri, 1999). However, other studies
indicated no enhanced dissociation for drugs  bound to Sudlow I (warfarin) or
Sudlow II (ibuprofen) or both (tolbutamide and valproate) as measured in human,
bovine and rat (Mandula et al., 2006).  
Although albumin levels are generally decreased in the elderly, changes in plasma
protein binding in the elderly are generally not attributed to age, but rather to
physiological and pathophysiological changes or disease states that may occur
more frequently in the elderly and which most often  affect the binding affinity
(Grandison and Boudinot, 2000). Furthermore, pathological conditions may alter
the plasma protein concentrations, thereby affecting the binding capacity. The α1-
acid glycoprotein is a major acute phase protein of which the concentration may
rise in response to systemic tissue injury, inflammation or infection (Fournier et
al., 2000). Surgical procedures such as instrumenting rats with permanent blood
cannulas will increase serum α1-acid glycoprotein levels and binding (van Steeg
et al., 2007). Also, genetic variation can influence plasma protein concentrations,
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as shown in a study on differences in the pharmacokinetics of indinavir and
lopinavir for the various phenotypes of the α1-acid glycoprotein (Colombo et al.,
2006). The impact of genetic variation, age and (patho)-physiological changes on
drug response will be discussed elsewhere in this paper. 
Cerebral blood flow
The cerebral blood flow determines the maximal rate at which the drug can be
delivered to the brain, if not restricted by the transport across the blood brain
barriers itself. In flow-limited transport conditions, alteration in blood flow thus
has an impact on drug delivery to the brain. Alteration in cerebral blood flow may
be the result of changes in two parameters: 1) changes in the linear velocity of
blood flow through the perfused capillaries and 2) variations in the total number
of the perfused capillaries in the brain ("effective perfusion") (Fenstermacher et al.,
1995). When the linear velocity of blood flow is increased, the diffusional influxes
of highly permeable drugs across the BBB will increase (and vice versa), while
BBB transport of slightly or virtually impermeable drugs will essentially be
unchanged. Increase in linear velocity of blood flow may result from situations
like hypercapnia, hypoxia, or may be induced by drugs such as nicotine. Also a
decrease in local cerebral blood flow may be drug induced as has been reported
for pentobarbital. Changes in the number of effectively perfused brain capillaries
will change the surface accesible for transport across BBB, and therefore
potentially affect blood-brain transport of all drugs. A small increase in the
number of perfused capillaries has been reported for hypercapnia and upon
administration of nicotine (Fenstermacher et al., 1995).
The blood-brain barrier (BBB) and blood-CSF-barrier (BCSFB)
The brain is separated from direct contact with blood by two barriers. The first
and largest barrier is the BBB. The BBB is mainly formed by brain capillary
endothelial cells (BCEC) which distinguish themselves from peripheral
endothelial cells by the presence of tight junctions, the lack of fenestrations, an
increased mitochondrial content and a very low pinocytotic activity (Hawkins
and Davis, 2005). Tight junctions prevent the transport of large hydrophylic
compounds between blood and brain (Brightman and Reese, 1969; Huber et al.,
2001). The BBB is a highly dynamic barrier with its functionality being regulated
by surrounding astrocytes, neurons, perivascular microglial cells and
microvascular pericytes (Abbott, 2002; Bodor and Brewster, 1982; Cornford, 1985;
Davson and Oldendorf, 1967; Hawkins and Davis, 2005; Hori et al., 2004; Kim et
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al., 2006; Pardridge, 1988b; Rubin and Staddon, 1999; Vorbrodt, 1988). The
morphology of the BBB restricts free flow of compounds between blood and the
brain making diffusion difficult for the required nutrients such as oxygen and
glucose and other essential substrates to penetrate into the brain. However, a
number of mechanisms and highly selective transporters on the membranes of the
BCEC are involved in the influx and efflux of the required substances (Abbott and
Romero, 1996; Kusuhara and Sugiyama, 2005; Ohtsuki, 2004; Tsuji, 2005). A
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schematic overview of these transport mechanisms is depicted in Figure 3. 
The second barrier is the BCSFB, which is a composite barrier made up of the
choroid plexus epithelial cells, the arachnoid membrane and the
circumventricular organs (such as the area postrema, median eminence,
neurohypophysis and pinal gland) (de Lange, 2004). The choroid plexus is a leaf
like structure that more or less floats in the brain ventricles. The BCSFB has
fenestrated and, therefore, highly permeable capillaries. The barrier function of
the BCSFB is provided by the tight junctions between the cells of the ependymal
layer at the apical site, which contacts the CSF. These tight junctions are slightly
more permeable than those of the BBB (Cserr, 1971; Meller, 1985; Milhorat, 1976;
Figure 3: Schematic overview of the influx (left side) and efflux (right side) transport mechanisms
at the BBB. The OAT transporters are both inlfux and eflux transporters. This picture is adapted
from Abbott and Romero (1996) and Kushuhara and Sugiyama (2005). AMT=absorptive
mediated trancytosis; RMT=receptor mediated transport; CMT=carrier mediated transport;
OAT= organic anion transporter; OATP= organic anion transporting polypeptide; P-gp=P-
glycoprotein; MRP= multi-drug Resistance Protein; BCRP= Breast Cancer Related Protein.
Spector and Johanson, 1989). It should be noted, however, that in the
circumventricular organs, the function and structure of the capillary endothelium
is different (Gross et al., 1986). In this small portion of the brain, the capillaries are
fenestrated and permeable, for instance to serum proteins, thus in general have
higher blood-to-tissue transport rates.
Passive transport
Solute molecules can cross membranes by the mechanisms of simple diffusion,
either the paracellular or the transcellular route (Figure 3). The rate and extent of
drug transport across the blood to brain barriers (Ghersi-Egea and Strazielle, 2001)
is determined both by blood to brain barrier characteristics as well as by the
physicochemical properties of the drug (Ghersi-Egea and Strazielle, 2001; Greig et
al., 1987; Groothuis and Levy, 1997; Gross et al., 1986; Hammarlund-Udenaes et al.,
1997; Hammarlund-Udenaes, 2000; Hesselink et al., 1999). Passive transport
(diffusion) depends on size, charge at actual pH, and lipid solubility of the drug.
Lipophilic, small, and non-charged drugs diffuse more easily across membrane
(transcellularly) than hydrophilic, large and charged drugs (de Boer et al., 2003).
For drugs that easily cross the BBB, the cerebral blood flow may become the
determinant in (mainly) the rate of transport across the barrier membranes. For
the more hydrophilic drugs, paracellular diffusion becomes more important,
which is restricted by the presence of the narrow tight junctions between the cells
of the BBB and BCSFB. This makes that for paracellular diffusion the size of the
drug relative to that of the space in the tight junctions is important (Groothuis and
Levy, 1997; Levin, 1980; Oldendorf, 1970; Oldendorf, 1974).
Active transport
Transport across the BBB does not only occur on the basis of diffusion only. The
brain endothelial cells and the choroid plexus epithelial cells express numerous
influx and efflux transporters (Angeletti et al., 1997; Bouw et al., 2001b; Collins and
Dedrick, 1983; Cordon-Cardo et al., 1989; de Lange, 2004; Gao and Meier, 2001;
Ghersi-Egea and Strazielle, 2001; Johnson et al., 1993; Jolliet et al., 1997; Loscher
and Potschka, 2005; Nishino et al., 1999; Ogawa et al., 1994; Ooie et al., 1997; Rao et
al., 1999; Schinkel et al., 1994; Wijnholds et al., 2000). Highly selective active
transporters perform the influx of required nutrients and essential substrates and
the efflux of waste and toxic product and can be divided into absorptive-mediated
transcytosis (AMT), receptor-mediated transport (RMT) and carrier-mediated
transport (CMT) (Figure 3). The AMT is based on the principle that polycations
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interact specifically with negatively charged substances in the membrane of the
endothelial cells. AMT mainly accounts for the transport of e.g. catonised
albumins and histones (Alavijeh et al., 2005; Bickel et al., 2001). RMT transport
large molecules like proteins and peptides which are required for metabolism
processes in the brain. There are different types of RMT's at the BBB that have
their own specific ligand such as the insulin receptor, the transferrin receptor or
the leptin receptor. The RMT's transport the ligand into the cytosol through
receptor mediated endocytosis (de Boer and Gaillard, 2007; Jones and Shusta,
2007). CMT's have the function to provide the brain with nutrients such as glucose
(mainly by the GLUT-1 transporter (Pardridge et al., 1990)), amino acids (e.g.
Large Neutral Amino Acid -LNAA or LAT-transporter (Boado et al., 1999)),
purine bases, nucleosides, vitamins, hormones and others (Abbott and Romero,
1996). Other influx transporters include the nucleoside transporter system, the
organic cation transport system (OCT), the organic anion transporter (OAT) and
the organic anion transporting polypeptide (OATP) (Anzai et al., 2006). The latter
two systems (OAT and OATP) also act as efflux transporters. These transport
systems may have a role in drug transport into the brain, although not for all
transporters such a role has been clearly observed. For the LAT transport system,
several amino-acid mimetic drugs like L-DOPA, α-methyl-dopa (Matsuo et al.,
2000; Wade and Katzman, 1975), α-methyl-trypsine, baclofen, gabapentin and
phenylalanine mustard probably are substrates. Melphalan uptake into the brain
is facilitated, by sharing the LAT system at the BBB (Greig et al., 1987). Drugs
bearing a monocarboxylic moiety such as simvastatin, lovastatin acid and
pravastin, cross the BBB via the monocarboxylic acid transport systems (Tsuji,
2005). Pramipexole, a D2 receptor agonist used in the treatment of Parkinson's
disease, is a cationic drug which not only crosses the BBB by diffusion but also via
an (still to be identified) organic cation-sensitive transporter (Okura et al., 2007).
Efflux transport
With regard to active drug transport, more is known about drug transport out of
the brain by efflux transporters (Figure 3). Examples of such transporters are P-
glycoprotein (P-gp or ABCB), the Multi-drug Resistance Protein family (MRP's or
ABCC's (de Lange, 2007)) and the more recently discovered Breast Cancer Related
Protein (BCRP, also known as ABCG2) (Cisternino et al., 2004; Eisenblatter et al.,
2003). P-gp, MRP and BCRP are energy-dependent efflux pumps and belong to
the ATP-binding cassette (ABC) transporter family. 
P-gp is a broad spectrum efflux pump which can recognize and transport basic
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and uncharged substrates in the size of 250Da -1850Da, as well as zwitterionic and
positively charged substrates. It has been shown to be present at the luminal face
(blood side) of the BBB (Cordon-Cardo et al., 1989) and is also expressed at the
choroid plexus (Rao et al., 1999), however at these epithelial cells at the abluminal
face (CSF side) then acting as an influx transporter. Substrates for both P-gp and
MRP1 (see below) actually are cleared from the choroidal epithelial cells and may
therefore protect these cells, thereby contributing to the detoxification of the
choroid plexus itself (de Lange, 2004). P-gp may be inducible (Tatsuta et al., 1994)
and has many structurally diverse substrates (Seelig, 1998). Especially the use of
mdr1a(-/-) mice (Schinkel et al., 1994) has clarified the impact of this efflux
transporter on brain concentrations of many drugs including dexamethasone,
domperidone, indinavir, digoxin, vinblastin, morphine, sparfloxacin,
amitryptiline, and cyclosporin A (de Lange et al., 1998; de Lange et al., 2000;
Desrayaud et al., 1998; Kim et al., 1998; Mayer et al., 1997; Meijer et al., 1998;
Schinkel et al., 1995; Schinkel et al., 1996; Uhr et al., 2000; Xie et al., 1999).
The influence of MRP transporters on BBB and BCSFB transport is dependent on
their localisation at these membranes. Using primary cultured bovine brain
microvessel endothelial cells (BBMEC) as a model for the BBB, Western blot
analysis for MRPs and confocal laser scanning microscopy to determine
membrane localisation of MRPs in BBMEC indicated that MRP1 and MRP5 are
predominantly present at the apical plasma membrane and an almost equal
distribution of MRP4 on the apical and basolateral plasma membrane of BBMEC.
These orientations are different from those observed in polarised epithelial cells
as model of the BCSFB (Zhang et al., 2004). The use of mrp1(-/-) and mdr1ab(-/-)
mice have shown the importance of MRP1 efflux transport at the level of the
BCSFB in lowering the CSF concentrations of etoposide at least in the absence of
P-gp for which it is also a substrate besides for MRP1 (Wijnholds et al., 2000).
BCRP is a half transporter that displays drug resistance. BCRP shows clear
similarity to P-gp in tissue distribution and to which substrates it binds. BCRP can
actively transport a wide range of substrates ranging from chemotherapeutic
agents to organic anion conjugates and also fluorescent compounds such as
rhodamine 123 and Hoechst 33342 as well as chemical toxicants. BCRP is involved
in multi drug resistance in cancer, especially with regard to acute myeloid
leukemia. Also, it plays a role in the survival of stem cells under hypoxic
conditions and might play a role in regulating stem-cell differentiation. BCRP is
highly expressed at the luminal surface of the endothelial cells of human brain
microvessels (de Lange, 2007; Mao and Unadkat, 2005).
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The probenecid (sensitive) transporter is another efflux transporter at the BBB and
BCSFB, involved in elimination of probenecid and a variety of other drugs.
Mainly brain elimination is increased for a number of anti(retro)viral drugs
(Groothuis and Levy, 1997; Takasawa et al., 1997; Wong et al., 1993) while
increased efflux from CSF has been reported for penicilline and to a smaller extent
other ß-lactam antibacterials like ampicilline, cefodizime cefotaxime and
ceftriaxone (Dacey and Sande, 1974; Ogawa et al., 1994; Spector, 1986; Spector,
1990), and methotrexate (Balis et al., 2000). Also, after coadministration of
probenecid, brain ECF concentrations of a few NMDA-receptor antagonists
increased, and a prolongation of their anticonvulsant activity was found
(Hesselink et al., 1999).
As mentioned before, OATP and OAT also belong to the efflux transporters
present at the BBB. However, OATPs and OATs are driven by a drug or ion
gradient and are not energy-consuming. For further information about the active
efflux transporters  please see Anzai et al., 2006; Borst et al., 2000; Dallas et al., 2006;
Ebinger and Uhr, 2006; Kusuhara and Sugiyama, 2005; Loscher and Potschka,
2005; Schinkel, 1999; Sun et al., 2003. The active-efflux transporters are multidrug
resistant and limit the penetration of drugs into the brain and, next to metabolic
degradation  (Lee et al., 2001), this can restrict its effect (Ebinger and Uhr, 2006;
Groenendaal et al., 2007b; Schinkel et al., 1996). Bromocriptine, a D2 agonist used
in the treatment of Parkinson's disease, has shown to be a substrate for P-gp
(Vautier et al., 2006). Changes on drug distribution into the brain for compounds
are expected upon coadministration of other substrates or inhibitors of the same
transporter, i.e. P-gp substrates or P-gp reversal agents or inhibitors (Klopman et
al., 1997; Mayer et al., 1997). Several overviews of drugs which are substrates for
the various efflux transporters have been published, for example by (Loscher and
Potschka, 2005) and by (Anzai et al., 2006).
Within brain distribution
A generalised physiological compartment model (Collins and Dedrick, 1983)
shows the main factors that determine the entry into and distribution of drugs
between brain extracellular fluid (brain ECF), intracellular brain compartments,
ventricular and lumbar CSF. Thus, once within the brain, the kinetics of drug
exchange between brain ECF, brain intracellular space (ICS) and CSF, as well as
elimination by bulk flow/CSF turnover and potential local metabolic enzymes
determine the time course of the concentration in specific parts of the brain
(Mayer et al., 1997)
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ECF-CSF exchange
Diffusion between brain ECF and CSF is governed by the concentration gradient
across the layer of ependymal cells that separates the brain ECF from the CSF (de
Lange and Danhof, 2002; Mayhan, 2001). This layer possesses structural and
enzymatic characteristics necessary for the clearance of a wide variety of
substances in the CSF, thus forming a metabolic barrier at the brain ECF-CSF
interface (Bruni, 1998; Del Bigio, 1995). Apart from that, concentrations in brain
ECF and CSF may influence each other by diffusion (Fenstermacher et al., 1974;
Malhotra et al., 1994). Diffusive transport will be more important in case of larger
concentration gradients. In relative terms, after systemic administration of a drug,
only small concentration gradients occur between brain ECF and CSF when
transcapillary passage is rapid compared with CSF turnover (de Lange and
Danhof, 2002; Meijer et al., 1998), whereas the situation is reversed for drugs with
permeability-limited BBB transport. For these compounds, significant
concentration gradients between brain ECF and CSF exist after systemic
administration (Agon et al., 1991). On the other hand, following administration of
a drug directly into the CSF, rapid BBB passage creates a steep gradient between
brain ECF and CSF, while for low permeability drugs there will be only small
gradients between brain ECF and CSF (Aird, 1984; Blasberg et al., 1975; de Lange
et al., 1994; Patlak and Fenstermacher, 1975). Differences in spatial distribution
due to differences in BBB transport have also been shown following local
administration of drugs in the brain (de Lange et al., 1995). Furthermore, processes
like brain metabolism and effective diffusion through brain tissue will
respectively increase and decrease the concentration gradient between CSF and
brain ECF following direct administration into the CSF. 
Then, bulk flow or convection of brain ECF, potentially by perivascular channels
of flow, into the direction of the CSF is another means by which drugs can be
redistributed within the brain. Finally, CSF does not present one compartment.
Clear differences in pharmacokinetics of drugs may exist at the CSF from lumbar
and ventricle sites (the ones most often used for obtaining CSF), due to diffusion
but also CSF dynamics (Baker et al., 1996; Balis et al., 2000; Blaney et al., 1995;
Freund et al., 2001; Kawakami et al., 1994; Marsala et al., 1995; Morikawa et al.,
1998).
In analogy to the effect of plasma component binding, also binding to brain
constituents may have a huge impact on within brain distribution (Goldbaum and
Smith, 1954; Kalvass et al., 2007; Kurz and Fichtl, 1983). Altogether, the
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relationships of the different clearances of a drug between blood and CNS, and
within the compartments of the CNS will ultimately determine the concentrations
of a drug within a specific part of the CNS. 
ECF-ICF exchange
After passage of the BBB, a drug enters the extracellular space of the brain and
may thereafter distribute into brain cells. In general, this intracellular distribution
is quantitatively more profound for the more lipophilic drugs. Extracellular
concentrations will depend on the relation between BBB- and extra-intracellular
clearances for the unbound drug and the fraction of the drug bound within the
brain cells. 
Drug metabolism
Drug metabolism may occur at the level of extracellular and intracellular sites of
the brain (Kerr et al., 1984), but also at the the BBB and BCSFB (Ghersi-Egea et al.,
1988). Several enzymes that are involved in hepatic drug metabolism have been
found in the small microvessels of the brain and the choroid plexus. Enzymes like
CYP haemoproteins, several CYP-dependent monooxygenases, NADPH-
cytochrome P450 reductase, epoxide hydrolase, and also conjugating enzymes
such as UDP-glucuronosyltransferase and α-class glutathion S-transferase have
been detected in blood vessels of the brain or closely surrounding cell types
obtained from both rat and human brain tissue (Ghersi-Egea et al., 1988; Ghersi-
Egea et al., 1994; Ghersi-Egea and Strazielle, 2001; Johnson et al., 1993). For the
BCSFB very high activities (similar to those in the liver) have been found for UDP-
glucuronosyltransferase and epoxide hydrolase, while also several CYP
isoenzymes are relatively highly expressed in the choroid plexus. Then for both
barriers, α and µ classes of gluthathion S-transferase and glutathion peroxidase in
relatively high values have been found (Ghersi-Egea et al., 1994; Johnson et al.,
1993).  All these enzymes may serve as "enzymatic barriers" to drug influx into the
brain, and even may be inducible (Volk et al., 1991). In how far drug metabolism
at this level will have an impact on drug concentrations in the brain compartments
remains to be elucidated (Kurata et al., 1995).  
Target site distribution
Most drugs exert their effects not within the plasma compartment, but within the
target containing tissue(s). The process of drug distribution to the active site is
reflected by the need of the "link-bridge" in many  PK-PD relationships (Lin, 2006).
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The pharmacological effect profile is determined by the concentration of drug at
the target site or, more precisely, by the time course of target site drug
concentration , (Danhof et al., 2007; Eichler and Muller, 1998). For CNS
compounds, an important question is whether the intra- or extracellular brain
concentrations reflects the target concentration at best. For drugs such as
corticosteroids (Falkenstein et al., 2000), anticancer drugs and anti-HIV drugs
(Fletcher, 1999; Peter and Gambertoglio, 1998), this is probably the intracellular
concentration. However, most CNS active drugs have their target at extracellular
recognition sites (membrane receptors), and for those drugs brain ECF
concentrations may provide the most relevant information. Both BBB transport
kinetics and intracellular distribution determine the concentration and time to
equilibrium between concentrations in plasma and brain ECF (Liu et al., 2005). In
general, active transport out of the brain decreases and brain tissue binding
increases the time to equilibrium in brain ECF. Apart from their role in BBB
transport, active transporters may also play a role in ECF-ICF exchange of drugs
because also at the brain parenchymal cells a number of transporters (P-gp and
MRP) have been localised (Groenendaal, 2007; Lee et al., 2001; Scism et al., 2000).
Target site distribution may represent a rate-limiting step in the onset to the
biological effect. This is reflected in a delay of the pharmacological effect relative
to the drug concentration in plasma, which is often referred to as hysteresis
(Danhof et al., 2007). Intracerebral microdialysis is a useful tool in obtaining
information on the kinetics of target site distribution of CNS compounds (de
Lange et al., 1997; Hammarlund-Udenaes et al., 1997; Hammarlund-Udenaes,
2000; Xie et al., 1999), which has been successfully applied to the characterisation
of target site distribution kinetics especially in a number of investigations of the
PK-PD correlation of morphine (Bouw et al., 2001a; Groenendaal et al., 2007a;
Groenendaal et al., 2008). Such knowledge is important for the progress in the
development of novel mechanism-based target site distribution modeling
concepts (Danhof et al., 2007).
Target interaction
At the target-site in the brain, the relationship between the target site
concentration of a drug and the response profile depends on several factors
related to the drug and the biological system. Differences in such concentration-
response relations are related to differences in receptor interaction kinetics (target
affinity and intrinsic efficacy) but also on the biological system (i.e., the receptor
density and the transducer function, relating receptor activation to
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pharmacological response) (Danhof et al., 2007; Kenakin, 1999). Therefore, the
incorporation of receptor theory in PK-PD modelling for the prediction of in vivo
drug concentration-response relationships is important as it enables a separation
between drug-specific and biological system specific parameters (Van der Graaf
and Danhof, 1997). Much of the conceptual framework regarding how to study
receptor function evolved from the pharmacological investigation of drug action.
A.V. Hill was the first to understand the relationship between drug concentration
and response when he derived the Langmuir binding equation in the course of his
studies on nicotine and curare (Hill, 1909). The occupancy theory evolved from
then onwards and was refined to describe the effects of partial agonists (Ariens,
1954; Stephenson, 1956) and receptor reserve. The development of the occupancy
theory has allowed the formulation of a series of mathematical models that
describe the interaction of agonists and antagonists with their receptors, in terms
of affinity and efficacy (Dougall, 2001). In the classical occupancy receptor theory,
efficacy is a dimensionless proportionality constant denoting the ability of
agonists to produce a pharmacological response. In theoretical terms, it is difficult
to separate affinity and efficacy estimates of agonists for receptors (Kenakin,
1999). The operational model of agonism which describes the relationship
between drug concentration, receptor interaction and response, was proposed by
Black and Leff (Black and Leff, 1983). Concepts from receptor theory have been
applied in the development of a PK-PD modeling strategy that constitutes a
scientific basis for the prediction of in vivo drug concentration-effect relationships,
for example in the PK-PD analysis of neuroactive steroids (Visser et al., 2002),
benzodiazepines (Tuk et al., 1999; Tuk et al., 2002; Visser et al., 2003b), adenosine
A1 receptor agonists (Van der Graaf et al., 1997), 5-HT1A receptor agonists
(Zuideveld et al., 2004), opioids (Groenendaal, 2007; Yassen et al., 2005) and 
β-blockers (van Steeg et al., 2008). The incorporation of receptor theory in PK-PD
modeling has recently been reviewed (Ploeger et al., 2009)
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5. Sources of Variation in Mechanisms Contributing to the
Response Profile
The mechanisms on the causal path between dose and response of CNS drugs, as
described above, can be viewed as being placed in series. Each mechanism may
influence the CNS drug response. Here we will discuss sources of variation  in
individual mechanisms, showing that changed conditions may change the
mechanism(s) which detremine the relationship between dose and response. For
interpretation, comparison and extrapolation of research data, one should be able
to identify the sources of variation in the individual mechanisms.
In most neuropharmacological studies the effect of drugs in the CNS are still
related to the dose (Girgin et al., 2008; Homma et al., 2008; Kinon et al., 2008; LeWitt
et al., 2008; Mischoulon et al., 2008; Stern et al., 2004; Walsh et al., 2008). 
However, a  unique dose-effect relationship it is not generally applicable. This is
because the above-mentioned mechanisms do not contribute equally in different
conditions. The individual mechanisms may differ quantitatively due to
differences in genetics, species, gender, age, environmental and pathological
conditions etc. Thus, knowledge of the variability in these mechanisms under
different circumstances, as well as their interplay is important in making
comparisons between different conditions or for making predictions of drug
response under certain conditions (Figure 4).
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Figure 4: Sources of variation in mechanisms between dose and response.
Species
In drug development many pharmacological and toxicological studies are
performed in small laboratory animals such as mice, rats, rabbits, dogs and
monkeys. Species differences and therefore interspecies scaling is an important
issue for the prediction of pharmacokinetic parameters from these animals to
humans. The onset, intensity and duration of drug response depend on the
absorption, distribution, metabolism and elimination that are inherent to the
biological system (Hurst et al., 2007). In addition to metabolic differences, the
anatomical, physiological, and biochemical differences in the gastrointestinal tract
(i.e. transit time, pH, microbial content, membrane transport) of the human and
common laboratory animals can cause significant variation in drug absorption
from the oral route (Kararli, 1995). 
Serum albumins from mammalian species differ in amino acid sequence and
protein structure. Consistent with this, binding-site affinity and selectivity vary
from species to species as was observed for warfarin in rat, bovine, and human
albumin. Because of these differences, albumins from separate species should not
be considered interchangeable (Mandula et al., 2006).
In general, small animals tend to eliminate drugs more rapidly than human beings
when compared on a weight-normalised basis. There are relatively small
differences in the primary amino acid sequences of the CYP enzymes across
species, although these might have an impact on substrate specificity and catalytic
activity and consequently on drug metabolism across species. Particularly
CYP1A, CYP2C, CYP2D and CYP3A appear to show interspecies difference
(Martignoni et al., 2006).
With regard to the brain, species differences have been shown in brain
microvessel MAO, with rat microvessels having one of the highest MAO activity
among all tissues, whereas MAO activities in brain microvessels from humans,
mice, and guinea pigs were very low (Kalaria and Harik, 1987). Species
differences were also found in the brain and brain-to-plasma concentrations of of
three P-gp substrates using PET technology showing higher brain distribution in
humans, monkeys, and minipigs than in rats and guinea pigs. The species
differences were still present after P-gp inhibition, specifically in rats. Differences
in plasma protein binding or metabolism did not explain the species-related
differences (Syvanen et al., 2009). 
Other physiological parameters, such as body temperature (36°C - 38°C), and
haematocrit (40% - 45%) are relatively conserved among animals and are
independent of animal size (Davies and Morris, 1993).
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Genetics
Genetic variability in drug response occurs as a result of molecular alterations at
the level of drug-metabolising enzymes (pharmacokinetics), drug transport
molecules that mediate drug uptake into and efflux from intra- and or extra-
cellular sites (pharmacokinetics) and drug targets/receptors (pharmacodynamics)
(El Desoky et al., 2006; Ensom et al., 2001). The pharmacokinetic and/or
pharmacodynamic consequences of gene polymorphisms may include increased
risk of toxicity or a change in response (Shah, 2005). 
Metabolising enzymes
The most widely known example in genetic polymorphisms of metabolising
enzymes are in the cytochrome P450 enzymes (CYPs). Specifically CYP2D6,
CYP2C19 and CYP2C9 are of interest as they metabolise a substantial portion of
all the drugs used (Ensom et al., 2001) with CYP2D6 being involved in the
metabolism of more than 30% of CNS drugs such as cholinesterase inhibitors,
antidepressants, neuroleptics, opioids and many others (Cacabelos, 2008a).
CYP2D6 is also the main metabolising enzyme for many antiarrhythmic drugs.
Cardiac patients who were phenotyped as being poor metabolisers for CYP2D6,
have been found at high risk of severe side effects or drug toxicity when using
propafenone or mexiletine (El Desoky et al., 2006). Ultrarapid and extensive
metabolisers for CYP2D6 are at risk of side effects caused by the active metabolite
of the antiarrhythmic drug encainide. Phenytoin, used in the treatment of
epilepsy, undergoes significant metabolism by CYP2C9 and CYP2C19 and is able
to induce intoxication in patients with polymorphisms in these enzymes
(Anderson, 2008b). Although the CYP enzymes are the most widely studied and
best characterised metabolic enzymes, polymorphic variants can also occur in
various dehydrogenases, esterases, NADPH-quinone oxidoreductase UDP-
glucuronyltransferases (UGT), various methyltransferases and sulfotransferases
(Cacabelos, 2008b). Differences in catechol-O-methyltransferase (COMT) activity
(one of the metabolising enzymes for L-DOPA) and genotype may determine
individual variations in the therapeutic response to L-DOPA or Parkinson's
disease susceptibility (Bialecka et al., 2008b).
Transporters
P-gp is a MDR-1 gene product and several polymorphisms have been reported,
some of which might affect P-gp expression and function (Hoffmeyer et al., 2000)
and could lead to elevated drug levels in many tissues (Schinkel et al., 1994). P-gp
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polymorphisms have also been associated with increased risk for Parkinson's
disease (Furuno et al., 2002; Lee et al., 2004). Bartels et al claimed a decreased P-gp
function in patients with Parkinson's disease (Bartels et al., 2008). Differences have
been observed in pharmacokinetic parameters of digoxin between different
genotypes of the MDR-1 gene (Johne et al., 2002; Kurata et al., 2002). Higher
concentrations of rhodamine-123, dexamethasone, digoxin, cyclosporin A,
ondansetron, loperamide and morphine were observed in brain tissue of mdr1a(-
/-) mice compared to wild-type mdr1a(+/+) mice (de Lange et al., 1998; Meijer et
al., 1998; Schinkel et al., 1995; Schinkel et al., 1996) incidating the consequence of
the absence of functional P-gp. 
Targets
Variant alleles are known to occur not only at the genes expressing target
enzymes, channels and receptors but also at the genes responsible for intracellular
signal transduction (Shah, 2005). There is evidence to indicate that the 
β2-adrenergic receptor is polymorphically expressed and that this contributes to
the interindividual variability in response of patients with asthma to certain
drugs. Similar evidence has been found in the promotor region of the serotonin
transporter with a consequence in the response to fluvoxamine (Shah, 2005). In a
study involving twins, about 30% to 35% of variance in heart rate acceleration as
induced by a 30-minute i.v. infusion of nicotine and cotinine was due to genetic
sources (Swan et al., 2007). The presence of APOE-4 allele in patients suffering
from Alzheimer's Disease (AD), differentially affects the quality and extent of
drug responsiveness when these patients were treated with cholinergic enhancers
such as galantamine or with non-cholinergic drugs (Cacabelos, 2008a). 
Gender
In general, females experience more adverse drug reactions (ADR) than males
(Zopf et al., 2008). Hormonal fluctuations in the menstrual cycle or pregnancy are
considered to be the main reason for gender differences in the pharmacokinetics
and pharmacodynamics of drugs. Evidence for physiological variation within the
menstrual cycle is limited. Variations have been observed in the renal,
gastrointestinal and cardiovascular systems as well as in plasma lipids and
haematological and immune function (Kashuba and Nafziger, 1998). Also,
variability during the menstrual cycle has been observed for α1-acid glycoprotein.
The influence of the menstrual cycle on the pharmacokinetics of drugs has been
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shown for e.g. paracetamol (acetaminophen) and ranitidine (Flores et al., 2003;
Gugilla et al., 2002) but was not seen for triazolam or caffeine (Kamimori et al.,
1999; Kamimori et al., 2000).
Non-hormonal or reproductive-related differences between male and female
subjects can be either physiological (body weight, body fat, glomerular filtration,
organ size, gastric motility) or molecular (drug transporters such as the dopamine
transporter (Dluzen and McDermott, 2008) or drug-metabolising enzymes). 
In general, females weigh less than males, so they often receive higher doses
which results in higher drug exposure. In the example of L-DOPA, used in the
treatment of Parkinson's disease, this difference in bodyweight might be the
reason for the difference in the proportion of men and women experiencing
dyskinesias during the course of the disease (Martinelli et al., 2003; Zappia et al.,
2002). Estrogen has been shown to inhibit COMT (Shulman, 2007) which would
explain the higher exposure to L-DOPA in women. Furthermore, females have a
higher percent body fat than males which can affect the volume of distribution of
certain drugs. Differences in the activity of hepatic enzymes (specifically CYP3A4
(Greenblatt and von Moltke, 2008)), drug transporters and renal excretion
between males and females could result in differences in elimination of a drug
(Anderson, 2008a). P-gp has been mentioned as a drug transporter whose activity
might be different in males and females but literature is contradicting on this
point (Schuetz et al., 1995; Wolbold et al., 2003). Differences in response to drugs
between men and women have been seen for various drugs, such as opiates
(Dahan et al., 2008), anti-HIV drugs (Floridia et al., 2008), paroxetine (Gex-Fabry et
al., 2008), midazolam (Sun et al., 2008) and citalopram (Young et al., 2008).
Age
Roughly three age-groups can be distinguished among patients, namely
paediatric, adult and geriatric patients. Both paediatric patients (0-18 years of age)
and geriatric patients (>65 years) are considered special populations in drug
discovery and development. Most drugs are first developed for the adult patient
population (19-65 years) with studies subsequently performed in elderly and
children. This review will not emphasize on drug disposition in the paediatric
population, as this is irrelevant for Parkinson's disease and reviewed elsewhere
(Kearns et al., 2003).
In elderly patients drug response is not only dependent on physiological changes
which are associated with age but the effects of disease and of comedications
should also be taken into consideration. In general, drug absorption from the gut
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is usually not diminished in elderly. However, compounds that cross the
intestinal epithelium by carrier-mediated transport mechanisms might be
absorbed at a lower rate in the elderly as well as for compounds which have been
administered via the dermal, subcutaneous or intramuscular route, due to
reduced tissue blood perfusion (Turnheim, 2003). Skeletal muscle mass and total
body water content declines with age but total body fat increases with age which
might have implications for the volume of distribution of a drug (for hydrophilic
drugs it decreases and for lipophilic drugs it increases) and consequently on the
half-life of a drug (Turnheim, 1998). 
Despite significant research efforts, the effect of age on hepatic drug metabolism
continues to be a controversial issue. Aging was found to be associated with a
reduction in liver weight of about 25% - 35% (Le Couteur and McLean, 1998).
Liver function, as measured via routine tests, however, does not change
significantly with advancing age, although serum albumin can decrease slightly.
Liver blood flow declines by about 40% with aging. Bile flow and bile salt
formation are reduced by about 50% (Fu and Nair, 1998; Herrlinger and Klotz,
2001; Le Couteur and McLean, 1998). At all ages there is a wide genetic variability
in the rates of drug clearance, specifically within the CYPs as described previously
in this review. Interindividual variability in drug clearance accounts for the
problems in detecting any changes due to aging (Zeeh and Platt, 2002) 
The most pronounced pharmacokinetic change in elderly is the reduction in renal
elimination of drugs due to reduced renal function. The glomerular filtration rate
declines by 25% - 50% between the ages of 20 and 90. Because of these changes, an
age-dependent decline of total clearance is to be expected for all drugs that are
predominantly eliminated by the kidneys (Herrlinger and Klotz, 2001). Other
physiological changes with age include altered structure of proteins (Gafni, 1997),
altered pulmonary function, reduced cardiac output, decrease in serum levels of
various hormones and decline in the immune system (Turnheim, 2003). Moreover,
phase-contrast magnetic resonance imaging has shown a significant decrease of
total cerebral blood flow in elderly individuals with a linear correlation with age
(Stoquart-ElSankari et al., 2007). Many studies have demonstrated substantial and
important age-related changes in neurochemistry and neurobiology. Data on the
decreases and alterations in the dopaminergic and serotonin neurotransmitter
pathways have been relatively consistent in both animal and human studies
(Adolfsson et al., 1979; Bucht et al., 1981; Wenk et al., 1989). The numbers of
dopamine D1 and D2 receptors, as well as serotonin 5HT1A and 5HT2A receptors
are reduced in several brain regions with aging. Studies in other receptors show
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that other neuronal systems and receptors are affected by age-related alterations
as well (Schwartz and Abernethy, 2009). The changes in these neurotransmitter
and receptor systems may account for, in addition to changes in drug reaction and
metabolism, alterations in behaviour, cognitive abilities, and mood in the elderly.
Other CNS signaling systems-the GABAergic (i.e., producing γ-aminobutyric
acid) and enkephalin-endorphin system have not been well studied in older
individuals; however, clinical studies of drugs acting on these systems have noted
age-related changes in their pharmacodynamics (Schwartz and Abernethy, 2009). 
Environmental factors
Cigarette smoking and other environmental factors have been shown to influence
the metabolism of some drugs (Vestal and Wood, 1980; Wood et al., 1979).
Cigarette smoking reduces the therapeutic response to certain drugs such as
theophylline through the induction of hepatic cytochrome P450 isoenzymes
(Braganza et al., 2008). Polycyclic aromatic hydrocarbons (PAHs) are some of the
major lung carcinogens found in tobacco smoke. PAHs are potent inducers of the
hepatic CYP1A1, CYP1A2, and, possibly, CYP2E1. Other compounds such as
acetone, pyridine, heavy metals, benzene, carbon monoxide, and nicotine may
also interact with hepatic enzymes but their effects appear to be less significant.
The primary pharmacokinetic interactions with smoking occur with drugs that
are CYP1A2 substrates, such as caffeine, clozapine, fluvoxamine, olanzapine,
tacrine, and theophylline. The primary pharmacodynamics drug interactions with
smoking are hormonal contraceptives and inhaled corticosteroids (Kroon, 2007).
Cigarette smoking can affect the pharmacokinetic and pharmacodynamics
properties of many psychotropic drugs as summarised elsewhere (Desai et al.,
2001).
Pharmacokinetic interactions between food and orally administered drugs
involve (1) before and during gastrointestinal absorption; (2) during distribution;
(3) during metabolism; and (4) during elimination (Singh, 1999). Absorption and
metabolism are the phases where food has most effect and this may have clinical
implications for drugs such as in the treatment of cancer (Singh and Malhotra,
2004). Food can decrease the rate of L-DOPA absorption, but has no effect on the
systemic exposure to L-DOPA and the degree of 3-O-methyldopa formation
(Crevoisier et al., 2003). 
Pathological conditions
Disease is defined as "any deviation from or interruption of the normal structure
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or function of any body part, organ, or system that is manifested by a
characteristic set of symptoms and signs" (The Free Dictionary, 2009). Given this,
alteration(s) at any place in the body as a result of a pathological condition might
influence the pharmacokinetics and/or the pharmacodynamics of a drug. Some
general examples are given below. The distict example of Parkinson's disease is
discussed later in this review.
Obesity is a condition in which excess body fat has accumulated to such an extent
that health may be negatively affected. It is commonly defined as a body mass
index (BMI) of 30 kg/m2 or higher. This distinguishes it from being overweight as
defined by a BMI of 25 kg/m2 or higher. Cardiac performance and adipose tissue
blood flow may be altered in obesity. There is uncertainty about the binding of
drugs to α1-acid glycoprotein in obese patients. Some data suggest that the
activities of hepatic CYPs are altered, but no clear overview of drug hepatic
metabolism in obesity is currently available. Pharmacokinetic studies provide
differing data on renal function in obese patients (Cheymol, 2000).
Alterations of drug transporters, as well as metabolic enzymes, in patients with
chronic renal failure (CRF) can be responsible for reduced drug clearance. CRF not
only alters the renal elimination of drugs. Pharmacokinetic studies conducted in
patients with CRF demonstrate that the nonrenal clearance of multiple drugs is
reduced. CRF affects the metabolism of drugs by inhibiting key enzymatic
systems in the liver, intestine and kidney. The down-regulation of CYPs has been
reported next to a decrease in gene expression. Liver phase II metabolic reactions
are also reduced in CRF. Moreover, intestinal drug disposition is affected in CRF.
Increased bioavailability of several drugs has been reported in CRF, reflecting
decrease in either intestinal first-pass metabolism or extrusion of drugs (mediated
by P-glycoprotein). Decreased activity of P-gp was observed in CRF rats with no
significant change of protein content, suggesting that uremic toxins may suppress
P-gp function. With the development of CRF, the renal secretion of organic ions
mediated by OAT and OCT is decreased. Organic anionic uremic toxins may
directly inhibit the renal excretion of various drugs and endogenous organic acids
by competitively inhibiting OAT. In addition, the expression of OAT1 and OCT2
was reduced in chronic CRF rats (Pichette and Leblond, 2003; Sun et al., 2006).
The capacity of the liver to metabolise drugs depends on hepatic blood flow and
liver enzyme activity, both of which can be affected by liver disease. Liver disease
can modify the kinetics of drugs biotransformed by the liver. Studies on the effects
of liver disease on specific isoenzymes of CYP have shown that some isoforms are
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more susceptible than others to liver disease. In addition, liver failure can
influence the binding of a drug to plasma proteins which in turn could influence
the processes of distribution and elimination. Portal-systemic shunting, which is
common in advanced liver cirrhosis, may substantially decrease the presystemic
elimination (i.e., first-pass effect) of high extraction drugs following their oral
administration, thus leading to a significant increase in the extent of absorption.
Glucuronidation is often considered to be affected to a lesser extent than CYP-
mediated reactions in mild to moderate cirrhosis but can also be substantially
impaired in patients with advanced cirrhosis (Rodighiero, 1999; Verbeeck, 2008).
Other
Circadian rhythms can influence the pharmacokinetics of a drug which has been
shown for over 100 drugs, among them is L-DOPA, for which a higher plasma
clearance and lower area under concentration curve was observed in rats after the
administration in the late evening (Andre et al., 1996). Absorption may be
influenced and most lipophilic drugs seem to be absorbed faster when the drug is
taken in the morning compared with the evening; for water-soluble compounds,
no circadian variation in the absorption of drugs has been found. Concerning
drug distribution, the higher the blood flow fraction an organ receives, the higher
the rate constant for transferring drugs out of the capillaries. This drug
pharmacokinetic phase may be influenced by circadian variations in the protein
binding of acidic and basic drugs. Drug metabolism may be influenced by daily
modifications of blood flow. For drugs with a high extraction ratio, metabolism
depends on hepatic blood flow, while that of drugs with a low extraction ratio
depends on liver enzyme activity. Hepatic blood flow has been shown to be
greatest at 8 am and metabolism seems to be reduced during the night. Finally,
concerning drug elimination, the clearance of 'flow-limited' drugs that present a
high extraction rate is affected by the blood flow delivered to the organ,
independent of the cardiac output fraction supplied (Baraldo, 2008). As the
cardiovascular system is the means of transport, blood flow fraction destined to
each organ determines the relative mass of solute in plasma, which is constantly
in contact with the tissue. Hence, not only the rate but also the extent of drug
transfer would be increased when tissues are irrigated by a higher fraction of
cardiac output. Aging and circadian rhythms present similar cardiac output
distribution patterns when moving from young to aged adult and from nocturnal
to diurnal hours. These two changes lead to an increased blood flow delivery to
the renal region in the elderly and in the morning, but with a decreased cardiac
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output in aged individuals and an increased one during the day. This scenario
allows us to forecast substance concentrations outside the blood vessels, which
are responsible for the extent of drug elimination and the intensity of drug effect
(Fagiolino et al., 2006).
Body position may influence physiological characteristics, such as perfusion,
gastrointestinal function and plasma volume. These characteristics may interact
with key factors determining the pharmacokinetics of drugs. Postures which favor
rapid gastric emptying accelerate the absorption of orally administered drugs.
Consequently, these postures favour a shorter time to reach peak plasma drug
concentration and a higher Cmax and-in the case of transient saturation of first-
pass metabolism-total exposure (area under the concentration-time curve, AUC)
in comparison to recumbent left and supine. For highly protein-bound drugs (e.g.
phenytoin, imipramine), the total plasma concentration has been found to be
approximately 10% higher in standing than lying subjects due to changes in
plasma volume (Queckenberg and Fuhr, 2008).
Research has shown ethnic differences in the clinical presentation, treatment,
clinical response and outcome of mental illnesses. A number of ethnically specific
variations have been found in the genetic and non-genetic mechanisms affecting
pharmacokinetics and dynamics of psychotropic drugs, which might underlie the
differences in drug use and response across ethnicities. Although some of these
ethnic differences could be partially explained by genetic factors, a number of
ethnically based variables like culture, diet and societal attitudes could potentially
have a significant, but as yet unquantified influence as well (Chaudhry et al.,
2008). The pharmacokinetic factors which can be expected to potentially exhibit
racial differences are (1) bioavailability for drugs which undergo gut or hepatic
first-pass metabolism, (2) protein binding, (3) volume of distribution, (4) hepatic
metabolism, and (5) renal tubular secretion. Absorption (unless active), filtration
at the glomerulus, and passive tubular reabsorption would not be expected to
exhibit racial differences (Johnson, 1997). 
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6. The BBB in Neurodegeneration: Implications for PK-PD
Relationships of Antiparkinson Drugs
The BBB is a key role player in the relationship between plasma and brain
pharmacokinetics as the rate of penetration into the brain tissue is limited by the
diffusion of the drug across the BBB. Drug transport to the brain is dependent on
physico-chemical properties of the drug suchs as lipophilicity, ionistation and pH
in relation to membrane properties. The BBB behaves differently from most other
membranes in the body due to the presence of tight junctions and active influx
and efflux transporters in the membrane resulting in an unequal (unbound) drug
concentration on both sides of the BBB at steady state. Other factors may also
contribute to this phenomenon, such as metabolism within the brain, or drug
transport to the CSF via interstitial fluid (ISF) bulk flow (Hammarlund-Udenaes
et al., 2008). In fact, for many drugs (both lipophilic and hydrophilic) unbound
brain concentrations are much lower than the corresponding blood concentrations
(Hammarlund-Udenaes et al., 1997). Hammarlund-Udenaes and collegues
(Hammarlund-Udenaes et al., 1997) have performed simulations using a model
with one body compartment and one brain compartment to describe unbound
brain concentration-time profiles in relation to unbound blood profiles to
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investigate the effect of changes in passive and active transport into and out of the
brain. Figure 5A shows the simulation of passive diffusion across the BBB
(Clin=Clout). Decreasing Clin and Clout, which simulates increasing hydrophilicity
of a drug (or a decrease in BBB permeability), results in a higher tmax and longer
half-life in the brain. Active, saturable transport into the brain and passive
transport out of the brain is depicted in Figure 5B. Clout is fixed in this simulation
and Tm,in/Km,in varies (Tm is the maximal transport rate and Km,in is the blood
concentration at half-maximal transport). A higher Tm results immediately in
higher brain concentrations, whereas a decrease in Km,out compared to blood
concentration results in brain concentrations to remain at a constant level for a
longer period of time. Active, saturable transport out of the brain and passive
transport into the brain is depicted in Figure 5C. Here, Clin = Clout and is fixed
and Km,out in Tm,out/Km,out varies (Km,out is the brain concentration at half-
maximal transport). With decreasing Km,out, the AUCbrain/AUCblood is smaller.
These simulations also give insight into altered brain concentrations of drugs due
to possible disease-induced changes in BBB transport characteristics. 
As already described above, BBB transport is related to BBB functionality and
occurs by passive diffusion as well as by active transport. BBB functionality is
dynamically controlled by blood components and the surrounding brain cells by
direct contact or indirectly by their extracellular products. Thus, BBB functionality
may vary among different physiological, pathological, and chronic drug
treatment conditions. As BBB transport of a particular CNS drug into and out of
the brain is the sum of all actual BBB transport mechanisms applicable to that
particular drug, any changes in BBB transport mechanisms may therefore affect
actual BBB transport as simulated in Figure 5 and therewith the effects of the
drug. This may also apply for neurodegenerative diseases like Parkinson’s
disease. PK-PD relationships of symptomatic drugs such as L-DOPA in patients
with different stages of Parkinson's disease have been described previously (Chan
et al., 2005; Harder and Baas, 1998) and indicate that Parkinson's disease
progression is able to influence the PK of anti-Parkinsonian drugs in plasma. It
has been known for many years that the BBB is less effective during aging. The
transport systems involved in the transport of e.g. choline, glucose, lactate or
peptides across the BBB have shown to be affected by age (Banks and Kastin, 1985;
Mooradian, 1988; Mooradian, 1994). Common age-related changes of the BBB are
reduced thickness of endothelial cells, vacuolar inclusions in pericytes and
decreased release of amino acids in the cerebral parenchyma (Barcia et al., 2004).
It has also long been proposed that neurodegeneration is associated with changes
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in the functional and biochemical integrity of the BBB (Mooradian, 1988;
Pardridge, 1988a). Evidence has been found in the break-down of the BBB in
patients with AD (Algotsson and Winblad, 2007; Bowman et al., 2007; Desai et al.,
2007), more specifically in white matter (Tomimoto et al., 1996) and in biopsy
tissue from AD patients (Claudio, 1996). Moreover, age-related changes in the
morphology of capillaries located in the white matter of dogs are thought to be
associated with BBB dysfunction (Morita et al., 2005) as well as the presence of
micro-angiogenesis in the Parkinson's diseased brain (Barcia et al., 2004). An
increase of vascular endothelial growth factor and increase of blood vessels in the
SNc of Parkinson's disease patients have been observed (Barcia et al., 2005) and
pathological changes in capillary microanatomy in patients with Parkinson's
disease and AD have been shown (Farkas et al., 2000). These studies all suggest
that neovasculation is observed in the (Parkinson's) diseased brain, which could
result in the disruption of the BBB. Monahan and colleagues propose that
Parkinson's disease is, in part, an autoimmune disease as a disrupted BBB could
result in the entry of immune cells leading to a progressive degenerative process
(Monahan et al., 2008).
Several studies have shown that oxidative stress in the SNc is associated with
inflammatory processes such as increase of microglia activation (Hirsch et al.,
2005; McGeer and McGeer, 2004a) and increase levels of pro-inflammatory
cytokines like tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6
(Teismann et al., 2003). In meningitis and sepsis, inflammation can disrupt the
function of the BBB, and this has also been shown in trauma, stroke, multiple
sclerosis and epilepsy (Huber et al., 2001). The activated microglia can stimulate
the release of TNF-alpha, and this pro-inflammatory cytokine can disrupt the
barrier function in vitro and in vivo (Lynch et al., 2004; Mark and Miller, 1999; Tsao
et al., 2001). Carvey et al have suggested that activation of microglia released TNF-
alpha leading to the breakdown of BBB (Carvey et al., 2005). They have
demonstrated the leakage of fluorescein isothiocynate (FITC)-labeled albumin
and horseradish peroxidase in the SNc and striatum of 6-OHDA-lesioned rats and
associated it with dopamine neuron loss, activated microglia, presence of
neovascularisation and the increase entry of small molecules into the brain. Also,
the areas of leakage in the BBB were associated with increased P-gp expression.
At the same time, a reduced P-gp function in patients with Parkinson's disease
was claimed using PET to measure brain uptake of [11C]-verapamil (Bartels et al.,
2008; Kortekaas et al., 2005). However, the elevated uptake of [11C]-verapamil
could also be related to an increase in paracellular transport of the compound
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instead of a reduced P-gp function as Carvey et al demonstrated in the same study
that domperidone, a dopamine antagonist which is normally not transported into
the brain, was able to inhibit dopamine-mediated behaviour in the 6-OHDA
lesioned rats (Carvey et al., 2005). Futhermore, 6-OHDA rat models with L-DOPA
induced dyskinesia have demonstrated that dyskinesias in animals were
associated with increased entry of L-DOPA into the striatum (Carta et al., 2006;
Westin et al., 2006) which was also seen using PET imaging in patients with peak-
dose dyskinesias at 1 hour after L-DOPA administration (Fuente-Fernandez et al.,
2004). The dyskinetic 6-OHDA rats also exhibited a significant increase in total
blood vessel length and a visible extravasation of serum albumin in the SNc
(Westin et al., 2006), indicating a role for the BBB in the altered transport of L-
DOPA to the brain. 
7. Summary and Concluding Remarks
Parkinson's disease is a progressive neurodegerative disease that lacks good
treatment especially at later stages. Apart from plasma pharmacokinetics,
mechanisms that govern CNS drug distribution and response include the rate and
extent of BBB transport and the kinetics of distribution within the brain including
the brain target distribution. For the development of new drugs as well as for the
optimisation of therapy with the current drugs, the variability of these individual
mechanisms and contribution in terms of rate and extent should be investigated.
As the BBB is a key player in the relationship between plasma and brain
pharmacokinetics, the influences of disease states on BBB functionality in the
various stages of the disease is important in order to judge on drug effects.  This
warrants the application of a systems pharmacology approach in investigations
on variability in drug response in Parkinson's disease.
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Abstract
Parkinson's disease is a progressive neurodegenerative disease, which is
composed of many components, each caused by interplay of a number of genetic
and nongenetic causes. This warrants a systems pharmacology approach to the
development of novel drug treatments of Parkinson's disease. Animal models of
disease are an essential asset in this research.
There is no single animal model which reflects all aspects of Parkinson's disease.
The available animal models however may reflect specific aspects, making each
animal model suitable for specific Parkinson's disease research questions. A
combination of models may provide pertinent information on Parkinson’s disease
characteristics and treatment effects in the system as a whole. 
Specifically, an animal model for Parkinson's disease displaying the slow
progressive nature of the disease constitutes a basis to obtain the essential
biological system-specific information to determine the neuroprotective
properties of new drugs, preclinically. 
In this review we have summarised the currently available animal models of
Parkinson’s disease, with their main characterstics, followed by a discussion on
the in vivo monitoring technique microdialysis, to obtain information on the target
site distribution. Here, the emphasis is on blood-brain barrier (BBB) functionality
in Parkinson's disease and the added value of intracerebral microdialysis to assess
disease related changes in BBB functionality affecting drug transport into and out
of the brain, and the within brain distribution to the target site. Furthermore, to be
able to determine the effect of drugs on the Parkinsonian behaviour in animal
models, we have summarised the most commonly used behavioural tests used.
Finally, the state of the art of mechanism PK-PD modelling is introduced as novel
systems pharmacology approach to characterise drug effects in vivo.
1. Introduction
Parkinson's disease is a neurological disorder characterised by resting tremors,
rigidity, bradykinesia and postural instability. These symptoms are a result of the
loss of dopamine-producing neurons in the substantia nigra pars compacta (SNc)
and a depletion of dopamine in the striatum. Clinical manifestations do not occur
until there is a loss of approximately 50% - 80% of the dopaminergic neurons
within the SNc and a loss of about 70% of the striatal dopamine (Bohlen Und,
2005; Dauer and Przedborski, 2003). A further histopathological hallmark of the
disease is the presence of intracytoplasmic inclusions called Lewy bodies (LBs) in
Chapter 3
92
the remaining dopaminergic neurons of the SNc. The major compounds in these
eosinophilic LBs are aggregated forms of the normally presynaptically located
protein α-synuclein (Bohlen Und, 2005; Dauer and Przedborski, 2003). 
Today's treatment of the symptoms of Parkinson's disease consists predominantly
of replacing the lost brain dopamine by means of the dopamine precursor 
L-DOPA (Mercuri and Bernardi, 2005), in combination with a peripheral
decarboxylase inhibitor. To overcome motor complications associated with long-
term treatment with L-DOPA, which occur in a later stage of the disease, L-DOPA
is often administered in combination with either a dopamine agonist, a catechol-
O-methyltransferase (COMT) inhibitor, or a monoamine-oxidase-B (MAO-B)
inhibitor. However, the further the progression of Parkinson's disease the less
effective symptomatic drug treatment becomes and the more complications occur.
It is clear that there is a need for drugs that can reduce or even halt disease
progression in Parkinson's disease by using drugs that have neuroprotective or
neurorestorative properties (Bonuccelli and Del Dotto, 2006; Chen and Le, 2006;
Schapira, 2008). Some of the drugs already in use as treatment in Parkinson's
disease (e.g. dopamine agonists), or currently under investigation (e.g. A2A
antagonists), seem to offer some neuroprotective benefits (Bonuccelli and Del
Dotto, 2006; Olanow, 2009). However, to date no drug has been proven to be
neuroprotective in Parkinson's disease (Olanow, 2009) or has been approved for a
neuroprotective indication  (Rascol, 2009). A major limitation in this respect is the
lack of an endpoint that accurately reflects the underlying disease state (Olanow,
2009) while also no 'optimal' clinical trial design is readily available for studying
neurprotective properties of drugs in Parkinson's disease (Rascol, 2009; Stocchi
and Olanow, 2003). For estimating the actual treatment effect a clinical trial should
allow the time course of treatment effects to be distinguished from those due to
natural disease progression (Ploeger and Holford, 2008). Other obstacles include
the absence of precise knowledge on the etiology and pathogenesis of Parkinson's
disease. Parkinson's disease, like other neurodegenerative diseases, consists of
many disease components, each caused by an interplay of a number of different
genetic and nongenetic causes (Gasser, 2009).
Investigation on the interplay between these disease components and drug
treatment efficiency cannot be studied in vitro alone, nor in the human situation.
This implies the need for in vivo animal studies. Indeed, animal models of
Parkinson’s disease (or neurodegenerative diseases in general) have their
restrictions, as there will be no animal model reflecting all  aspects of this disease.
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As a result it has been stated that there is a lack of relevant animal models
(Kieburtz and Olanow, 2007). However, various animal models of Parkinson's
disease reflect particular aspects of the disease, making each animal model
suitable for specific Parkinson's disease research questions, while a combination
of models may provide important answers on Parkinson’s disease features and
treatment effects in the system as a whole. 
Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) models are
useful here in the sense that they aim to characterise, in strictly quantitative
manner drug effects in vivo under physiological and pathological conditions. To
this end mechanism-based PK-PD models contain specific expression to
characterise processes on the causal path between drug administration and
response (e.g. target site distribution, target binding and activation,
transduction/homeostatic feedback and diseases processes/progression). In the
meantime it has been demonstrated that mechanism-based PK-PD models have
excellent properties for extrapolation and prediction in systems pharmacology
research  (Danhof et al., 2007). Systems pharmacology aims at the development of
an understanding of the interactions between pathophysiology and drug action.
To develop such an understanding it is necessary to analyse interactions across
and between various scales of organisation (Wist et al., 2009). To date most 
PK-PD modeling research has focused on healthy systems. A major challenge is
the characterisation of drug effects on disease processes and disease progression.
A particularly intriguing challenge is the prediction of drug effects on disease
progression in man from preclinical research. For this, the development of
chronically instrumented animal models to determine the time course of drug
concentration at the target site along with the effect on disease progression is very
important. An animal model for Parkinson's disease displaying the slow
progressive nature of the disease is essential and would provide the necessary
biological system specific information to determine the neuroprotective
properties of new drugs, preclinically. Relevant biomarkers will enable a detailed
and mechanistic description of disease progression and serve as useful tools in
these disease models. Within the context of mechanism-based PK-PD modeling, a
biomarker is defined as a measure that characterises, in a strictly quantitative
manner, a process, which is on the causal path between drug administration and
effect (Danhof et al., 2005). However, a combination of biomarkers may be needed
to provide a complete characterisation of the treatment effects (beneficial and
harmful) or disease progression (Lesko and Atkinson, Jr., 2001). 
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In this review we have summarised the characteristics of the currently available
animal models of Parkinson’s disease, followed by a discussion on in vivo
monitoring techniques to obtain information on the target site distribution (PK).
Here, the emphasis is on blood-brain barrier (BBB) functionality in Parkinson’s
disease and on the effects of Parkinson's disease on drug transport into and out of
the brain, and the within brain distribution to the target site. Furthermore, to be
able to determine the effect (PD) of drugs on the Parkinsonian behaviour in
animal models, we have summarised the most commonly used behavioural tests
used. Subsequently, the main concepts of mechanism-based PK-PD modelling are
presented and discussed.
2. Animal Models of Parkinson's Disease
Animal models are "experimental preparations developed in one species for the
purpose of studying phenomena occurring in another species" (McKinney, 1984).
Suitable research models display clear face validity (isomorphism), predictive
validity (pharmacological correlation), and construct validity (homology and
similarity in the underlying neurobiological mechanisms) (Fuchs and Fliugge,
2006). In the case of animal models of Parkinson's disease, the model should
reproduce the main characteristics of the human disease, such as (1) selective
lesion of dopaminergic neurons that evolves over time; (2) depletion of dopamine
from the striatum; (3) presence of LBs in the remaining dopaminergic neurons,
and (4) easily detectable motor deficits (Bohlen Und, 2005; Yuan et al., 2005).
Currently applied animal models for Parkinson's disease can be separated in
toxin-induced models and genetic animal models (Meredith et al., 2008). 
Toxin-induced animal models
A common feature of all neurotoxin-induced models is that they affect
mitochondrial function, either by inhibiting mitochondrial complex I or complex
III (see Figure. 1) (Schober, 2004). The mechanisms through which systemic
dysfunction of complex I produces neurotoxicity are as yet unknown (Uversky,
2004). 
This review gives an overview of the commonly used neurotoxins in models for
Parkinson's disease, namely 6-hydroxydopamine (6-OHDA), 1-methyl-4-phenyl-
1,2,3,6-tertahydropyridine (MPTP), paraquat, maneb and rotenone, as well as a
number of less-known neurotoxins like reserpine, methamphetamine (METH)
and proteosome inhibitors (PSI). A summary of the neurotoxin-induced models is
given in Table 1.
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Reserpine 
The administration of reserpine in rabbits was the one of the first animal models
of Parkinson's disease. It caused a temporary slowness in movement that was
reversed by the administration of L-DOPA (Carlsson et al., 1957). Reserpine is a
naturally occurring alkaloid and when administered systemically to rodents, it is
able to deplete dopamine at the nerve terminals and induce a hypokinetic state in
the animals. However, since the effect of reserpine on the dopaminergic cells is
temporary and striatal reserpine administration does not induce morphological
changes in the nigral dopaminergic neurons, the model has limited use. Reserpine
doesn't replicate the extensive biochemical and pathological changes seen in
Parkinson's disease (Betarbet et al., 2002). 
Methamphetamine
Methamphetamine (METH) is a psychostimulant which causes oxidative damage
of nigrostriatal dopaminergic terminals (LaVoie and Hastings, 1999). In addition,
METH-induced neurotoxicity may be linked to the glutamate and nitric oxide
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Figure 1: Schematic overview of molecular and intracellular pathways of dopaminergic
neurotoxins applied in animal models of Parkinson's disease. (taken with permission from Schober
et al, 2004; Cell TissueRes 318:215-224)
systems within the striatum as it has been shown that glutamate antagonists are
able to prevent METH-induced dopamine depletion (Kita et al., 2003; Sonsalla et
al., 1989; Zeevalk et al., 1994). METH is an indirect catecholamine agonist, causing
dopamine and norepinephrine release, and a potent inhibitor of MAO leading to
an overall increase in cathecholaminergic activity in the brain (Green et al., 1992;
Kita et al., 2003). METH presents an opportunity for modeling Parkinson's disease
in that the neuropathology does overlap in terms of dopamine depletion,
decreased tyrosine hydroxylase activity, loss of dopamine uptake sites and the
loss of cell bodies in the SNc. However, there are no LBs present and striatal
damage occurs in both the dopaminergic and serotonergic systems  (Kita et al.,
2003).
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Table 1: Neurotoxin-induced animal models of Parkinson's disease
Proteosomal inhibitors
A relatively new rodent toxin-induced model in adult rats has been proposed that
uses systemic administration of proteasomal inhibitors (PSI) such as epoxomicin.
Animals treated with proteosomal inhibitors have been shown to develop
behavioural symptoms like bradykinesia, rigidity, tremor, and an abnormal
posture, which improved upon apomorphine treatment. Also, striatal dopamine
depletion and dopaminergic cell death with apoptosis and inflammation in the
SNc has been observed. In addition, α-synuclein/ubiquitin-containing inclusions
resembling LBs were present in some of the remaining neurons (McNaught et al.,
2004). Since the publication by McNaught, several laboratories have tried to
reproduce these results; some groups with success, in rats or mice (Schapira et al.,
2006; Sun et al., 2006; Zeng et al., 2006), others have unfortunately failed (Bove et
al., 2006; Hirst and Ferger, 2008; Kadoguchi et al., 2008; Kordower et al., 2006;
Landau et al., 2007; Manning-Bog et al., 2006; Mathur et al., 2007). There could be
various factors explaining these discrepancies between laboratories, i.e.
manufacturing, storage, preparation and administration of PSI or animal-specific
differences in the metabolism of the toxin (Hirst and Ferger, 2008; McNaught and
Olanow, 2006). Furthermore, not much is known about the plasma and brain
kinetics of PSI's (Hirst and Ferger, 2008). Conceptually the application of PSIs
might be a good PD model, as proteosomal inhibition could work slowly and
progressively like the disease. A prerequisite is to and a small molecule PSI
(ideally for systemic administration), which enables a significant and effective
proteasome inhibition in the nigrostriatal system (Hirst and Ferger, 2008). 
6-OHDA
6-OHDA is the first animal model of Parkinson's disease associated with SNc
dopaminergic neuronal death (Ungerstedt, 1968). 6-OHDA-induced pathology
differs from Parkinson's disease as its induced toxicity is relatively selective for
monoaminergic neurons, resulting from preferential uptake by dopaminergic and
noradrenergic transporters  (Luthman et al., 1989). Other brain areas involved in
Parkinson's disease, such as the anterior olfactory structures, lower brain stem
areas or the locus coeruleus are not affected by 6-OHDA (Betarbet et al., 2002; Del
Tredici et al., 2002). Inside neurons, 6-OHDA accumulates in the cytosol, where it
induces cell death through oxidative stress and inhibition of mitochondrial
complex I and IV (Figure 1) (Jeon et al., 1995). As 6-OHDA is not able to cross the
BBB, it must be administered by local stereotaxic injection into the SNc, median
forebrain bundle (MFB; which carries ascending dopaminergic and serotonergic
projections to the forebrain), or the striatum to target the nigrostriatal
dopaminergic pathway (Dauer and Przedborski, 2003; Javoy et al., 1976). Different
models have been developed in mainly rodents and small monkeys (marmosets)
using 6-OHDA, most of them unilaterally, resulting in a model that is commonly
referred to as the "hemiparkinson model". At least in mice, rats, cats and primates,
6-OHDA is a highly effective toxin for dopaminergic neurons  (Beal, 2001).
Bilaterally affected animals cope with adipsia, aphagia and high mortality and
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require intensive nursing care. In the hemiparkinson model, the contralateral side
serves as an internal control, albeit that this side may also be influenced by the
lesion, as is reflected in  changes of striatal peptide and dopamine concentrations
or changes in the electrical activity of neurons located in the subthalamic nucleus
(Nieoullon et al., 1977; Perier et al., 2000; Salin et al., 1996). Unilateral 6-OHDA
injections into the SNc or the MFB cause an anterograde degeneration of the
whole nigrostriatal dopaminergic system (O'Neill et al., 2004; Sachs and Jonsson,
1975; Ungerstedt, 1968). Dopaminergic neurons start degenerating within 12-24 hr
and die without apoptotic morphology. Striatal dopamine levels are depleted 
2-3 days later (Faull and Laverty, 1969; Jeon et al., 1995). After intrastriatal
injection of 6-OHDA, it is taken up into the striatal terminals and causes a slow,
progressive, induced neuron death, retrogradely, which lasts for 1-3 weeks
(Murray et al., 2003; Przedborski et al., 1995; Sauer and Oertel, 1994). The
magnitude of the lesion depends on the amount of 6-OHDA injected, the site of
the injection, and the species used (Betarbet et al., 2002). So far, none of the modes
of 6-OHDA intoxication have led to the formation of LB-like inclusions (Dauer
and Przedborski, 2003). 
MPTP 
MPTP currently represents the most important and most frequently used
Parkinsonian toxin applied in animal models (Beal, 2001). MPTP is the byproduct
of the unlawful manufacture of a synthetic meperidine derivative. Drug addicts
who took MPTP accidentally developed a syndrome that clinically and
pathologically resembled Parkinson's disease. After repeated injection of MPTP
intravenously, chronic and severe parkinsonism developed, which was L-DOPA
responsive. A tremor which was indistinguishable from the characteristic resting
tremor occurred and neuropathological examination revealed moderate to severe
depletion of pigmented nerve cells in the SNc, but an absence of LBs (Langston et
al., 1983). MPTP, which is a pro-toxin and highly lipophilic, crosses the BBB and
is converted to 1-methyl-4-phenyl-2,3-dihydropyridium (MPDP) in non-
dopaminergic cells (especially in astrocytes and serotonergic neurons) by MAO-B
and then oxidixed to 1-methyl-4-phenylpyridinium (MPP+). Released from these
cells, MPP+ is then actively transported into dopamine neurons where it impairs
mitochondrial respiration by inhibiting complex I of the electron transport chain
(Nicklas et al., 1985; Vila and Przedborski, 2003). Endothelial cells in the
microvasculature that make up the BBB contain MAO. Several studies have
correlated levels of MAO with MPTP-induced neuronal loss (Kalaria et al., 1987;
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Riachi et al., 1988). Since MPP+ cannot be transported through the BBB (Riachi et
al., 1990), the BBB can be a first line of defense against exogenous agents (Smeyne
and Jackson-Lewis, 2005).
MPTP is mainly applied in nonhuman primates and in mice but also in several
other species such as dog, cat, rat and goldfish  (Bohlen Und, 2005). With regard
to the species used, several distinct routes of MPTP administration have been
established such as oral or stereotactical injection, but also systemic
administration by injection  (e.g. subcutaneous, intravenous, intraperitoneal or
intramuscular; (Przedborski et al., 2001)) which is still the most common and
reproducible form.
In contrast to primates, rodents are less sensitive to MPTP toxicity but the MPTP
mouse model provides the most useful animal model of PD to study
neuropathological and neurochemical changes (Schmidt and Ferger, 2001). In
mice, systemic or intracranial administration of MPTP can result in severe damage
of the nigrostriatal dopaminergic system, including symptoms such as akinesia,
rigidity, tremor, gait and posture abnormalities. In MPTP-injected mice, a
dramatic loss of dopaminergic neurons has been detected leading to impaired
dopaminergic neurotransmission, which is accompanied by a loss of
dopaminergic nerve terminals in the striatum and a dramatic reduction in striatal
dopamine levels. The cell loss in the SNc is accompanied by an increase in the
number of  α-synuclein-immunoreactive neurons located in this brain area and an
increase in  α-synuclein mRNA (Vila et al., 2000). However, when MPTP-treated
animals developed α-synuclein inclusion bodies, these were not conform the
distinctive architecture of LBs in Parkinson's disease (Maries et al., 2003). Due to
the insensitivity for MPTP, mice require relatively high doses to induce a
significant loss of dopaminergic neurons resulting generally in acute pathology.
Nevertheless, acute, low doses of MPTP are administered to mice to study
compensatory mechanisms (Schmidt and Ferger, 2001). An acute treatment with
a medial dose of MPTP induces a rapid dopaminergic degeneration with
predominantly necrotic cell death (Schober, 2004) but for a subchronic induction
of Parkinson's disease, medial doses of MPTP are injected 1-2 times a day for at
least 5 days and for progressive chronic Parkinson's disease MPTP is given once
daily at low doses over a time period of 20 days. The chronic MPTP-mouse
protocol mirrors most closely the pattern of progression assumed to be that of
Parkinson's disease and appears useful (Bezard et al., 1997). Different mouse
strains react very differently to MPTP. Systemic MPTP treatment of C57BL/6 and
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BALB/c mice indicated a higher susceptibility to MTPT toxicity in C57BL/6 mice.
No difference between gender was observed (Sedelis et al., 2000). 
Rats are relatively resistant to MPTP (Terzioglu and Galter, 2008). Only injections
of high doses of MPTP in rats which are therapeutically pretreated, e.g. with
guanethidine, to prevent peripheral catecholamine release and extensive
mortality, cause significant dopaminergic neurodegeneration. Rats are therefore
not recommended for MPTP studies (Giovanni et al., 1994).
The MPTP monkey model remains the gold standard for the preclinical
evaluation of new symptomatic therapies for Parkinson's disease (Dauer and
Przedborski, 2003). The most commonly used administration mode in monkeys
are multiple intraperitoneal or intramuscular injections as well as intracarotid
infusions (Schober, 2004). In the past, primates were nearly always treated with
high doses of MPTP to induce an acute and severe degeneration of dopaminergic
neurons. However, views have changed and currently, monkeys are treated more
and more with low doses of the neurotoxin for a prolonged period of time
resulting for a more chronic degeneration and thereby mirroring the human
pathogenesis more appropriately (Przedborski et al., 2001). Unilateral intracarotid
artery (ICA) administration of MPTP and subsequent intravenous injections of
MPTP in rhesus monkeys induces an advanced stable Parkinsonian syndrome, in
which the ICA injection of MPTP initiates the Parkinsonian syndrome primarily
in one hemisphere and the subsequent iv. doses (administered as needed) further
deplete the dopamine system to induce a bilateral lesion in a shorter period of
time, with fewer side effects (Oiwa et al., 2003). Although MPTP is able to mimick
the features of Parkinson's disease well, other brain areas involved in Parkinson's
disease, such as the locus coeruleus are not affected (Dauer and Przedborski,
2003). Moreover, continuous MPTP infusion by minipumps has been reported to
induce development of intracellular inclusion bodies in baboons (Kowall et al.,
2000), but these inclusions are not similar to the LBs typically found in human
disease (Maries et al., 2003).
Paraquat and maneb
Exposure to environmental toxins has been associated with an increased risk for
developing Parkinson's disease (Chade et al., 2006; Tanner, 1989). The herbicide
paraquat (N,N’-dimethyl-4-4’-bipiridinium) and the fungicide maneb (manganese
ethylenebisdithiocarbamate) are two pesticides which have shown to induce
dopaminergic neuron degeneration in the SNc. Paraquat is structurally similar to
MPTP, but has no selectivity for the dopamine transporter and therefore does not
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accumulate in dopamine neurons after systemic administration. It does not easily
penetrate the BBB but is possibly taken up into the brain by the 
L-neutral amino acid transport system, then transported into striatal, possibly
neuronal, cells in a Na+-dependent manner (Shimizu et al., 2001). Pretreatment of
paraquat-treated mice with L-valine or L-phenylalanine seems to prevent
neurodegeneration completely and thus confirms the uptake of paraquat into the
brain by the neutral amino acid transporter (McCormack and DiMonte, 2003).
Paraquat induces a specific, although modest, dose-dependent loss of striatal
dopaminergic nerve fibres and SNc neural cell bodies (Brooks et al., 1999;
Terzioglu and Galter, 2008), although evidence in literature seems contradictory
(McCormack et al., 2002; Thiruchelvam et al., 2000a; Thiruchelvam et al., 2000b).
The toxicity of paraquat appears to be mediated by the formation of superoxide
radicals and the activation of cholinergic and glutamatergic transmission
(Corasaniti et al., 1998; Dauer and Przedborski, 2003). Subchronic treatment of rats
with systemic paraquat significantly decreases brain dopamine content in the
striatum and slightly in the midbrain and cortex and stimulates glutamate efflux
from neural cells or inhibits the glutamate uptake system and thereby initiating a
cascade of excitotoxic reactions (Shimizu et al., 2003). Levels of α-synuclein were
reported as elevated in both the frontal cortex and ventral midbrains. Finally 
α-synuclein-positive inclusions in the SNc neurons of mice treated with paraquat
were observed (Manning-Bog et al., 2002). 
Much less is known about the mechanisms of maneb toxicity. Maneb consists of
manganese and ethylene-bis-dithiocarbamate, both of these components being
potentially neurotoxic. Which of the two components of maneb is responsible for
the decreased locomotor activity and potentiation of the paraquat effects on the
nigrostriatal pathway, remains to be clarified (Uversky, 2004). Paraquat in
combination with maneb produces synergistic effects on the nigrostriatal
dopamine system. Paraquat/maneb reduces striatal TH and dopamine
transporter immunoreactivity, striatal TH protein levels, and TH
immunoreactivity and cell counts in the SNc but not in the ventral techmental area
(VTA) (Thiruchelvam et al., 2000b). The effects of paraquat/maneb on the
dopaminergic system are age-dependent. A greater decrease in dopamine
turnover, dopamine metabolites, nigrostriatal dopaminergic neurons and striatal
TH protein levels compared with younger mice as was shown in 18-month old
mice compared with younger mice treated with paraquat/maneb (Thiruchelvam
et al., 2003). A study in 6-month-old rats also indicated an increased susceptibility
of older animals to toxicity from paraquat/maneb compared to a study with 
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2-moth-old rats (Cicchetti et al., 2005; Saint-Pierre et al., 2006). 
The animal models using paraquat alone or in combination with maneb are
currently not applied for the evaluation of new therapies for Parkinson's disease.
Thier use is limited to investigations into therelationship between exposure to
environmental toxins such as paraquat and maneb and the development of
Parkinson's disease in humans.
Rotenone
Another candidate for experimental work onthe role of environmental toxins in
Parkinson's disease, is the pesticide, rotenone. Rotenone is the most potent
member of the rotenoids, a family of natural cytotoxic compounds extracted from
tropical plants and it is widely used as an insecticide and fish poison. Rotenone is
highly lipophilic and readily gains access to all organs (Talpade et al., 2000) and
therefore it does not require the dopamine transporter to gain access to the neural
interior. Rotenone binds (at the same site as MPP+) to and inhibits mitochondrial
complex I, leading to a homogenous reduction of complex I activity throughout
the brain. In vitro, subacute rotenone treatment of differentiated SH-SY5Y
neuroblastoma cells resulted in death of approximately 60% of the cells.
Furthermore, it appears to reproduce the Lewy neuritic changes of early
Parkinson's disease pathology, although no LB inclusions were seen (Borland et
al., 2008). In vivo, the administration of low-dose intravenous or subcutaneous
rotenone to rats produces selective degeneration of nigrostriatal dopaminergic
neurons accompanied by α-synuclein-positive LB-like inclusions (Betarbet et al.,
2000; Sherer et al., 2003). Rotenone can cross cell membranes and is therefore likely
to affect all cells. However, rotenone seems to preferentially target dopamine
neurons. These neurons are particularly sensitive to oxidative stress because of
the permanent elevated level of free radicals generated by dopamine metabolism
and auto-oxidation (Giasson and Lee, 2000; Olanow, 1990). However, differences
were observed in rotenone vulnerability between different populations of
dopaminergic neurons within the SNc, and between dopaminergic fiber
projections and cell bodies (Betarbet et al., 2000). In contrast to these findings,
acute intoxication with rotenone seems to produce selective damage in the
striatum and the globus pallidus, but spare dopaminergic neurons in the SNc
(Ferrante et al., 1997). The variability in the development of dopaminergic lesions
in the brain of systemically administered rotenone as well as the high mortality
rate have been reported previously (Betarbet et al., 2000; Fleming et al., 2004;
Hoglinger et al., 2003; Lapointe et al., 2004; Zhu et al., 2004). This high-variability
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demonstrates the inter-individual susceptibility to rotenone, reflecting genetic
differences among rats, providing insight into the interaction between
environmental and genetic influences of Parkinson's disease pathogenesis (Perier
et al., 2003). Systemic administration of rotenone in rats seems to affect locomotor
behaviour, however this can not be correlated to the degree of nigrostriatial injury
seen in these animals. Most probably, changes in locomotion are a consequence of
peripheral organ toxicity (Fleming et al., 2004; Lapointe et al., 2004; ). These results
were confirmed after repeated daily subcutaneous or oral doses of rotenone in
C57BL/6 mice (Inden et al., 2007; Richter et al., 2007) although at high daily oral
doses of 10 and 30 mg/kg a reduction of TH immunoreactivity in SNc was seen
with variability being the lowest at the highest dose (Inden et al., 2007).
Interestingly, absorption of rotenone in the gastrointestinal tract is slow and
incomplete and rotenone is effectively metabolised by the liver which would not
favor the oral route for rotenone administration (Bove et al., 2005). In another
study systemic exposure of mice to rotenone demonstrated an acute increase in
dopamine turnover which seems to be common to other mitochondrial toxins
(Thiffault et al., 2000).
It was demonstrated in a model of Drosophila melanogaster that L-DOPA is able
to reverse rotenone-induced locomotor changes (Coulom and Birman, 2004) and
a study with rats showed similar results whereby L-DOPA (in combination with
a decarboxylase inhibitor) was able to reverse rotenone-induced catalepsy,
postural changes and decreased locomotion, indicating that the behaviour was a
consequence of the degeneration of dopaminergic neurons, rather than from
systemic toxicity of rotenone. The rats were treated daily with low systemic doses
of rotenone via i.p. administration for 60 days or rotenone was infused directly
into medial forebrain bundle of the brain  (Alam and Schmidt, 2004). These modes
of administration cause a slow degeneration which makes it suitable to study
neuroprotective agents (Schmidt and Alam, 2006).
Due to its inconsistent and unpredictable effect on the nigrostriatal pathway, the
chronic (systemic) administration of rotenone is not yet suitable to become a
routine animal model for Parkinson's disease (Bove et al., 2005). Next to genetics
(Perier et al., 2003), various factors such as age (Phinney et al., 2006; Richter et al.,
2007), rat species (Betarbet et al., 2000; Schmidt and Alam, 2006) and even
environmental temperature (Crutchfield and Dluzen, 2006) might contribute to
the variability in results. An alternative approach is when rotenone is
administered directly into the brain. Although this does not represent the natural
exposure to environmental toxins, it might develop into an animal model which
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could be applied in preclinical (PK-PD) studies in the search for neuroprotective
strategies for Parkinson's disease. 
Intracerebral-administered rotenone (2 µg dissolved in 5 µl 10% DMSO solution
into the MFB) produced a decrease in dopamine and its metabolites in the
striatum (about 70%) and SNc (35% for dopamine and 55% for DOPAC), without
affecting the serotonin system (Antkiewicz-Michaluk et al., 2004). Another study
demonstrated that stereotaxic administration of rotenone into the MFB, SNc or
striatum decreased dopamine levels in the striatum (96%, 62% and 30%,
respectively). Furthermore, these animals showed behavioural changes to a
similar degree as seen in 6-OHDA lesioned rats (Sindhu et al., 2006). Intranigrally,
rotenone-infused animals exhibited progressive ipsilateral rotations when
challenged with amphetamine on days 7, 14, 21 and 28 whereas animals that
received a MFB infusion of rotenone only displayed this behaviour on day 28
(Sindhu et al., 2005). Thus, an infusion of rotenone into the MFB might develop a
slower, more progressive degeneration of dopaminergic cells compared to an
intranigral infusion. Moreover, the decrease in striatal dopamine on day 32 seems
greater in MFB-infused animals compared with intranigrally infused animals
(Sindhu et al., 2005). In another study, an intranigral infusion caused a time-
dependent reduction of complex-I activity, an increased production of hydroxyl
radicals and a significant depletion of striatal dopamine in the ipsilateral SNc. No
changes were seen in striatal serotonin levels. TH immunostaining revealed a
highly significant decrease in the staining intensity in the striatum and an overt
decrease in the area positive for TH in the ipsilateral SNc (Saravanan et al., 2005).
Bilateral infusion of rotenone into the MFB showed a strong increase in catalepsy,
a decrease in locomotor activity and a significant depletion of striatal dopamine
levels compared to sham-lesioned rats. L-DOPA is able to reverse the motor
deficits in rats, confirming the depletion of dopaminergic neurons in these
animals (Alam et al., 2004). In our opinion, the intracerebral infusion of rotenone,
specifically into the MFB, has the most potential as an animal model for
mechanism-based PK-PD studies in search for treatments with neuroprotective
properties.
Genetic animal models
The majority of Parkinson's disease cases (>95%) are sporadic, although some
genes (associated with the PARK loci) have been identified and linked to rare
forms of Parkinson's disease. Currently, there are six clearly defined genetic
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causes of Parkinson's disease. There are α-synuclein (PARK1) and LRRK2
(PARK8), which result in autosomal dominant Parkinson's disease and Parkin
(PARK2), DJ-1 (PARK7) and PINK1 (PARK6), which result in autosomal recessive
Parkinson's disease (Pankratz and Foroud, 2007). The gene UCHL1 (PARK5) has
been implicated but not confirmed.
For Parkin, DJ1 and PINK1, all of which cause early-onset Parkinson's disease,
genetic mouse models can easily be made by null mutation of such genes
(knockout mice). For the dominantly inherited gain-of-function mutations such as
in α-synuclein (PARK1) and LRRK2 (PARK8), transgenic mouse models have
been created in which extra copies of the gene are introduced into the mouse
genome or delivered by lenti- or adeno-associated virus (Terzioglu and Galter,
2008). Since α-synuclein is a major component of LBs, and mutations in 
α-synuclein may result in nigrostriatal dopaminergic degeneration in familial
Parkinson's disease it has gained the most focus in the development of transgenic
mice or Drosophila flies, which express the wild-type or mutated α-synuclein.
Transgenic mice overexpressing α-synuclein or expressing mutated forms of 
α-synuclein display a number of features seen in Parkinson's disease such as
progressive accumulation of α-synuclein-and ubiquitin-immunoreactive
inclusions in neurons in the neocortex, hippocampus, and SNc, mitochondrial
DNA damage and degeneration, loss of dopaminergic terminals in the basal
ganglia and motor impairments (Martin et al., 2006; Masliah et al., 2000). Similar
results were found in rats overexpressing α-synuclein (Mochizuki et al., 2006).
Interestingly, several lines of α-synuclein null mice have a complete or partial
resistance to MPTP (Dauer et al., 2002; Drolet et al., 2004; Schluter et al., 2003).
Animal models based on the transgenic expression of wild-type and mutated 
α-synuclein do not demonstrate all of the key features of Parkinson's disease, like
a massive loss of dopamine nigrostriatal neurons (Betarbet et al., 2002; Fleming et
al., 2005). Rapid neurodegeneration is observed after viral transduction but is
limited to the targeted region and does not mimic the broad pathology observed
in the disease (Chesselet, 2008). Nevertheless, they provide an important
opportunity to study the involvement of α-synuclein in Parkinson's disease
pathogenesis.
Other genetic models include the Parkin knockout mice, DJ-1 knockout mice,
NURR1 and PITX3-APHAKIA, among others. The reader is referred to some
excellent reviews for a more detailed description of these models (Fleming et al.,
2005; Terzioglu and Galter, 2008).
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3. Measuring Target Site Distribution and BBB Functionality in
Animal Models of Parkinson's Disease
The distribution of drug molecules between plasma and the target site in the brain
is a crucial factor in the effects of drugs used in the treatment of Parkinson's
disease. In the previous chapter it has been outlined that multiple mechanisms are
involved in the distribution of drug molecules to the target site in the brain (i.e.
brain perfusion, transport across the BBB, distribution within the brain).
Moreover it has been demostrated that the functionality of the BBB may change
under disease conditions. This underscores the need of studying the brain
distribution kinetics of drugs used in the treatment of Parkinson's disease. In this
pragraph we discuss principles and applications of intracebral microdialysis as a
tool monitor the time course of extracellular brain concentrations.
Intracerebral microdialysis involves the insertion of a microdialysis probe into a
selected area of the brain. The probe, consisting of a hollow tube and a semi-
permeable membrane, is constantly perfused with a physiological solution.
During perfusion, substances around the semipermeable part of the probe will
diffuse from higher to lower concentration into the dialysate (Figure 2). 
Drug concentrations in brain dialysate reflect but do not equal free (unbound)
concentrations in brain ECF due to the constant flow of perfusion fluid (de Lange
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Figure 2: The principle of microdialysis
et al., 1999). In vitro recovery, or better, in vivo recovery methods such as
retrodialysis, no-net-flux and dynamic-no-net-flux need to be applied to be able to
relate the concentration in the dialysate to the true concentration in the ECF
(Bouw and Hammarlund-Udenaes, 1998; de Lange et al., 1997; de Lange et al.,
1999).
Many studies using intracerebral microdialysis in experimental animals have
already shown its usefulness and special value in monitoring brain
pharmacokinetics. It has been shown that this technique providies better
estimates of BBB transport parameters compared with the more classical tissue
homogenate-pharmacokinetic approach (de Lange et al., 1997; de Lange et al.,
1998; Hammarlund-Udenaes et al., 1997; Hammarlund-Udenaes, 2000; Sawchuk
and Elmquist, 2000; Wang and Welty, 1996; Xie et al., 1999). A prerequisite for this
application is that BBB transport characteristics are not significantly influenced by
the microdialysis probe implantation and its presence in the brain. This was an
initial concern but based on a series of studies performed to validate intracerebral
microdialysis in the characterisation of passive, as well as active, BBB transport
(de Lange et al., 1994; de Lange et al., 1995a; de Lange et al., 1995b; de Lange et al.,
1998; de Lange et al., 2000; Malhotra et al., 1994; Ooie et al., 1997; Wang and Welty,
1996),  it has been demonstrated that this prerequisite holds, provided that the
technique is used under well-controlled surgical and experimental conditions  (de
Lange et al., 1997).
Intracerebral microdialysis is not only able to measure kinetics of exogenous
compounds but also offers the possibility of monitoring endogenous compounds
such as neurotransmitters and any changes in their kinetics as a consequence of a
disease and/or its treatment (Baskaya et al., 1997; Carter et al., 1995; Frantz et al.,
2002; Fuchs and Hauber, 2003; Glick et al., 1994; Hashiguti et al., 1993; Jonkers et
al., 2001; Kaakkola and Wurtman, 1992; Napolitano et al., 2003; Souza Silva et al.,
1997). Specifically in Parkinson's disease, intracerebral microdialysis has been
applied to study the kinetics of L-DOPA and its metabolites in healthy and
diseased rodents (Cannazza et al., 2005; Fedrowitz et al., 2000; Gerin, 2002;
Giovanni et al., 1994; Holmer et al., 2005; Kannari et al., 2006; Kostrzewa et al., 2005;
Marti et al., 2000; Sarre et al., 1992) or monkeys (Alexander et al., 1994; Zhang et al.,
2003). Using intracerebral microdialysis, one is able to measure the PK of a (new)
drug for Parkinson's disease and determine its distinct brain penetration
properties and consequently measure its effect (PD) on brain neurotransmitters.
Simultaneously, intracerebral microdialysis is able to measure a biomarker or a
combination of biomarkers specific for Parkinson's disease in the same animal.
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Furthermore, by means of dual probe microdialysis, one is able to measure
compounds in different brain areas, in the same rat, at the same time (Galeffi et al.,
2003; Pudovkina et al., 2002; Westerink et al., 1998). Using mechanism-based PK-
PD disease progression modeling, presumed neuroprotective properties of new
treatments for Parkinson's disease can thus be investigated in a preclinical setting.
4. Measuring Behaviour and Drug Effects in Animal Models of
Parkinson's Disease
To be able to assess lesion-induced disability and/or treatment-induced recovery,
the appropriate but simple testing routines should be chosen. Behavioural tests
should reflect histological and/or functional deficits or preservation of the injured
tissue (Yuan et al., 2005). Animal models of Parkinson's disease can be either
unilateral as well as bilateral, requiring different behavioural assessments. The
following section summarises behavioural tests which are commonly used in
animal models of Parkinson's disease. 
Rotometry 
Rotational behaviour of unilateral-lesioned animals in response to dopamine
receptor agonists has been the conventional method in the assessment of
dopamine-mediated responses since the 1970s (Ungerstedt and Arbuthnott, 1970).
Unilateral lesions (mainly by 6-OHDA) produce a hemiparkinsonian syndrome,
which includes asymmetries of body posture, and contralateral sensorimotor
deficits (Cenci et al., 2002). The rotometry test consists of recording the number of
turns that are performed by an animal after a challenge with dopamine agonists
(amphetamine or apomorphine). The net rotational assymetry score is expressed
as full body turns per minute (Moore et al., 2001). Animals with unilateral
dopamine depletion will turn contralaterally to the hemisphere in which
dopamine-receptor stimulation is stronger; that is, they will turn towards the side
of the lesion after challenge with dopamine-releasing drugs and away from it after
treatment with L-DOPA or dopamine agonists (Yuan et al., 2004). 
Elevated body swing test 
The elevated body swing test allows behavioural testing of unilateral lesioned
animals without using drugs, to determine the natural response following a lesion
(Roghani et al., 2002). This test was first described by Borlongan (Borlongan and
Sanberg, 1995) and adapted for various studies (Roghani et al., 2002; Yuan et al.,
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2004) including the assessment of body axis bias ('curling') (Henderson et al.,
1999). The elevated body swing test involves elevating the animal by handling its
tail and recording the frequency and direction of the swing behaviour. Unilateral
nigral 6-OHDA-lesioned rats exhibited significant biased swing activity with the
direction contralateral to the lesioned side, corresponding to the direction of
apomorphine-induced rotations. A 30 seconds elevated body swing test was
noted as the peak time for biased swing activity (Borlongan and Sanberg, 1995). 
Head turning 
In this test, the position of the head relative to the body axis is measured by
placing the rat into a standard cage and allowing it to habituate. The position of
the head (> 10 ° deviation left or right of the midline, or neutral) was noted every
second for 60 seconds. The net number of seconds the head was positioned
ipsilaterally minus the number of seconds positioned contralaterally is calculated
over 3 min of observations (Henderson et al., 1999). From this, ipsilateral side bias
and overall head-turning activity indices can be calculated (Moore et al., 2001). 
Staircase test 
The staircase test, also referred to in modified versions as the skilled paw reaching
test, is a behavioural test that consists in reaching for food inside a special box and
allows for a sensitive measure of skilled reaching by each limb in an independent
manner (Montoya et al., 1991). This test is not only applied in unilateral-lesioned
animals of Parkinson's disease, but aso in animals with experimental stroke,
hypoxia and peripheral neuropathy (Pagnussat et al., 2009). The staircase
apparatus comprises a test box from which runs a narrow corridor with a central
plinth. On either side of the plinth is a descending 'staircase' of steps. Two food
pellets are placed onto each step of two staircases located one on either side of the
plinth. Rats are placed in the box and can reach down either side of a plinth to
grasp lift and retrieve food pellets from the steps of the staircase. The numbers of
pellets removed provides a quantifiable measure of the distance and efficiency of
reaching skill. The design is such that the rat can only reach pellets on one
staircase with its left paw and on the other with its right paw, thereby providing
separate measures of performance for each limb (Jeyasingham et al., 2001; Kirik et
al., 1998; Montoya et al., 1991; Moore et al., 2001; Pagnussat et al., 2009). 
Stepping test 
This test is a modification of the bracing test (Schallert et al., 1979). The rat is held
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by the experimenter fixing its hindlimbs with one hand and the forelimb not to be
monitored with the other, while the unrestrained forepaw is touching the table.
The number of adjusting steps was counted while the rat is moved sideways along
the table surface (90 cm in 5 s), in the forehand direction, for both forelimbs (Kirik
et al., 1998; Olsson et al., 1995; Paille et al., 2007). 
Grip strength 
The grip strength test measures fore- and hindlimb grip-strength in rats or mice
and is able to asses the effect of drugs, age and toxins on muscle strength (Meyer
et al., 1979). This test was later modified to provide measurement of the two
forelimbs, separately but simultaneously. A description of the apparatus is
described elsewhere (Dunnett et al., 1998). Rats and mice naturally cling to the
bars until they can no longer resist the pull, and then let go. The applied force at
the point at which the rodent releases its grip for each paw is recorded by two
spearate strain gauses connected to a digital readout (Jeyasingham et al., 2001). 
Catalepsy test 
Catalepsy in laboratory animals is defined as a failure to correct an externally
imposed posture, so the typical catalepsy test consists of placing an animal into an
unusual posture and recording the time taken to correct this posture (Sanberg et
al., 1988). The most common catalepsy test is the 'bar test' where rats are placed
with both forepaws on bars 9 cm above and parallel from the base and were in a
half-rearing position. Latency time of the removal of the paw is then recorded
(Nehru et al., 2008; Zhou et al., 2007). There are, however, many variations of this
bar test as summarised elsewhere (Sanberg et al., 1988). Other tests applied to
measure catalepsy are by using parallel bars, platforms or pegs to situate animals
in unusual positions (Sanberg et al., 1988).
Rotorod 
The rotorod (Rota-Rod) test, in which animals walk on a rotating drum, is widely
used to assess motor status in laboratory rodents. Animals are pre-trained on the
rotorod and then tested at a series of increasing rod speeds. This test is suitable for
initial screening of lesions or therapies both in unilateral and bilateral lesioned
animals (Rozas et al., 1997; Rozas and Labandeira Garcia, 1997). Performance is
measured by the duration that an animal stays up on the drum as a function of
drum speed. High-speed video recording methods of the animal walking on the
rotorod gives information about qualitative aspects of walking movements
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(Whishaw et al., 2008). Using the rotorod test, 6-OHDA-lesioned rats showed
chronic impairment in their posture and in the use of the limbs contralateral to the
lesion (Whishaw et al., 2003). 
5. Mechanism-Based PK-PD Modelling Techniques
PK-PD modeling is increasingly applied in modern drug research. PK-PD
modeling aims at characterisation and prediction of the time course of drug action
in health and disease (Breimer and Danhof, 1997). In recent years PK-PD
modeling has evolved from a descriptive discipline into a mechanistic science that
is applied in all phases of drug discovery and development In this context
advanced mechanism-based PK-PD models are now being developed, which have
improved properties for in vitro/in vivo-, interspecies- and healthy volunteers to
patients extrapolation and prediction. 
Mechanism-based models
PK-PD has evolved from the basic concept of the dose-response relationship to
sophisticated models enabling the understanding of the underlying mechanisms
of drug action (Csajka and Verotta, 2006). Mechanism-based PK-PD models
contain specific expression to characterise specific processes on the causal path
between drug administration and response. These processes include: 1) target
distribution, 2) target binding and activation, 3) transduction/homeostatic
feedback and 4) disease processes/progression. As such mechanism-based PK-PD
modeling utilizes concepts from physiologically-based pharmacokinetic (PBPK)
modeling, receptor theory, dynamical systems analysis and disease systems
analysis (Danhof et al., 2007). A key element of mechanism-based PK-PD
modeling is the explicit distinction between the drug-specific and biological
system-specific parameters. Drug-specific parameters (target affinity and target
activation) can often be predicted on the basis of in vitro bioassays and are often
identical between species and individuals, whereas biological system-specific
parameters (PD interactions, time-dependent transduction mechanisms,
homeostatic feedback mechanisms, disease processes and disease progression)
can only be estimated by in vivo systems analysis and typically their values can
vary between species, individuals, disease state and experimental conditions
(Danhof et al., 2007; Danhof et al., 2008). 
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Interspecies scaling / allometry
In drug development many pharmacological and toxicological studies are
performed in small laboratory animals such as mice, rats, rabbits, dogs and
monkeys. Species differences and therefore interspecies scaling is an important
issue for the prediction of pharmacokinetic parameters from these animals to
humans. The assumption that animals have similar physiology, biochemistry and
cellular structure has allowed interspecies scaling of heart rate, blood flow, blood
volume and organ size (Mordenti, 1986). Clearance (Cl), Vd, and elimination half-
life (t1/2) are the three most frequently extrapolated pharmacokinetic parameters.
Over the years, many approaches have been suggested to improve the prediction
of these pharmacokinetic parameters in humans from animal data and consist of
allometric methods (Mahmood, 1999) and PBPK models (Danhof et al., 2008;
Rowland, 1985).
In short, the allometric approach is based on the power function Y = aWb, where
the bodyweight of the species is plotted against the pharmacokinetic parameter of
interest on a log-log scale. Using this approach, Cl is not predicted very well (error
between predicted and observed clearance > 30%). Thus, several other approaches
have been proposed, which have been described elsewhere (Feng et al., 2000; Fura
et al., 2008; Mahmood and Balian, 1999; Sinha et al., 2008). The PBPK models
provide a mechanistic-based evaluation of drug disposition in which they use a
physiologically realistic compartmental structure (Danhof et al., 2008; De Buck et
al., 2007) and therefore is a better approach for interspecies extrapolation as it uses
species-specific data on tissue structure, volume and composition and on the
associated blood flows (Danhof et al., 2008). The structure of the PBPK model is
essentially common to all mammalian systems, thereby facilitating interspecies
scaling, and these models are uniquely suited to predict tissue and organ
exposure (Rowland et al., 2004). 
Compared with the allometric approach, PBPK models also seem to have a higher
percentage of successful predictions (Ito and Houston, 2005; Jones et al., 2006;
Zuegge et al., 2001). PBPK modeling has been applied successfully to take species
differences in functionality of transporters at the BBB into account and was used
to predict target exposure of drugs such as selective serotonin re-uptake inhibitors
and semi-synthetic opioids (Geldof et al., 2008; Groenendaal et al., 2007a;
Groenendaal et al., 2007b; Liefaard et al., 2005). 
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Disease progression
In vivo systems analysis aims at the explanation of physiology and disease from
the level of interacting components such as molecular pathways, regulatory
networks, cells, organs, and ultimately the entire organism. In conventional 
PK-PD analyses, the values of these biological system-specific parameters in the
absence of a drug are kept invariable with time, and physiology is generally
considered constant at baseline. However, for progressive, chronic diseases like
Parkinson's disease, this is not a realistic description as the biological functions
(e.g. dopaminergic neurons) deteriorate over the time course of the (mostly
symptomatic) treatment period. Therefore, disease progression analysis has been
proposed where the influence of a drug effect on the change in disease status over
time is characterised (Chan and Holford, 2001; Holford and Peace, 1992). In these
first disease-progression models for clinical Parkinson's disease rating scales, the
signs and/or symptoms of disease and their response to treatment are modeled
directly, without consideration of the underlying biological system as only
information on clinical symptoms or outcome was available. 
A theoretical framework for mechanism-based disease progression models has
been proposed, in which time-dependent changes in the biological system-specific
parameters of diseased subjects are taken into account (Post et al., 2005). This is an
important factor when searching for a drug treatment for Parkinson's disease
intended to slow or stop the disease processes and disease progression. PK-PD
modeling is increasingly applied in drug discovery and preclinical development
i.e. in the selection of drug candidates with the most favorable PK and PD
properties. For this purpose, the development of chronically instrumented animal
models for the determination of the time course of drug concentration and effect
is very important. An animal model for Parkinson's disease displaying the slow
progressive nature of the disease would be able to provide the necessary
information (biological system-specific parameters) needed to determine the
neuroprotective properties of new drugs, preclinically. Availability of relevant
biomarkers could result in a more detailed and mechanistic description of disease
progression and serve as useful tools in these disease models. Within the context
of mechanism-based PK-PD modeling, a biomarker is defined as a measure that
characterises, in a strictly quantitative manner, a process, which is on the causal
path between drug administration and effect (Danhof et al., 2005). However, a
combination of biomarkers ("fingerprint") might be needed to provide a complete
characterisation of the treatment effects (beneficial and harmful) or disease




As we have stated in the introduction, there is no single animal model which
reflects all aspects of Parkinson's disease but one model may reflect specific
aspects suitable for specific Parkinson's disease research questions. Specifically,
an animal model for Parkinson's disease displaying the slow progressive nature
of the disease constitutes a basis to obtain the essential biological system-specific
information to determine the neuroprotective properties of new drugs,
preclinically. In this review we have summarised the currently available animal
models of Parkinson’s disease. An animal model of Parkinson's disease should
reproduce the main characteristics of the human disease, such as (1) selective
lesion of dopaminergic neurons that evolves over time; (2) depletion of dopamine
from the striatum; (3) presence of LBs in the remaining dopaminergic neurons,
and (4) easily detectable motor deficits (Bohlen Und, 2005; Yuan et al., 2005).
Although all of the models display some means of damage to the nigrostriatal
dopaminergic system (Table 1), causing a decrease of striatal dopamine, only the
MPTP and rotenone models have shown to develop LB-like inclusion bodies.
However, when MPTP-treated animals developed  α-synuclein inclusion bodies,
these were not conform the distinctive architecture of LBs in Parkinson's disease
(Maries et al., 2003). MPTP, 6-OHDA and rotenone can be applied to induce a
(sub)chronic disease progression. For MPTP, the chronic MPTP-mouse protocol
mirrors most closely the pattern of progression assumed to be that of Parkinson's
disease and appears useful (Bezard et al., 1997). In the case of 6-OHDA, an
intrastriatal injection causes a slow, progressive, induced neuron death with the
disadvantage that is is retrogradely and thus not displaying the normal disease
progression which is from the SNc to the striatum and not vice versa. Given this,
rotenone seems to be the best candidate for the development of an animal model
for Parkinson's disease with a slow, progressive induction of the disease.
Rotenone is usually administered systemically. Due to its inconsistent and
unpredictable effect on the nigrostriatal pathway, the chronic (systemic)
administration of rotenone is not yet suitable to become a routine animal model
for Parkinson's disease (Bove et al., 2005). Next to genetics (Perier et al., 2003),
various factors such as age (Phinney et al., 2006; Richter et al., 2007), rat species
(Betarbet et al., 2000; Schmidt and Alam, 2006) and even environmental
temperature (Crutchfield and Dluzen, 2006) might contribute to the variability in
results. An alternative approach is when rotenone is administered directly into
the brain. Although this does not represent the natural exposure to environmental
toxins, it might develop into an animal model which could be applied in
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preclinical (PK-PD) studies in the search for neuroprotective strategies for
Parkinson's disease. Either way, rotenone was able to induce Parkinson's disease
symptoms such as catalepsy, postural changes and decreased locomotion (Alam
and Schmidt, 2004). These modes of administration cause a slow degeneration
which makes it suitable to study neuroprotective agents (Schmidt and Alam,
2006).
An unilateral model using rotenone would create a model where the contralateral
side serves as an internal control. Caution should be made, however, as this side
may also be influenced by the lesion. Using intracerebral microdialysis,
extracellular, unbound concentrations of endogenous compounds (e.g.
biomarkers for Parkinson's disease or BBB functionality) as well as of exogenous
compounds (e.g. antiparkinson drugs or marker compounds for specific transport
mechanisms of the BBB) could be quantified simultaneously at various time point
during the progression of the disease. Any, or a combination, of the behavioural
tests may be applied for the unilateral lesioned animal model although one should
always take the influence of a microdialysis probe on the behaviour into
consideration, if applicable. 
A bilateral model using rotenone (administration either systemically or
intrecerebrally) would give a more realistic representation of the human disease
progression and behaviours. A separate control (sham-lesioned) group of animals
would be needed for comparison of brainECF concentrations of endogenous or
exogenous compounds as well as for the behavioural experiments. In the latter
case, not all of the summarised tests as described here, can be applied. The grip
strength test, the catalepsy test and the rotorod test are suitable for use in the
bilateral animal model. The staircase test may be applied to determine the
difference in the total amount of food pellets taken between control and lesioned
rats, irrespective of which paw was used. Similarly with the stepping test, where
the number of total adjusting steps could be counted between control and
lesioned rats, again, irrespective of which paw was used. 
The data obtained from these experiments give information on processes on the
causal path between drug administration and response (e.g. target site
distribution, target binding and activation, transduction/homeostatic feedback
and diseases processes/progression). With this, mechanism-based PK-PD models
can be developed which can have properties for extrapolation and prediction in
systems pharmacology research (Danhof et al., 2007). Systems pharmacology aims
at the development of an understanding of the interactions between
pathophysiology and drug action. To date most PK-PD modeling research has
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focused on healthy systems. The use of a chronic animal model for Parkinson's
disease is a first step in the characterisation of drug effects on disease processes
and disease progression. The next particularly intriguing challenge is the
prediction of drug effects on disease progression in man from this preclinical
research. 
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Abstract
In search for a suitable rat model to study alterations in blood-brain barrier (BBB)
transport mechanisms in the course of Parkinson’s disease progression,
experiments were performed to characterise Parkinson’s disease and safety
markers following subcutaneous (SC) and intracerebral (IC) infusion of the toxin
rotenone in the rat. Studies were performed using male Lewis rats. SC infusion of
rotenone (3 mg/kg/day) was performed via an osmotic minipump. IC infusion of
rotenone occurred directly into the right medial forebrain bundle (MFB) at three
different dosages. At different times following rotenone infusion, behaviour,
histopathology (tyrosine hydroxylase (TH) and α-synuclein immunocyto-
chemistry), peripheral organ pathology (adrenals, heart, kidney, liver, lung,
spleen and stomach) were assessed. In part of the SC and IC rats, BBB transport
profiles of the permeability marker sodium fluorescein were determined using
microdialysis. SC rotenone failed to produce dopaminergic lesions and led to
extensive peripheral organ toxicity.  BBB permeability for fluorescein following
SC rotenone was changed due peripheral toxicity. In contrast, IC rotenone
produced a progressive lesion of the nigrostriatal dopaminergic pathway over 28
days with no associated peripheral toxicity. IC rotenone also exhibited a large
increase in amphetamine induced rotational behaviour. In addition, a few IC rats
showed α-synuclein immunoreactivity and aggregation. Following IC rotenone,
no changes in passive BBB permeability were detected after 14 days. SC rotenone
only produced peripheral toxicity affecting BBB permeability. IC rotenone
appeared to create a progressive lesion of the rat nigrostrial pathway, and may
therefore be a more appropriate model of Parkinson's disease progression,
compared with the most commonly used 6-OHDA rat model. 
1. Introduction
Parkinson's disease is a chronic, progressive neurodegenerative disease in which
nigrostratial dopaminergic neurons are gradually lost, leading to a decrease in
dopamine concentration in the striatum (Dauer and Przedborski, 2003). It is the
second most common neurodegenerative disease and its current therapy focuses
mainly on symptomatic treatment by replacing the loss of dopamine in the
striatum (Mercuri and Bernardi, 2005) by L-DOPA, the dopamine precursor. The
main goal for future treatment of Parkinson's disease is the discovery and
development of neuroprotective/neurotrophic drugs to diminish or, better, to
halt the disease progression (Bonuccelli and Del Dotto, 2006; Chen and Le, 2006).
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An important consideration for the development of neuroprotective drugs for the
treatment of Parkinson's disease is the relationship between disease progression
and the pharmacokinetic and pharmacodynamic (PK-PD) properties of the drug.
In the PK-PD relationship of anti-Parkinsonian drugs a number of factors are of
importance. One factor is transport of the drug across BBB. Drug transport
between blood and the brain is governed by a number of BBB transport
mechanisms as described in Chapter 2 of this thesis.
BBB functionality is dynamically controlled by blood components and the
surrounding brain cells by direct contact or indirectly by their extracellular
products. Thus, BBB functionality may vary among different physiologic,
pathologic, and chronic drug treatment conditions, and this may affect the BBB
transport of the drug.
It is important to reveal in which direction and to what extent the different BBB
transport mechanisms (and actual BBB transport of a drug) are influenced by
Parkinson's disease progression. This should be adressed in a systematic manner,
in relation to the physico-chemical properties of the drug. To that end preclinical
studies are needed using an adequate animal model of Parkinson’s disease in
which Parkinson’s disease progression can be identified. The most widely used
animal models of Parkinson's disease are neurotoxin models with MPTP (mice,
cats and primates) or 6-OHDA (mice, rats, cats and primates) (Chapter3, Beal,
2001). These models are generally acute (Betarbet et al., 2002; Schober, 2004), but
in some cases MPTP subchronic models in both primates and mice have been used
(Schober, 2004). Recently, a mouse Parkinson's disease model was introduced in
which MPTP was continuously administered through an osmotic minipump
(Fornai et al., 2005). This models appears to have the advantage over the other
MPTP models that there is formation of inclusion bodies in the SNc. Although
these data look very promising, it has not yet been described elsewhere. 
An intrastriatal injection of 6-OHDA seems to also show a more progressive
degeneration of nigral dopaminergic cells compared to intranigral injections or
injections into the MFB (Sauer and Oertel, 1994; Cicchetti et al., 2002). However, no
Lewy body formation has yet been observed in any of the 6-OHDA models. Other
approaches, which have extensively been reviewed elsewhere (Betarbet et al.,
2002; Uversky, 2004) include the genetic models of Parkinson's disease and the use
of reserpine, methamphetamine, 3-nitrotyrosine paraquat in combination with
maneb and rotenone to induce Parkinson-like symptoms. The SC infusion of
rotenone to induce Parkinson's disease in the rat neurons has been reported, in




Table 1: Setup of the experiments performed for the subcutaneous and intracerebral rotenone
models. In the experiments for the subcutaneous model a 3 mg/kg/day dose of rotenone was used.
In the experiments for the intracerebral rotenone model, three doses were used unless otherwise
indicated: 0.5 µg, 2.0 µg and 5.0 µg.
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which a gradual increase in striatal dopaminergic denervation with associated
α-synuclein-positive cytoplasmic inclusions in nigral neurons (Betarbet et al.,
2000; Sherer et al., 2003). Most recently, the IC infusion of rotenone into the MFB
or SNc has been reported to affect the nigrostriatal pathway and produce deficits
which were reversed by L-DOPA (Alam et al., 2004; Antkiewicz-Michaluk et al.,
2004; Saravanan et al., 2005; Sindhu et al., 2005). 
In this study, we have first investigated the influences of SC administration of
rotenone (3 mg/kg/day) via an osmotic minipump in the rat on bodyweight and
behaviour (locomotor activity) as measured frequently within a period of 4 weeks.
Within this period, at different time intervals, rats were sacrificed and brains were
used to assess nigrostriatal damage based on immunohistological staining on
tyrosine hydroxylase, while in addition for all rats peripheral organ pathology
was determined. In a separate experiment, at 14 days of SC administration of
rotenone, BBB permeability was assessed using sodium fluorescein as a marker.
In a last experiment, peripheral organ pathology was performed to determine the
effect of 3 mg/kg/day rotenone systemically. In a subsequent series of
experiments, the influence of IC administration of rotenone in the MFB at three
different doses of rotenone (0.5, 2.0 and 5.0 µg) on nigrostriatal damage
(immunohistological staining on tyrosine hydroxylase) was determined. To be
able to compare these results to the results obtained in the experiments using the
subcutaneous rotenone model, we carefully monitored bodyweight and
peripheral organ pathology was also performed on these rats. After confirming
we were producing a suitable lesion we used the highest rotenone dose (5.0 µg) in
behavioural experiments and in a microdialysis experiment using sodium
fluorescein as a BBB permeability marker. A summary of all the experiments
which are presented in this paper is shown in Table 1. 
2. Materials and Methods
Statement on use and care of animals
The experiments described in this paper were approved by the Ethical Committee
on Animal Experimentation of the University of Leiden (DEC numbers 118 and
5069). For all experiments (Table 1) inbred adult male Lewis rats (250-300 g,
Charles River BV, Maastricht, The Netherlands) were used. The rats were housed
in standard plastic cages (six per cage before surgery and individually after
surgery) with a normal 12-hour day/night schedule (lights on 7:30 AM) and a
temperature of 21°C. The animals had access to standard laboratory chow (RMH-
TM; Hope Farms, Woerden, The Netherlands) and acidified water ad libitum.
Surgical methods
Placement of osmotic minipumps
In these experiments, the rats were inplanted with an Alzet osmotic minipump
(2ML-4, Alzet CR, Maastricht, The Netherlands) placed subcutaneously on the
back of the rat. For the rats in the microdialysis experiment, the pump was placed
7 days after microdialysis surgery. The osmotic minipump was filled with either
3mg/kg/day Rotenone (Pestanal, Sigma Alldrich BV, Zwijndrecht, the
Netherlands) dissolved in a 1:1-mixture of dimethylsulfoxide (DMSO, Sigma
Alldrich BV, Zwijndrecht, the Netherlands) with polyethylene glycol (PEG 200,
Sigma Alldrich BV, Zwijndrecht, the Netherlands) as the vehicle (DMSO:PEG;
1:1), or filled with the vehicle alone or saline (0.9% NaCl). 
Pumps were incubated in sterile saline at 37 °C overnight. For the implantation,
rats were deeply anesthetised using isoflurane (Forene, Abbott B.V., Hoofddorp,
The Netherlands). The Alzet osmotic minipumps were implanted under the skin
on the back of the rat. The rats were weighed on regular basis to monitor general
well-being. Rats were euthanised either after 7, 14, 21 or 28 days or after the
development of hunched posture suggestive of abdominal pain and upon
inadequate feeding or grooming, suggestive of ongoing toxicity.
Implantation of blood cannulas 
The surgery for the microdialysis study was performed under anesthesia with an
intramuscular injection of 0.1 mg/kg medetomidine hydrochloride (Domitor 1
mg/ml, Pfizer, Capelle a/d IJssel, The Netherlands) and 1 mg/kg ketamine base
(Ketalar 50 mg/ml, Parke-Davis, Hoofddorp, The Netherlands). Two indwelling
cannulae (pyrogen-free, nonsterile polyethylene tubing, Portex Limited) were
implanted, one in the left femoral artery and one in the left femoral vein. The
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cannula in the left femoral vein was used for administration of fluorescein,
whereas the cannula in the left femoral artery was used for serial collection of
arterial blood samples. The cannulae were tunneled subcutaneously and fixed at
the back of the neck with a rubber ring. The skin in the neck was stitched with
normal sutures. The skin in the groin was closed with wound clips. 
To prevent clotting and cannula obstruction, the cannulae were filled with a 25%
(w/v) polyvinylpyrrolidone solution (PVP; Brocacef, Maarssen, The Netherlands)
in pyrogen-free physiological saline (B. Braun Melsungen AG, Melsungen,
Germany) containing 20 IU/ml heparin (Hospital Pharmacy, Leiden University
Medical Center, Leiden, The Netherlands). After the implantation of the cannulae,
the rats were placed in a stereotaxic frame and the skull was exposed for brain
surgery.
Microdialysis surgery for the subcutaneous model
After the implantation of the cannulas, a small hole was drilled to allow the
implantation of a microdialysis guide cannula (CMA/12, Aurora Borealis Control
B.V. Schoonebeek, The Netherlands) in the striatum (relative to bregma (Paxinos
et al., 1985):  AP: +0.4; L: +3.2; V: -3.5). Two support screws were placed to hold
the guide, which was glued to the skull with dental acrylic cement (Howmedia
simplex rapid + methylacrylate, Drijfhout, Amsterdam, The Netherlands). The
osmotic minipump was placed 7 days after the microdialysis surgery and the
experiment was carried out 14 days after pump implantation.
Microdialysis surgery for the intracerebral model
After the implantation of the cannulas, the rats received a unilateral infusion into
the right MFB (AP: -2.8; L: +2.0; V: -9.0 relative to bregma; (Paxinos et al., 1985)) at
a rate of 0.1 µl/min for 30 minutes of either vehicle (DMSO/PEG, 1:1; n=8;
referred to as sham) or 5.0 µg of rotenone (n=12). After the infusion, the needle
was kept in place for another 5 minutes to allow diffusion of the fluid without
leakage along the track of the needle. Subsequently, two small holes were drilled
into the skull to allow implantation of a microdialysis guide cannula (CMA/12,
Aurora Borealis Control B.V. Schoonebeek, The Netherlands) in the left and in the
right striatum relative to bregma (AP: +0.4; L: +/-3.2; V: -3.5, relative to bregma;
(Paxinos et al., 1985)). 
One support screw was placed as an extra anchor for fixation of the guide, which
was glued to the skull with dental acrylic cement (Howmedia simplex rapid +
methylacrylate, Drijfhout, Amsterdam, The Netherlands). The microdialysis
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experiment was carried out 14 days after microdialysis surgery.
Experimental methods
Subcutaneous model: Behavioural experiment
For this study (in total n=108), the rats received an Alzet osmotic minipump filled
with either rotenone in vehicle (n=60, for a dose of 3mg/kg/day), vehicle alone
(n=24), or saline (n=24). For each treatment, the rats were divided into 4 groups
with different treatment durations of respectively 4, 14, 21 and 28 days after which
the rats were given an overdose of Nembutal (Natriumpentobarbital 60 mg/ml,
Ceva Sante Animale, Naaldwijk, The Netherlands) and the thorax was opened
and the rat was perfused with 30 ml of saline followed by 30 ml of 10% phosphate
buffered formalin (pH=7.0) via the left ventricle of the heart. Brains were removed
for histopathology. During the entire course of the experiment, the bodyweight of
the rats was monitored daily from Monday to Friday (Table 1). Before
implantation of the minipump, the rats were trained daily for two weeks on the
Rotarod (Ugo Basile, Comerio, Italy). After implantation, the rats' ability to stay
on the Rotarod was tested on a daily basis during the week, in two sessions.
Before the first session the rat was weighed, and then placed on the drum of the
Rotarod with the head facing in the direction opposite to the direction of rotation.
This forced the rat to move forward in order to stay on the rotating drum. The
drum was started at a speed of 2 rotations per minute (r.p.m) and accelerated
every 30 seconds to a final maximum speed of 20 r.p.m. after 5 minutes. At this
time, the session was ended and the rat was allowed  to recover for a 30 minute
period before the second session was started. As a behavioural read-out, the time
that the rat was able to stay on the drum was recorded. All rats that were unable
to remain on the Rotarod for at least 250 seconds before the start of the treatment
were excluded from data analysis.
Intracerebral model: Behavioural experiment
For this study, male Lewis rats received a unilateral infusion into the MFB of
either DMSO/PEG (1:1; n=8; vehicle) or 5.0 µg of rotenone (n=12). Approximately
21 days after rotenone infusion the animals were placed in automated rotometers
(Med. Associates Ltd.).  The apparatus consisted of perspex bowls where each rat
was linked to a harness carrying an infrared sensor at the top connected to a
computer with ROTORAT software. The animals were tested for rotations in
absence (baseline) and in the presence (stimulation) of amphetamine (5 mg/kg
i.p.) to evaluate the effects of rotenone treatment on stimulant-induced rotations.
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On the day of sacrifice (day 28), the animals were given an overdose of anaesthetic
and the thorax was opened and perfused with 30 ml of saline followed by 30 ml
of 10% phosphate buffered formalin (pH 7.0) via the left ventricle of the heart.
Brains were removed for histopathology.
Microdialysis experiment
At 18-24 hours prior to the experiment, the microdialysis probes (CMA12,
membrane length of 4.0 mm; Aurora Borealis Control B.V. Schoonebeek, the
Netherlands) were gently inserted into the guide cannulas after removal of the
probe dummies.
The microdialysis experiment was started between 7:00 and 8:00 a.m. The inlets of
both microdialysis probes were connected by FEP tubing (fluorinated ethylene
propylene tubing; internal volume of 1.2 µL/100 mm length; Aurora Borealis
Control B.V. Schoonebeek, the Netherlands) to syringe pumps (Beehive, Bas
Technicol, Congleton, United Kingdom). The probes were perfused with aECF
(composition in mM: NaCl 145; KCl 2.7; CaCl2 1.2; MgCl2 1.0; ascorbic acid 0.2 in
a 2 mM phosphate buffer pH 7.4 (Moghaddam and Bunney, 1989) at a flow rate
of 2 µl/min. The outlets consisted of fused silica tubing (I.D. 150 µm, O.D. 375 µm;
Composite Metal Services Ltd, Iikley, United Kingdom) and were connected to a
microsample collector (Univentor 820; Antec, Leiden, The Netherlands), in which
the samples were collected and cooled (4ºC). After a stabilisation period of 60
minutes, the in vivo recovery of fluorescein was determined by the retrodialysis
method. For this purpose, the probes were first perfused with a fluorescein
solution (10 or 20 ng/ml in aECF) for 60 minutes to collect 6 fractions. The relative
loss of fluorescein was calculated as an average of this period. After this period,
the syringes were switched to blank aECF for the washout phase of 90 minutes.
After the washout period, the intravenous administration of fluorescein was
started. The venous cannula was connected to a syringe containing fluorescein
(Sigma Alldrich BV, Zwijndrecht, the Netherlands) in saline (0.9% NaCl). For a
dose of 6 mg/kg of fluorescein, a 2-minute intravenous infusion was started at a
rate of 50 µl/min. In the first 120 minutes of the experiment, microdialysis
fractions were collected at 10-minute intervals and from 120-180 minutes and
from 180-240 minutes at 20- and 30-minute intervals, respectively. Blood samples
(50 µl in heparinised Eppendorf vials) were taken at 0, 0.5, 2, 4, 6, 8, 10, 15, 20, 25,
30, 45, 60, 90, 120, 180 and 240 minutes after start of the fluorescein infusion. The
blood samples were centrifuged for 10 minutes at 5000 r.p.m. and the plasma was
pipetted into Eppendorf vials. All samples were stored at -20 C. 
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Histopathology
TH immunohistochemistry was performed to quantify the degree of
dopaminergic neurodegeneration. In short, the brains were cut twice into 6-mm
segments using a rodent brain matrix, processed, and embedded in paraffin wax.
Coronal sections (8 µm) were cut through the striatum (at 1.2 mm caudal to
bregma) and the SNc (from -4.5 to -6.2 mm caudal to bregma) (Paxinos et al., 1985)
with a sledge microtome (Microm, Walldorf, Germany). The sections were
deparaffinised and rehydrated and endogenous peroxidase was quenched with
0.3% H2O2 for 30 min. The slides were placed in pepsin (0.2 g of Sigma-p-7000
pepsin in 50 ml of 0.01 M HCl) for 30 min, washed, and non-specific binding was
blocked with 1.5% normal goat serum (Vectastain rabbit IgG ABC kit; Vector
Laboratories, Burlingame, CA). This was followed by the application of the
primary rabbit polyclonal anti-tyrosine hydroxylase antibody (AB152 incubated
for 18 h at room temperature; Chemicon International, Temecula, CA), the
secondary biotinylated antibody (Vectastain rabbit IgG ABC kit for 30 min) and
the horseradish peroxidase conjugate (Vectastain rabbit IgG ABC kit for 30 min).
Visualisation was carried out using 3,3'-diaminobenzidine (Vector SK-4100 Vector
Laboratories, Burlingame, CA) as a chromogen. The slides were coverslipped
using DPX mountant. Adjacent nigral sections were immunostained for 
α-synuclein using an anti-α-synuclein (1:200, AB15530, Abcam, UK).
After staining, striatal sections were scanned using SprintScan 35 with PathScan
Enabler™ at a resolution of 1012 dpi. Optimas 5.2 software was used to measure
the optical density of manually-defined areas of each black and white image
produced as a mean grey value (MGV). TH-IR was measured for the slide
(background), cortex (control tissue staining), corpus callosum (control non-
cellular staining), dorsal striatum (caudate putamen, CPu) and ventral striatum
(nucleus accumbens, NAcc). The values were adjusted for non-specific staining by
subtracting the MGV of the corpus callosum or cortex, an area that should have
no specific TH-staining. Values obtained were entered into a spreadsheet sorted
by treatment group, and the mean, standard deviation and standard error (sem)
calculated using formulas. These means and errors were subsequently plotted and
unless otherwise stated, all striatal TH-IR values are corrected for cortical TH-IR.  
A series of sections through the SN (-4.5 mm -6.2 mm) were evaluated and
stained.  After careful evaluation under the microcope the TH-positive cells
within the SNc were counted at one selected stereotaxic level (-5.2 to 5.4 mm
caudal to bregma) in both vehicle treated and the rotenone-lesioned animals. The
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cells were counted manually using a digital camera (Hitachi HV-C20A) attached
to a light microscope (LEICA DMLB, Leica Microsystem Wetzlar GmbH) at ×20
magnification and the lesioned side is expressed as a percentage of the intact side.
Light microscopy was also used to provide a qualitative assessment of the
presence of α-synuclein in the SNc in the intracerebral experiment.
Peripheral organ pathology
The pathological evaluation of the brain and peripheral organs of the
subcutaneous experiment was performed on 56 rats and of the intracerebral
experiment on 96 rats (Table 1). After 7, 14, 21 or 28 days of treatment (for the
subcutaneous experiment only 14 or 28 days), the animals were given an overdose
of Nembutal (Natriumpentobarbital 60 mg/ml, Ceva Sante Animale, Naaldwijk,
The Netherlands) and the thorax was opened and the rat was perfused with 30 ml
of saline followed by 30 ml of 10% phosphate buffered formalin (pH=7.0) via the
left ventricle of the heart.  Adrenals, heart, kidney, liver, lung, spleen and stomach
were removed and immersed in 10% neutral buffered formalin (pH=7.0), trimmed
after adequate fixation according to a standard operating procedure inspired from
the Registry of Industrial Toxicology Animal-data (RITA) standards (Bahnemann
et al., 1995), and appropriate samples routinely processed to tissue blocks
embedded with paraffin wax. Tissue sections were cut at approximately 3 µm,
stained with Harris' hematoxylin and eosin (HE), Oil red O for neutral fat and Von
Kossa's stain for mineral/calcium deposits and examined by light microscopy for
relevant changes by a pathologist, without knowledge of the treatment status.  
Analysis of Fluorescein
The plasma and microdialysate samples obtained in the subctaneous model
experiment were analysed for fluorescein concentrations by HPLC with
fluorescence detection. The HPLC system comprised a PSS Suprema size
exclusion column (8x300 mm, 10 µm particle size), with a mobile phase of 0.05 M
ammoniumacetate (pH=9.0) and acetonitrile (4:1 v/v). The flow rate was
maintained at a flow of 1.5 ml/min. The detection was performed using a
fluorescence detector (LC240, Perkin Elmer, United Kingdom) with the excitation
wavelength set at 488 nm and the emission wavelength set at 512 nm. The
microdialysate samples (15 µl) were injected directly onto the HPLC column. For
the analysis of the plasma samples, 10 µl of plasma was added to 990 µl of an
icecold artificial extracellular fluid (described above) and vortexed for 10 seconds.
A 50 µl aliquot of this mixture was injected directly onto the HPLC system
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equipped with a refill guard column (2 mm I.D. x 20 mm) (Upchurch Scientific,
Oak Harbor, WA, USA) packed with C18 (particle size 20-40 µm) (Alltech, Breda,
The Netherlands). 
For the analysis of fluorescein in plasma and microdialysate samples from the
intracerebral experiment, we developed an assay using the Fluostar Optima,
which was a fast and reliable method. The results of the validation of this assay
are presented in Table 2. The detection limit was 0.08 ng/ml. For the analysis of
the microdialysate samples, 10 µl microdialysate was pipetted onto a black 96-
well plate (FIA-plate flat bottom/medium binding, Greiner, Alphen a/d Rijn, The
Netherlands) and 40 µl of a 0.25 M NaOH solution was added. For the analysis of
the plasma samples, an aliquot of 10 µl plasma was pipetted onto a black 96-well
plate and 90 µl of a 0.1 M NaOH solution was added. The fluorescence intensity
was measured on the Fluostar Optima (BMG Labtech, Offenburg, Germany) at the
emission wavelength of 530 nm and the excitation wavelength of 480 nm. 
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Table 2: Validation of the determination of fluorescein: intra-assay and inter-assay variability,
coefficients of variability and accuracy
Statistical analysis
All data were statistically evaluated for significance by one-way analysis of
variance (ANOVA) and a Tukey-Kramer multiple comparison test except for the
microdialysis fluorescein data from the subcutaneous experiment which were
evaluated using Student's t-test due to the small sample size of the saline and
vehicle groups. Values of P<0.05 were considered significant.
3. Results
Subcutaneous model: bodyweight and locomotor activity
The subcutaneous infusion of rotenone produced a time-related reduction
(P<0.001) in bodyweight of rotenone treated rats, compared with vehicle- or
saline-treated rats (Figure 1). This reduction was most pronounced in the first 10-
14 days following the start of the treatment. Behavioural analysis using the
Rotarod was performed at various time points after infusion of saline, vehicle or
rotenone (Figure 2A). The analysis was based on the time-period in which the rat
was able to remain on the Rotarod (latency time). Results were categorised into 3
panels; panel 1 for latency times ranging between 0 and 100 sec, for panel 2
between 100 and 200 sec, and for panel 3 between 200 and 300 sec. In saline-
treated rats and vehicle-treated rats only 2-3% of the animals had a Rotarod
latency lower than 100 seconds whereas in rotenone-treated rats this number had
increased to 30% (panels A1, B1, C1). Also, 77% of the saline-treated rats and 86%
of the vehicle treated rats were able to stay on the apparatus for more than 200
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Figure 1: (LEFT panel) The effect of the subcutaneous infusion of (o) saline, ( ) vehicle
(DMSO/PEG) and (•) 3.0 mg/kg/day rotenone on bodyweight over time. The data are expressed
as mean values ±SEM. Statistical analysis (one-way ANOVA) showed no significant difference in
weight between all treatment groups on day 0 (P>0.05) and no significant change between the
saline and vehicle groups for any time point (P>0.05). Significant differences were observed
between the rotenone treated group and the saline treated group (P<0.001) or vehicle treated group
(P<0.001) for all time points. (RIGHT panel) The effect of an intracerebral infusion of (o) artificial
ECF, (• light grey) 0.5 µg rotenone, ( ) 2.0 µg rotenone or ( ) 5.0 µg rotenone (n=24) on the
bodyweight over time. The data are mean values±SEM. Statistical analysis (one-way ANOVA)
showed no significant difference between all groups.
seconds, but only 45% of the rotenone-treated rats were able to stay on the
Rotarod for that period of time (panels A3, B3, C3). Therefore, rotenone-treatment
impaired Rotarod performance, with a greater percentage of these animals falling
off the apparatus at early time points and fewer animals staying on for the full
testing period (300 seconds).
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Figure 2A: Behaviour in the subcutaneous rotenone model: The time that a rat was able to remain
walking on the Rotarod at different days following implantation of the osmotic minipump in (o)
saline treated rats, ( ) vehicle (DMSO/PEG)-treated rats, ( ) 3.0 mg/kg/day rotenone-treated
rats. Panels A1-C1 represent the amount of data points in the 0-100 seconds region. Panels A2-
C2 represent the amount of data points in the 100-200 seconds region. Panels A3-C3 respresent
the amount of data points in the 200-300 second region.
Intracerebral model: bodyweight and rotational behaviour 
The effect of the intracerebral infusion of either aECF, 0.5 µg rotenone, 2.0 µg
rotenone or 5.0 µg rotenone into the MFB on the bodyweight of the rat (Figure 1)
indicated that was a decrease in bodyweight of about 10-15% in all treatment
groups in the first 2 days after surgery. However, from 2 days onwards until the
end of the experiment (day 28) the bodyweight increased as normal in all
treatment groups and overall there were no statistically significant differences
among the various treatment groups. In agreement with this, the experimenter's
observations of the rats with regard to grooming indicated no noticeable
differences among control rats and rotenone treated rats. To determine the
behavioural consequences of intracerebral infusion of rotenone, we performed an
experiment in which we measured amphetamine (5 mg/kg i.p.) induced rotations
in rats infused with 5.0 µg of rotenone and compared these results to sham
(=DMSO/PEG; 1:1) infused rats (Figure 2B). The left panel depicts the mean total
rotation score and the right panel illustrates the time course of the rotations for
both the sham infused rats and the rotenone infused rats. The baseline of both
groups, measured before the injection of amphetamine, shows no preference of
any group for a particular side. However, after the amphetamine challenge the
rotenone infused had a large and significant increase in the number of ipsiversive
rotations.
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Figure 2B: Behaviour in the intracerebral rotenone model: Amphetamine (5 mg/kg i.p.) induced
rotations measured on day 21 after infusion of either sham (DMSO/PEG; 1:1) or 5µg of rotenone
into the MFB. Left panel depicts the mean total rotation score (±SEM) after amphetamine injection
and the right panel shows the mean asymmetry score over time after amphetamine injection.
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Table 3: The effect of a subcutaneous infusion of saline (n=6 per timepoint), vehicle (n=6 per
timepoint) or 3 mg/kg/day of rotenone (n=15 per timepoint) on the intensity of the striatal TH-
immunoreactivity. The effect of different doses of rotenone (n=8 per dose and per timepoint) and
artificial ECF (n=8 per timepoint) infused into the MBF on the percentage (lesioned vs. intact
brain side) striatal TH immunostaining in time. 
Table 4: The effect of a subcutaneous infusion of saline (n=6 per timepoint), vehicle (n=6 per
timepoint) or 3 mg/kg/day of rotenone (n=15 per timepoint) on the nigral cell count. The effect of
different doses of rotenone (n=8 per dose and per timepoint) and artificial ECF(n=8 per timepoint)
infused into the MBF on the percentage (lesioned vs. intact brain side) nigral cell count in time. 
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Figure 3A: Intracerebral rotenone model: Images of tyrosine hydroxylase immunostaining of
coronal sections taken at the level of the striatum from aECF or rotenone-infused rats (0.5, 2.0 or
5.0 µg) taken 14 days after infusion. Each treatment group is represented by 4 rats, the left
striatum represents the intact side of the animal and the right striatum represents the lesioned side
of the same animal. The lowest (0.5 µg) and middle (2.0 µg) rotenone doses show partial
dopaminergic denervation whereas the highest rotenone dose (5.0 µg) had more pronounced loss
in staining and some rats had almost complete dopaminergic denervation.  
Histopathology
Subcutaneous model
Looking at the individual subcutaneous rotenone rat model data from the
behavioural and microdialysis experiments, only 2% of the rotenone-treated rats
showed any loss of TH staining in the striatum. The loss of striatal staining in
these particular rats showed a similar pattern to that reported by Betarbet
(Betarbet et al., 2000). No loss of cell bodies in the SNc of any animals in the
present studies was observed. The mean data for the striatum and SNc are shown
in Table 3 and Table 4, respectively. No significant difference was seen in the
mean striatal TH immunostaining of control, vehicle and rotenone treated rats or
in the mean number of TH positive cells in the SNc among these groups.
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Figure 3B: Intracerebral rotenone model: Images of tyrosine hydoxylase staining at the level of the
substantia nigra from aECF (a) or rotenone-infused rats (0.5 (b), 2.0 (c) or 5.0 (d) µg) on day 14
after infusion. The left hand images show the intact substantia nigra with higher magnification of
the cell bodies as insets. The right hand side shows the lesioned side of the brain with insets
showing a higher magnification of the cell bodies. There is a clear dose dependent loss in TH
positive cells and processes (see arrows) with increasing concentrations of rotenone.
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Figure 4: Intracerebral rotenone model: Examples of α-synuclein positive staining in the SNc of
rats that have received 0.5 µg (C and D), 2.0 µg (E and F) or 5.0 µg (G and H) rotenone or aECF
(A and B) into the left medial forebrain bundle (MFB, stereotaxic coordinates: AP: -2.8, Lat: +2.0,
V: -9.0) and killed off 28 days post surgery. Both the intact SNc (A, C, E and G) and the lesioned
SNc (B, D, F and H) are shown at 20x magnification. α-synuclein staining was visualised with
3-6-diaminobenzidine (DAB) with a haematoxylin counter stain.
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Figure 5: Intracerebral rotenone model: Examples of possible α-synuclein overexpression (o) and
aggregation (a) in dopaminergic cells compared to non-expressing cells (n) within the SNc of rats
with rotenone-induced lesions of the MFB. Images are at 100x magnification, α-synuclein was
visualised with DAB and a haematoxylin counterstain.
Intracerebral model
The histological evaluation of the intracerebral infusion of rotenone indicated that
there was no effect of the aECF infusion on the percentage of striatal TH
immunostaining (Table 3 and Figure 3A), while there was a dose-dependent
decrease in TH staining in rats with rotenone infusion. The dose-dependent
nature of the toxin effect was most pronounced on day 14 after infusion. However,
while the damage appeared to be progressive, there were no significant
differences among any of the rotenone doses on day 28 compared to day 14 and a
time-dependent decrease can only be observed for the 5.0 µg rotenone dose. Also,
there appears to 
be an increase in TH staining in both the striatum and SNc for the 2.0 µg dose
between day 14 and 28. The TH immunostaining of the SNc (Table 4 and 
Figure 3B) showed that aECF infusion did not alter the number of TH positive
nigral cells, but infusion of rotenone produced dose-dependent decrease in cell
number, although less pronounced than that observed in the striatum. 
Time related increase in incidence and severity of gastric mineralisation,
confirmed by a Von Kossa stain, was observed in the smooth muscles fibers, the
elastic connective tissue and occasionally in the glandular epithelial cells of the
muscular layer, the submucosa, the muscularis mucosae and glandular crypts of
the stomach (Figure 6A and Figure 6B). In the heart, minimal myofiber necrosis
characterised by significant coagulative necrosis of myofibers and an
inflammatory response was observed in two rotenone treated rats sacrificed on
day 14 (Figure 6C). In the liver, slight increase in centrilobular single cell necrosis
and/or inflammation was noted in 2 rats sacrificed on day 14, above what is
usually seen in overnight fasted albino rat controls (Figure 6D). A decrease in




Four rats (20%) died spontaneously after 3-5 days of rotenone administration (3.0
mg/kg/day). No peripheral organ pathology was performed on these rats. In the
surviving rats, significant treatment-related changes were observed in the
stomach and minor changes were observed in the liver and heart. These changes
were attributed to rotenone administration and are summarised in Table 5. Some
minor changes were also seen in the liver and adrenals. The latter changes were
most probably the consequence of decreased food consumption or complete
anorexia and stress, respectively.
Table 5: Subcutaneous rotenone model: Incidence (%) of rotenone-related histopathological
changes in Lewis rats (n=56) sacrificed on schedule.
The results of α-synuclein immunostaining of the SNc indicated that there were
α-synuclein positive cells in a few of the rotenone treated rats (Figure 4 and 
Figure 5). The α-synuclein staining was variable among rats while there were
more positive cells in some of the rotenone treated rats, without an increase 
α-synuclein staining in several others.
glycogen content was found in a majority of rats (Table 5), which was
characterised by a marked decrease or an absence of clear cytoplasmic spaces
without sharp outlines, a smaller size of hepatocellular trabeculae and was
accompanied by centrilobular hepatocellular atrophy in the most severe cases
(Figures 6E-F). Even though it is only of minor importance since it is anorexia-
related, the change was clearly the most dramatic in terms of incidence and
severity. In the adrenal, minimal multifocal mineralisation (calcification) was seen
in the cortex of a single rat sacrificed on day 28. 
Intracerebral model
For the intracerebral rotenone model, no dose or time related changes were
observed in the lungs, heart, liver, stomach, spleen, kidney or adrenals of rats
given up to 5.0 µg of rotenone up to 28 days, suggesting no peripheral toxicity.
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Figure 6: Subcutaneous rotenone model: 6A: Limiting ridge of the stomach, Lewis rat given 
3.0 µg/day of rotenone for 28 days. The muscularis and submucosa have extensive mineralisation
(arrow). Hematoxylin and Eosin (HE) stain. Original magnification 100x. 6B: Serial section of the
change observed in figure 6A stained according to von Kossa's method for calcium precipitates
(arrow). Original magnification 100x. 6C: Right ventricular free wall of the myocardium, Lewis
rat given 3.0 µg/day of rotenone for 14 days. Minimal focus of myocardial necrosis (arrowheads)
and adjacent perivascular mononuclear cell infiltration. HE. Original magnification 400x. 
6D: Median lobe of the liver of a Lewis rat given 3.0 µg/day of rotenone for 14 days. Slightly
increased single cell necrosis (inset) and slight inflammation (aggregates of mixed cells - arrow)
are observed in numerous centrilobular areas adjacent to the central veins (CV), along with slight
diffuse cytoplasmic hepatocellular vacuolation (arrowheads). Occasional focal widening of the
perivenous centrilobular spaces suggests loss of centrilobular hepatocytes. HE. Original
magnification 100x. 6E: Median liver lobe from a Lewis rat given saline for 14 days. Clear cells
with empty spaces (interpreted as washed-off glycogen storage) and a few vacuolation (interpreted
as lipid droplets) typical of normal liver of a non-fasted rat. CV: central vein. PV: portal vein. HE.
Original magnification 100x. 6F: Median lobe of the liver of a Lewis rat given 3.0 µg/day of
rotenone for 28 days. Simple severe thinning of hepatic cords due to hepatocellular atrophy, with
loss of clear cytoplasm and lipid vacuoles, interpreted as loss of glycogen content, typical of rats
with anorexia. HE. Original magnification 100x.




For the subcutaneous rotenone model, all microdialysis concentrations were
corrected for in vitro recovery (10.6 ± 0.7 %) in order to estimate brain extracellular
(brainECF) concentrations. No statistically significant difference was found in
concentration-time profiles or in area under the curves (AUC) in plasma among
any of the groups indicating that the treatment with rotenone or the vehicle had
no effect on the overall disposition of fluorescein (Figure 7A and Table 6).
However a significant difference in the estimated brainECF profiles was seen
between rotenone treated rats and saline treated rats (P<0.05) and between
vehicle-treated rats and saline-treated rats (P<0.01) from 80-150 minutes 
(Figure 8A). The BBB transport of fluorescein was calculated as the ratio of
AUCECF and AUCplasma multiplyed by 100%. The results are shown in Table 6.
No statistically significant difference was seen among all treatment groups.
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Table 6: Mean area under the curves (AUC in µg/ml*min) of the plasma and estimated
extracellular fluid (ECF) curves for both the subcutaneous rotenone model as well as the
intracerebral rotenone model as shown in Figure 7 and Figure 8. To determine transport of
fluorescein across the BBB, the AUCECF/AUCplasma ratio was calculated. The data are presented
as mean values ± SEM.
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Figure 7: (Left panel) Plasma fluorescein concentration (µg/mL) vs. time (min) on day 14 after
the subcutaneous infusion of (o) saline, ( ) vehicle (DMSO/PEG) or (•) 3.0 mg/kg/day rotenone.
The data are expressed as mean values ±SEM. (Right panel) Plasma fluorescein concentration
(µg/mL) vs. time (min) on day 14 after an intracerebral infusion of (o) artificial ECF or (•) 5.0
µg rotenone. The data are mean values±SEM. Statistical analysis (one-way ANOVA) showed no
significant difference between all groups for both rotenone models.
Intracerebral model
For the intracerebral rotenone model, the concentration-time profiles of
fluorescein in plasma are shown in Figure 7B. All microdialysate concentrations
were corrected for the average in vivo recovery as determined during the
retrodialysis period (25 ± 1 %) in order to estimate brainECF concentrations. The in
vivo recovery was equal for the two concentrations of fluorescein used. The
concentration-time profiles of fluorescein in brainECF are shown in Figure 8. No
significant differences were found in area under the curves (AUC) in plasma or in
brainECF among any of the groups indicating that the treatment with rotenone or
DMSO/PEG had no effect on the overall disposition of fluorescein (Table 6). No
statistical difference was observed in overall BBB transport of fluorescein among
any of the groups as indicated by the AUC ratios (Table 6).
4. Discussion
In this study we compared the subcutaneous and intracerebral administration of
rotenone to develop a rat model for Parkinson's disease. We examined brain
histology, peripheral toxicity, behaviour and BBB permeability. 
Subcutaneous model
The subcutaneous infusion of rotenone resulted in minor development of
dopaminergic lesions whereas profound peripheral organ toxicity was found.
Although the subcutaneous infusion seemed to affect locomotor behaviour and
seemed to induce an increase in BBB permeability compared to the control
infusion (saline and vehicle), these results could not be correlated to nigrostriatial
injury, but were most probably a consequence of peripheral organ toxicity. A
time-related increase in incidence and severity of mineralisation (calcification) in
the stomach was observed in rotenone-treated rats and is clearly related to the
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Figure 8: (Left panel) Microdialysate fluorescein concentration (µg/mL) vs. time (min) on day 14
after the subcutaneous infusion of (o) saline, ( ) vehicle (DMSO/PEG) or (•) 3.0 mg/kg/day
rotenone. A significant difference was seen (time>60 min) between rotenone- and saline treated
rats (P<0.05; Student's unpaired t-test) and between vehicle- saline treated rats (P<0.01;
Student's unpaired t-test).
(Right panel) Microdialysate fluorescein concentration (µg/mL) vs. time (min) on day 14 after an
intracerebral infusion of (o, ) artificial ECF or (•, ) 5.0 µg rotenone. Circles represent the
control-side of the brain and squares represent the infused side of the brain.The data are mean
values±SEM. Statistical analysis (one-way ANOVA) showed no significant difference between all
groups.
systemic rotenone administration. Since there were no significant kidney lesions,
the mineralisation is probably dystrophic secondary to cellular injury/necrosis,
instead of metastatic associated with hypercalcemia or systemic Ca/P imbalance
related to renal failure (uremia) (Cotran et al., 1999; Palmer, 1993). However, this
change would deserve further investigations to definitively rule out a metastatic
mechanism. The mineralisation (calcification) in the stomach of rotenone-treated
rats could be the consequence of mitochondrial injury due to inhibition of
complex I and/or oxidative stress and secondary calcium influx (Sousa et al.,
2003; Sousa and Castilho, 2005). The reason as to why the damaged is localised to
the stomach remains unsolved. A reduced blood-flow to the stomach as a result
of chronic excessive stomach distension could be an explanation, although
mucosal thinning which is indicative of excessive distension was not consistently
observed. This change has not been, to our knowledge, previously reported in rats
that received rotenone systemically. Stomach distension is usually a non-specific
change related to physiological demise, nausea (pica), severe stress or
exaggerated pharmacological effect and there were no morphological evidences
of atrophy of parietal cells, which could support the previously published
hypothesis of achloridria with decreased wall mass (Lapointe et al., 2004). The
observed cardiac changes in 2 rotenone treated rats were attributed to treatment,
since none were observed in any of the saline or vehicle treated rats and this
change is not common in albino rats of that age; however, a background change
cannot strictly be ruled out, since this change may occasionally be found in control
Fischer 344 or Sprague Dawley rats  (Boorman et al., 1990). Liver changes were
minor and related to decreased bodyweight with time and suspected decrease in
food consumption. All of these changes could be secondary to the gastric lesions,
especially the observed decrease in glycogen content. In addition, a few animals
had atrophy of hepatocellular cords along with increased single cell necrosis,
inflammation and hepatocellular microvacuolation. Although these changes
could be associated with starvation, a rotenone-related effect cannot be ruled out.
In contrast to a previous report with similar experimental conditions,
hepatocellular coagulative necrosis was not reported in this study (Lapointe et al.,
2004). 
The peripheral toxicity, high mortality and variability in the development of
dopaminergic lesions in the brain of systemically administered rotenone as we
have seen in our experiments is confirmed by literature (Betarbet et al., 2000;
Fleming et al., 2004; Hoglinger et al., 2003; Lapointe et al., 2004; Sherer et al., 2003;
Zhu et al., 2004) although it has not been so extensively investigated as in the
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experiments described in this paper. In conclusion, these results indicate that the
subcutaneous infusion of rotenone in the rat causes significant systemic toxicity,
notably important and adverse changes in the stomach and heart, while not able
to produce a sufficient amount of nigrostriatal damage as referred to as golden
standard for Parkinson's disease. 
Intracerebral model
The intracerebral infusion caused a progressive, dose-dependent decrease in
dopaminergic neurons to about 30% in 28 days, with in a few cases α-synuclein
immunoreactivity and aggregation but without any peripheral toxicity or any
effect on bodyweight. Although the α-synuclein inclusions were not directly
related to the severity of the dopamine lesions, they have not been observed in
previous experiments using an intracerebral infusion of rotenone (Alam et al.,
2004; Antkiewicz-Michaluk et al., 2004; Saravanan et al., 2005; Sindhu et al., 2005)
and this result is therefore one step closer to mimicking the human pathology of
Parkinson's disease. Saravan et al observed a dose-depentdent (2, 6 and 12 µg)
decrease was in striatal biogenic levels already on day 5 after the infusion
(Saravanan et al., 2005). In our studies, we used a lower concentration range which
may account for the fact that we do not see a clear dose-dependent decrease in the
first 4 to 7 days. Furthermore, the decrease TH staining in time is most evident at
5.0 µg, specifically in the SNc. In the striatum the decrease seems to reach a
minimal plateau after 28 days. Moreover, there appears to be an increase in TH
staining in both the striatum and SNc for the 2.0 µg dose between day 14 and 28.
This could perhaps be explained by the relatively low concentration infused, some
rats being less susceptible to rotenone and general variability wit this toxin.
Variability has also been observed in response to systemically treated rotenone
rats (Betarbet et al., 2000; Sherer et al., 2003). It would be of interest to look at
higher doses and for a longer period of time and perhaps compare different
strains of rats specifically for the infusion of rotenone into the MFB. The
amphetamine induced rotational behaviour of the intracerebral infused rotenone
rats (5.0 µg) showed a significant preference of these rats for rotating in the
ipsiversive direction on day 21 which was consistent with a unilateral lesion in the
brain dopaminergic system. These results were somewhat different from a study
by Sindhu et al. (2005) where they did not see any significant stereotypic rotations
in MFB-lesioned rats (12 µg) until day 28.  Again these difference may be due to
variation among rat strains (Lewis rats compared to Sprague-Dawley rats).    
In contrast to what would be expected on the basis of literature (Alexander et al.,
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1994; Carvey et al., 2005; Kortekaas et al., 2005), no difference in BBB permeability
was found in the striatum in the Parkinson's diseased brain at 14 days post-
injection. It remains to be answered if changes would occur at other post-injection
intervals or at other locations in the brain because microdialysis (being a good
technique to study BBB transport characteristics as it monitors in time (de Lange
et al., 1997; Hammarlund-Udenaes et al., 1997)) does not provide spatial
information. In our view further investigations on BBB transport mechanisms are
needed, to be performed in a strict mechanistic and quantitative manner, as a
function of the disease-state.
The intracerebral administration of rotenone creates the opportunity to develop
an animal model for Parkinson's disease, in which the toxin is delivered in its
target brain area thereby reducing side-effects in other parts of the body that may
interfere in the investigations, with features getting closer to those in Parkinson's
disease patients. However, upon local delivery of the toxin, the question remains
to be answered on how toxins which are capable of inducing Parkinson's disease
in human are able to reach their target in the brain. Further experiments to follow
the progression at longer post-injection intervals would be required to evaluate if
indeed there is further disease progression and further α-synuclein development
beyond 28 days. Since age seems to increase the sensitivity of dopaminergic
neurons to rotenone toxicity (Phinney et al., 2006), it would be worthwhile to
investigate this for the IC infused rotenone rats and the influence that age might
have on the development of α-synuclein inclusions.
Comparing these results to the more commonly used 6-OHDA model, in our
hands, 6-OHDA infusion into the nigral cell bodies (O'Neill et al., 2004) or into the
MFB (Visanji et al., 2006) produces a more rapid (5-10 days) loss in terminals. Also,
when infused into the SNc, 6-OHDA causes an anterograde degeneration of the
whole nigrostriatal dopaminergic system (O'Neill et al., 2004; Sachs and Jonsson,
1975), resulting in a more rapid loss of TH positive cells. Thus, the seemingly
slower effects of MFB infused rotenone obtained thusfar favours a more chronic
model than 6-OHDA. This might be due to differences in the solubility, stability,
and diffusion of the toxin or to the mechanism by which the toxin produces cell
death. 6-OHDA can be infused into the striatum and while a rapid loss in
dopamine terminals is observed, this model also produces slow progressive
retrograde damage to the nigral cells (Murray et al., 2003; Rosenblad et al., 1999),
however, so far no α-synuclein inclusions have been observed in this model. In
conclusion, the data presented here indicate that rotenone infused intracerebrally
is able to create a progressive rat model for Parkinson's disease.
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Abstract
The aim was to study the pharmacokinetics (PK) and blood-brain barrier (BBB)
transport in conjunction with the conversion of L-DOPA into DOPAC and HVA
in the rat rotenone model of Parkinson's disease. 
Male Lewis rats were unilaterally infused with rotenone in the medial forebrain
bundle (MFB). The contralateral side served as a control. After 14 days, L-DOPA
(10, 25 or 50 mg/kg) was intravenously infused. Blood samples and brain striatal
microdialysates were collected and analysed. Brains were histologically evaluated
on tyrosine hydroxylase staining to identify responders and non-responders.
Population PK analysis was performed by NONMEM to determine the influence
of the Parkinson's disease state on plasma PK, BBB transport of L-DOPA and
DOPAC and HVA levels in the brain. 
Rotenone infusion resulted in 71% of the rats developing neurostriatal
degeneration. The plasma PK of L-DOPA could be adequately described by a 
3-compartmental model. No difference was observed between BBB transport of 
L-DOPA in lesioned and untreated brain side. DOPAC and HVA basal
microdialysate levels were substantially lower in the lesioned striatum, while
also, following L-DOPA administration, their elimination rates were higher in
lesioned striatum. 
Our study demonstrates that Parkinson's disease-like pathology induced by
rotenone does not result in changes in the kinetics and BBB transport of L-DOPA.
Merely, a clear effect of disease on the levels and elimination rates of DOPAC and
HVA in brain were found, providing information on decreased dopamine
concentrations at the lesioned brain side.
1. Introduction
Parkinson's disease is a progressive neurodegenerative disease in which
dopamine-producing cells in the nigrostriatal pathway are affected. The chronic
and progressive decrease in dopamine concentration in the striatum leads to the
development of the classic symptoms of Parkinson's disease, such as tremor,
rigidity and bradykinesia (Dauer and Przedborski, 2003). The current therapies of
Parkinson's disease are mainly focussed on symptomatic treatment by replacing
the striatal dopamine (Factor, 2008; Nyholm, 2006; Savitt at al., 2006; Schapira,
2008). Among the antiparkinson drugs available, L-3,4-dihydroxyphenylalanine
(L-DOPA) is still considered the most efficacious treatment of Parkinson's
symptoms (Deleu at al., 2002; Factor, 2008; Nyholm, 2006; Schapira, 2008). 
Chapter 5
174
To investigate the mechanisms of action of antiparkinsonian drugs, one would
like to use a preclinical Parkinson's disease model that allows for investigation at
different stages of the disease. In chapter 4, we have explored the intracerebral
rotenone rat model for Parkinson's disease, which showed to be capable of
producing a relatively slow progressive degeneration of the nigrostriatal system
and was associated with the formation of inclusion bodies similar to that observed
in Parkinson's disease (Ravenstijn at al., 2008).
The goal of this study was to determine the PK in plasma, BBB transport, and
within-brain conversion of L-DOPA into dopamine and its major metabolites
DOPAC and HVA in this rat model for Parkinson's disease. The microdialysis
technique (de Lange at al., 1999; Hammarlund-Udenaes, 2000) was used to
measure free L-DOPA, dopamine, DOPAC and HVA concentrations. To examine
the influence of Parkinson's disease, two microdialysis probes were inserted in the
lesioned side and in the contralateral healthy side of the brain respectively.
Microdialysates were collected in parallel with serial blood samples.
Concentrations of the compounds were determined under basal conditions and
following i.v. administration of 10, 25 and 50 mg/kg of L-DOPA. At the end of the
experiment brains were removed for immunostaining on tyrosine hydroxylase
(TH) to determine responders and non-responders on the basis of the percentage
loss of dopaminergic terminals in the striatum in control and rotenone-infused
rats. A compartmental, population-based analysis was performed to determine
the influence of the Parkinson's disease state on plasma PK, BBB transport of 
L-DOPA and DOPAC and HVA levels in the brain. 
2. Materials and Methods
All animal procedures described in this paper were approved by the Ethical
Committee on Animal Experimentation of the University of Leiden (DEC
numbers 118 and 5069).
Animals and surgical procedures
Experiments were performed on male Lewis rats (Charles River BV, Maastricht,
The Netherlands) weighing 311 ± 17g (mean ± s.d., n=18) and 288 ± 13g (mean ±
s.d., n=17) before surgery and before start of the experiment, respectively. The rats
were housed in standard plastic cages (six per cage before surgery and
individually after surgery) with a 12-hour day/night schedule (lights on 7:30 AM)
and at a temperature of 21°C. 
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The animals had access to standard laboratory chow (RMH-TM; Hope Farms,
Woerden, The Netherlands) and acidified water ad libitum.
The surgery was performed under anesthesia with an intramuscular injection of
0.1 mg/kg medetomidine hydrochloride (Domitor 1 mg/ml, Pfizer, Capelle a/d
IJssel, The Netherlands) and 1 mg/kg ketamine base (Ketalar 50 mg/ml, Parke-
Davis, Hoofddorp, The Netherlands). Three indwelling cannulas (pyrogen-free,
nonsterile polyethylene tubing, Portex Limited) were implanted, one in the left
femoral artery (for blood sampling) and two in the left femoral vein (for drug
administration). The cannulas were tunnelled subcutaneously and fixed at the
back of the neck with a rubber ring. The skin in the neck was stitched with normal
sutures. The skin in the groin was closed with wound clips. To prevent clotting
and cannula obstruction, the cannulas were filled with a 25% (w/v)
polyvinylpyrrolidone solution (PVP; Brocacef, Maarssen, The Netherlands) in
pyrogen-free physiological saline (B. Braun Melsungen AG, Melsungen,
Germany) containing 20 IU/ml heparin (Hospital Pharmacy, Leiden University
Medical Center, Leiden, The Netherlands). 
After the implantation of the blood cannulas, the rats were placed in a stereotaxic
frame and the skull was exposed for brain surgery. The skull was cleaned and a
hole was burred to allow a needle to be lowered into the right median forebrain
bundle (MFB: AP: -2.8; L: +2.0; V: -9.0 relative to bregma (Paxinos at al., 1985)) for
unilateral infusion of 5.0 µg of rotenone (Rotenone Pestanal ; Sigma Alldrich BV,
Zwijndrecht, the Netherlands) at a rate of 0.1 µl/min for 30 minutes. Rotenone
was dissolved in a 1:1-mixture of dimethylsulfoxide (DMSO, Sigma Alldrich BV,
Zwijndrecht, the Netherlands) with polyethylene glycol (PEG 200, Sigma Alldrich
BV, Zwijndrecht, the Netherlands). After the infusion, the needle was kept in
place for another 5 minutes to allow diffusion of the fluid without leakage along
the track of the needle. Subsequently, two small holes were drilled into the skull
to allow implantation of a microdialysis guide cannula (CMA/12, Aurora Borealis
Control B.V. Schoonebeek, The Netherlands) in the left and in the right striatum
(AP: +0.4; L: +/-3.2; V: -3.5, relative to bregma; (Paxinos at al., 1985)). One support
screw was placed as an extra anchor for fixation of the guide, which was glued to
the skull with dental acrylic cement (Howmedia simplex rapid + methylacrylate,
Drijfhout, Amsterdam, The Netherlands). After surgery, the rats were assigned to
one of three dosing groups (n=6 per group). The microdialysis experiment was
carried out 14 days after surgery. The details of the intracerebral rotenone model




At 13 days after the unilateral infusion of rotenone into the right MFB, and 18-24
hours prior to the experiment, the microdialysis probes (CMA12, membrane
length of 4.0 mm; Aurora Borealis Control B.V. Schoonebeek, the Netherlands)
were inserted into the guide cannulas. All animals were fasted overnight prior to
the experiment in order to rule out any competition in BBB transport of L-DOPA
with food-related amino acids (Nutt at al., 1984).
The microdialysis experiment, 14 days post rotenone treatment, was started
between 7:00 and 8:00 a.m. The inlets of the microdialysis probes were connected
by FEP tubing (fluorinated ethylene propylene tubing; Aurora Borealis Control
B.V. Schoonebeek, the Netherlands) to syringe pumps (Beehive, Bas Technicol,
Congleton, United Kingdom). The probes were perfused with artificial ECF
(composition in mM: NaCl 145; KCl 2.7; CaCl2 1.2; MgCl2 1.0; ascorbic acid 0.2 in
a 2 mM phosphate buffer pH 7.4; (Moghaddam and Bunney, 1989)) at a flow rate
of 2 µl/min. The outlets also consisted of FEP tubing and were connected to a
microsample collector (Univentor 820; Antec, Leiden, The Netherlands), in which
the samples were collected at 4ºC. The vials contained an antioxidant fluid (0.1 M
acetic acid, 3.3 mM L-cysteine, 0.27 M EDTA, 0.0125 mM ascorbic acid dissolved
in millipore water) in a ratio of 1:4 with the expected volume of the microdialysate
to prevent the breakdown of the catecholamines. After a stabilisation period of 60
minutes, the in vivo recovery of L-DOPA was determined by the retrodialysis
method. For this purpose, the probes were perfused with a L-DOPA solution (10,
100 or 200 ng/ml for the 10, 25 and 50 mg/kg dose group, respectively) for 60
minutes to collect 6 fractions. The relative loss of L-DOPA was used for estimating
brainECF concentrations. After the retrodialysis, the syringes were switched to
blank perfusion fluid for a washout phase of 90 minutes. After the washout
period, the intravenous administration of L-DOPA was started. One venous
cannula was connected to a syringe containing L-DOPA (Sigma Alldrich BV,
Zwijndrecht, the Netherlands) in 0.2 M HCl in saline (0.9% NaCl) and ascorbic
acid (5% of the L-DOPA amount) and the second venous cannula was connected
to a syringe containing 7% NaHCO3 (to neutralise the acidic L-DOPA solution).
Both infusions were started at the same time for 20 minutes at a rate of 20 µl/min.
In the first 120 minutes of the experiment, microdialysis fractions were collected
at 10-minute intervals. From 120-180 minutes, microdialysis fractions were
collected at 20-minute intervals. From 180 minutes until the end of the experiment
(360 minutes), microdialysis fractions were collected at 30-minute intervals. Blood
samples (50 µl in heparinised Eppendorf vials) were taken predose and at 5, 10,
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15, 20, 22, 24, 26, 28, 30, 45, 50, 60, 75, 90, 120, 180, 240, 360 minutes after start of
the L-DOPA infusion. The blood samples were centrifuged for 10 minutes at 5000
rpm and the plasma was pipetted into Eppendorf vials. All samples were stored
at -80 C before analysis. After the experiment, the animals were given an overdose
of sodium pentobarbital (Nembutal, Ceva Santa Animale, Maassluis, The
Netherlands) and the thorax was opened and the vascular bed was perfused via
the left ventricle of the heart with 30 ml of saline followed by 30 ml of 10%
phosphate buffered formalin (pH 7.0). Brains were removed for histopathology. 
Immunohistopathology
TH immunohistochemistry was performed to quantify the degree of
dopaminergic depletion as described previously in Chapter 4. The percentage of
intact TH staining in the rotenone-treated hemisphere was calculated as the
percentage of striatal MGV compared to the striatal MGV of the untreated
hemisphere. In the clinical setting, symptoms of Parkinson's disease arise when
about 80% of striatal dopamine and about 60% of dopamine neurons are lost
(Dauer and Przedborski, 2003). Therefore, the rats which failed to show significant
loss in TH staining were considered as 'non-responders' to the rotenone treatment.
Bioanalysis of L-DOPA, DOPAC and HVA
All plasma samples were analysed for L-DOPA and all microdialysate samples
were analysed for L-DOPA, dopamine, DOPAC and HVA using a high
performance liquid chromatography (HPLC) system with electrochemical
detection (ECD). 
HPLC and ECD system
The HPLC system consisted of a LC-10AD HPLC pump (Shimadzu, 
's Hertogenbosch, The Netherlands), a Waters 717 Plus autosampler (Waters,
Etten-Leur, The Netherlands), a pulse damper (Antec Leyden, Zoeterwoude, The
Netherlands) and a digital electrochemical amperometric detector (DECADE,
software version 3.02, Antec Leyden, Zoeterwoude, The Netherlands). The
electrochemical detector consisted of a VT-03 electrochemical flow cell combined
with a 25 µm spacer and an in situ Ag/AgCl (ISAAC) reference electrode
operating in the DC mode. For the analysis, a standard Ag/AgCl reference
electrode, filled with a saturated KCl solution was used. Data acquisition and
processing was performed using the Empower® data-acquisition software




Chromatography of plasma samples of L-DOPA was performed on a Beckman
Coulter™ Ultrasphere® 5 µm C-18 column (4.6 mm I.D. x 150 mm, Alltech, Breda,
The Netherlands) equipped with a refill guard column (2 mm I.D. x 20 mm,
Upchurch Scientific, Oak Harbor, WA, USA) packed with pellicular C18 material
(particle size 20-40 µm, Alltech, Breda, The Netherlands) at a constant
temperature of 30°C. The mobile phase was a mixture of 0.05 M sodium
phosphate buffer (pH 2.8) and methanol (90:10, v/v), supplemented with 0.3 mM
EDTA (sodium salt) and 10 mM octane-sulfonic acid. Before the addition of
methanol, the mobile phase was filtered through a 0.2 µm nylon filter (Alltech,
Breda, The Netherlands), then the methanol was added and it was mixed and
degassed with helium. The flow rate was set at 1 mL/min. The optimal working
potential for L-DOPA was +0.75 V, as determined by a voltammogram and
sensitivity plot. Concentrations were measured at a sensitivity range of 5 nA for
L-DOPA and 20 nA for 3,4-dihydroxybenzylamine hydrobromide (DHBA;
internal standard). Stock solutions of L-DOPA were prepared at a concentration
of 1 mg/mL in Millipore water. The stock solutions were diluted with Millipore
water to obtain calibration solutions in the range of 2 to100 ng/mL. The internal
standard (DHBA) solution was prepared by dilution of the stock solution to a final
concentration of 500 ng/mL. The stock solutions were stored at -80 °C up to one
month. The assay solutions were prepared freshly before each analysis. For
determination of the L-DOPA in plasma, 25 µL of internal standard solution
(DHBA 500 ng/mL) was added to 45 µL plasma samples and 50 µL of Millipore
water in glass centrifuge tubes. Next, 25 µL of 20% TCA was added and the
mixture was vortexed for 5 min. After centrifugation for 10 min at 4000 rpm
(2000g), 100 µL of the supernatant was added to 50 µL of phosphoric buffer (1M,
pH 5.5) of which 25 µL was injected into the HPLC system.
Bioanalysis in microdialysate 
For analysis of L-DOPA, dopamine, DOPAC and HVA brain microdialysate
concentrations, 5 µL of internal standard (isoproterenol; 100 ng/mL) solution was
added per 10 µL of microdialysis sample or calibration curve sample. The samples
were then injected (20 µL) into the HPLC system without further sample pre-
treatment. Chromatography of brain microdialysate samples was performed on a
Beckman Coulter™ Ultrasphere® 5 µm C-18 column (2 mm I.D. x 250 mm,
Alltech, Breda, The Netherlands) at a constant temperature of 30 °C. The mobile
The Intracerebral Rotenone Model of Parkinson's Disease in Rats
179
phase was a mixture of 0.05 M sodium phosphate buffer (pH 2.8) and methanol
(88:12, v/v), supplemented with 0.3 mM EDTA (sodium salt) and 1.5 mM octane-
sulfonic acid. Mobile phase solvents were filtered through a 0.2 µm nylon filter.
Then, the methanol was added and the mobile phase was mixed and degassed
with helium. The flow rate was set at 0.2 mL/min. The optimal working potential
for a mixture of L-DOPA, dopamine, DOPAC and HVA was +0.66 V, as
determined by a voltammogram and sensitivity plot. Concentrations were
measured at a sensitivity range of 0.1 nA for dopamine, 0.5 nA for L-DOPA, HVA
and isoproterenol; and 10 nA for DOPAC. For analysis of brain microdialysate
samples, stock solutions of L-DOPA, DOPAC and HVA were prepared at a
concentration of 0.5 µg/mL for dopamine, 1 µg/mL for L-DOPA and 5 µg/mL for
DOPAC and HVA in microdialysis perfusion fluid with aqueous antioxidant
solution consisting of 0.1 M acetic acid, 3.3 mM L-cysteine, 0.27 M EDTA (sodium
salt) and 0.0125 mM ascorbic acid (4:1 v/v). Internal standard solution was
prepared fresh before each analysis by dilution of a 1 mg/mL isoproterenol stock
solution to 100 ng/mL perfusion fluid with antioxidant (4:1 v/v). All the stock
solutions were stored at -80 °C up to one month. Before each analysis a first
calibration solution containing all compounds was freshly prepared by mixing
one volume part of each compounds' stock solution (L-DOPA, dopamine, DOPAC
and HVA) and adding 5 volume parts of perfusion fluid with antioxidant 
(4:1 v/v). This first calibration solution now contained all compounds at a
concentration 10 times lower than their stock solution and from this solution the
other calibration solutions were prepared.
Population pharmacokinetic analysis
The pharmacokinetics of L-DOPA, DOPAC and HVA were analysed utilizing a
population PK modelling approach. Dopamine concentrations were all below the
limit of detection. Compartmental modelling was performed using the ADVAN6
subroutine in NONMEM VI release 2 (GloboMax LLC, Hanover, MD, USA). All
fitting procedures were performed on an IBM-compatible computer (Pentium IV,
1500 MHz) running under Windows XP with the Compaq Visual Fortran
compiler version 6.6.
The inter-individual variability of model parameters was described by an
exponential equation, according to:
P1i = θ1∗ exp(ηi),
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where θ1 is the population (typical) estimate for parameter P1, P1i is the individual
estimate and ηi determines the random deviation of P1i from P1. The values of ηi
are assumed to be randomly, normally distributed with mean zero and variance
ω112. The residual error in the L-DOPA concentration was described by a
proportional error model:
Cobs,ij = Cpred,ij * (1+εij),
and the residual error in the DOPAC or HVA concentration was described by an
additive error model:
Cobs,ij = Cpred,ij +εij
where Cobs,ij represents the jth measured L-DOPA, DOPAC or HVA concentration
for the ith individual predicted by the model. Cpred,ij represents the prediction of
concentration and εij is the deviation of the model-predicted value from the
observed concentration. The values of ε are assumed to be randomly, normally
distributed with mean zero and variance σ2. The first order conditional estimation
method with interaction (FOCE interaction) was used in NONMEM to fit the
models to the data and to estimate θ's, ω2's and σ2's. 
Structural model selection for all models was based on the likelihood ratio test,
diagnostic plots (observed concentrations vs. individual and population predicted
concentrations, conditional weighted residuals vs. time and predicted
concentrations), parameter correlations and precision in parameter estimates.
Inclusion of one parameter into the model was assumed to be significant if this led
to a decrease of 10.8 points or more of the minimum value of the objective
function (MVOF) after fitting the model to the data. This corresponds to a
theoretical significance level of p=0.001 under the assumption that the difference
in MVOF between two nested models is χ2 distributed. 
In total, the L-DOPA plasma profiles of 13 rats (10 mg/kg: n=4; 25 mg/kg: n=4; 50
mg/kg: n=5) and the L-DOPA brainECF profiles from the untreated brain side of
12 rats (10 mg/kg: n=4; 25 mg/kg: n=3; 50 mg/kg: n=5) and the L-DOPA brainECF
profiles from the lesioned brain side of 7 rats (10 mg/kg: n=1; 25 mg/kg: n=2; 50
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mg/kg: n=4) were included in the population PK analysis. On the basis of
selection criteria, the plasma and brainECF L-DOPA data from all individual rats
were simultaneously analysed (Figure 1). Individual model parameters (post hoc
estimates) for each animal from this analysis and typical values from this model
(Table 1) were then used as input for the subsequent analysis of DOPAC (Figure
1; compartments 6 and 8) and HVA (Figure 1; compartments 7 and 9). In total, the
DOPAC and HVA microdialysate concentrations from the healthy/untreated
brain side of 12 rats (10 mg/kg: n=4; 25 mg/kg: n=3; 50 mg/kg: n=5) and the
DOPAC and HVA microdialysate concentrations from the lesioned brain side of




Figure 1: The population pharmacokinetic model for L-DOPA, DOPAC and HVA comprising of
three compartments (1-3) describing the PK of L-DOPA in plasma, two compartments (4 & 5)
describing the PK of L-DOPA in brainECF, one for the untreated brain side and one for the
lesioned brain side, two compartments (6 & 8) describing the PK of DOPAC in brainECF, one for
the untreated brain side and one for the lesioned brain side and two compartments (7 & 9)




The percentage of intact TH staining in the rotenone-treated hemisphere
compared to the untreated hemisphere was below 40% in 12 out of 17 rats, and
higher than 90% in the remaining 5 rats. The rats which exhibited a TH staining
level lower than 40% (60-100% of the dopamine terminals were lost) were
considered as 'responders' to the rotenone treatment and those brain sides were
considered as diseased (lesioned). 
No quantifiable concentrations of dopamine could be detected throughout the
experiment (LOQ of 0.01 ng/mL in a 20 µl microdialysate sample). As a
consequence, dopamine concentrations were not included in the data analysis.
A total of 17 rats (n=6 in the 10- and 25 mg/kg dose group and n=5 in the 50
mg/kg dose group) were used in the microdialysis experiments. All
microdialysate concentrations of L-DOPA were corrected for the average in vivo
recovery as determined during the retrodialysis period (30 ± 6 %) in order to
estimate brainECF concentrations. The in vivo recovery was equal for the three
concentrations of L-DOPA used.
Data analysis
L-DOPA pharmacokinetic modelling 
The individual plasma concentration-time profiles following intravenous infusion
of L-DOPA are shown in Figure 2. The individual brainECF concentration-time
profiles are shown in Figure 3. The L-DOPA in plasma and in brainECF (both
lesioned and untreated brain sides) were analysed simultaneously. All structural
parameters of the population PK model for L-DOPA could be adequately
estimated (Table 1). The goodness-of-fit plots for L-DOPA are depicted in 
Figure 4. No dose-dependency was observed in the plasma PK for L-DOPA.
No significant difference could be detected between the inter-compartmental
clearances Q4 and Q5, the volumes of distribution V4 and V5 or the elimination
rate constants k40 and k50 when these models were fitted to the L-DOPA brain
concentration data. Table 2 shows a summary of the MVOF and parameters
estimates after the different assumptions (Q4=Q5, V4=V5, k40=k50 or a
combination of any of these assumptions). Also, the separate estimation of
endogenous brain production rate of L-DOPA (Kin) for compartment 4 and 5
resulted in similar estimated values (5.8 min-1).  Striatal microdialysate baseline L-
DOPA levels in the lesioned brain sides were insignificantly lower (P-value=0.07;
Welch's t-test) than in the untreated brain side and averaged 
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0.010 ± 0.004 pmol/mL and 0.024 ± 0.011 pmol/mL (mean ± SEM), respectively.
Therefore, it can be concluded that no significant difference can be identified
between the PK of L-DOPA in the untreated brain side versus the lesioned brain
side. 
DOPAC and HVA kinetic modelling 
Striatal microdialysate baseline DOPAC levels in the lesioned brain side were
about 6 times lower than in the untreated brain side and averaged 0.2 ± 0.19
pmol/mL and 1.3 ± 0.17 pmol/mL (mean ± SEM), respectively (P-value<0.01;
Welch's t-test). Also, striatal microdialysate baseline HVA levels in the lesioned
brain side were lower (approximately 4 times) than in the healthy brain side and
averaged 0.25 ± 0.14 pmol/mL and 0.9 ± 0.08 pmol/mL (mean ± SEM),
respectively (P-value=0.02; Welch's t-test). Figure 5 shows the population
predicted microdialysate concentrations of DOPAC and HVA versus time for a
typical rat per dose group. The goodness-of-fit plots for DOPAC and HVA in
microdialysate are depicted in Figure 6. All structural parameters of the
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Figure 2: L-DOPA concentration-time profiles in plasma, obtained after a 20-min i.v. infusion in
Lewis rats. Depicted are the observed concentrations (dots), individual predictions (solid lines),
separated by L-DOPA dose (in total 13 rats: 10 mg/kg: n=4; 25 mg/kg: n=4; 50 mg/kg: n=5).
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Figure 3: L-DOPA concentration-time profiles in ECF in the untreated brain side (upper panel;
in total 12 rats: 10 mg/kg: n=4; 25 mg/kg: n=3; 50 mg/kg: n=5) and in the lesioned brain side
(lower panel; in total 7 rats: 10 mg/kg: n=1; 25 mg/kg: n=2; 50 mg/kg: n=4), obtained after a 20-
min i.v. infusion in Lewis rats. Depicted are the observed concentrations (dots), individual
predictions (solid lines), separated by L-DOPA dose.
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Table 1: Population pharmacokinetic parameter estimates with the corresponding inter-individual
coefficient of variation (CV%) and lower -and upper limit confidence intervals (LLCI and ULCI). 
population kinetic model for DOPAC as well as for HVA could be adequately
estimated (Table 1). No dose-dependency was found in any of the parameters for
DOPAC or HVA. For DOPAC, k46 and k58 (rate constants which describe the
conversion of L-DOPA, via dopamine, to DOPAC) do not significantly differ,
which means that there appears to be no effect of disease on the metabolism of 
L-DOPA via dopamine to DOPAC. The same can be said for HVA for which the
values of  k47 and k59 do not significantly differ. On the other hand, the
elimination rate constants were found to be 7-fold and 2.5-fold higher in lesioned
brain side compared to untreated side for DOPAC (k60 and k80) and HVA (k70
and k90), respectively.
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Table 2: Summary of goodness-of-fit based on the minimum value of objective function, of eight
assumptions within the modelling of L-DOPA in plasma and brainECF. The assumption 'NONE'
is where all parameters were estimated.
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Figure 4: Goodness-of-fit plots of L-DOPA concentrations in plasma and brainECF as described
by the model depicted in Figure 1. The left panel depicts a scatterplot of the observed L-DOPA
concentrations versus the individual model predictions. The line represents the line of unity. The
right panel depicts a scatterplot of the conditional weighted residuals versus time. 
4. Discussion
In this study the relationship between plasma and brainECF kinetics of L-DOPA
and its conversion into the dopamine metabolites DOPAC and HVA was
measured in rats, in parallel in the lesioned and untreated brain side, at 14 days
post-rotenone injection. NONMEM was used to develop a population based PK
model. Basal concentrations of DOPAC and HVA in striatal microdialysate
differed between the lesioned and the untreated brain side. Furthermore, the
model showed that without changes in BBB transport of L-DOPA, disease-related
changes were observed in the kinetics of these dopamine metabolites following L-
DOPA administration. 
The results described in this paper are the first in which both plasma PK and
brainECF PK of L-DOPA in untreated and diseased (lesioned) conditions are
described by one population PK model. The PK of L-DOPA in plasma following
i.v. administration was best described by a three-compartmental model, like
previously reported (Doller at al., 1978). In our study, we were not able to measure
endogenous plasma concentrations of L-DOPA (LLQ was 1 µg/mL). Sato et al
(1994a) found in their study in rats a basal level of 2.1 ± 0.6 mg/L. In our study,
rats were fasted overnight which might be the reason for much lower endogenous
L-DOPA in plasma. The total clearance of exogenous plasma in the study by Sato
et al (1994a) was 3.13 L/h/kg which is in the same range as our value of 6.25
L/h/kg (Cl= 30 mL/min, Table 1; mean weight of the rats before start of the
experiment was 288 ± 13g). 
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Figure 5: Depicted are the population predicted concentrations of DOPAC (upper panel) and
HVA (lower panel) in the untreated brain side (-----) and lesioned brain side (- - - ) according to
the model as described in Figure 1, separated by L-DOPA dose. For each dose, a typical rat is
depicted.
In our study, following the rotenone infusion in the MFB, Parkinson's disease
state was defined as a density of TH immunostaining in the striatum that was less
than 40% of control (responders). Data indicated that the success of the model to
induce neurodegeneration was similar to our previous study (Ravenstijn at al.,
2008), and the disease pathology was induced in about 70% of the rats. No
difference in BBB transport of L-DOPA between the untreated and lesioned brain
side were found. Also, our results did not indicate a disease-induced change in the
endogenous production of L-DOPA in the brain (Kin; 5.8 min-1). Since dopamine-
producing neurons are diminished in Parkinson's disease (Dauer and
Przedborski, 2003), one would expect a decrease in the endogenous concentration
of L-DOPA, as it is a product of the metabolism of L-tyrosine by TH. However, it
has been reported that TH enzyme activity, as a function of the degree of
dopamine loss, is upregulated in the striatum of 6-OHDA lesioned rats and of
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Figure 6: Goodness-of-fit plots of DOPAC (upper panel) and HVA (lower panel) concentrations
in microdialysate as described by the model depicted in Figure 1. The left graph of each panel
depicts a scatterplot of the observed dialysate concentrations versus the individual model
predictions. The line represents the line of unity. The right graph of each panel depicts a scatterplot
of the weighted residuals versus time.
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MPTP-treated rhesus monkeys (Pifl and Hornykiewicz, 2006). This phenomenon
is assumed to be a compensatory mechanism of the remaining dopaminergic
neurons triggered by the synaptic dopamine loss (Rose at al., 1989). Upregulation
of TH in the rotenone lesioned brain side seems therefore to explain our results. 
Furthermore, the metabolism of L-DOPA via dopamine to DOPAC in the
untreated brain (0.000044 min-1) was indistinguishable from this metabolism in
the lesioned brain side (0.000054 min-1). Also, the metabolism of L-DOPA via
dopamine to HVA in the untreated brain side (0.000023 min-1) was similar to that
in the lesioned brain side (0.000016 min-1). These relatively low values, reflecting
a slow conversion of L-DOPA via dopamine to these metabolites, is due to
dopamine being the main metabolite of L-DOPA in the early phase after drug
administration (Miwa at al., 1992). Furthermore, this newly synthesised dopamine
is localised exclusively in the intracellular compartment within this timeframe
(DeJesus at al., 2000; Miwa at al., 1992). It is therefore not readily available for
metabolism to DOPAC and/or HVA. Overall, in contrast to our expectations, it
can be said that the disease conditions at 2 weeks post-rotenone-injection in the
MFB did not result in any change in the kinetics of L-DOPA. 
Differences for the dopamine metabolites DOPAC and HVA between lesioned
and untreated brain side were observed for baseline concentrations as well as for
elimination rate constants following L-DOPA administration, while their
formation rate constants remained unaffected. The baseline concentrations of
DOPAC and HVA were about 10-fold decreased in the lesioned brain side 
(Figure 5). These findings are similar to what has been reported in other studies
in rats, after an intracerebral injection of rotenone into the MFB (Antkiewicz-
Michaluk at al., 2004), and intracerebral 6-OHDA injection (Brannan at al., 1990;
Sarre at al., 1992). Such concentrations result from the rate of formation relative to
that of elimination. As no changes in formation rate constants of DOPAC and
HVA were found in the lesioned relative to the untreated brain side, decrease in
baseline concentrations were the result of solely the increased elimination rate
constants. 
In our model, the metabolism from dopamine to DOPAC and HVA was explained
by first-order kinetics (Figure 1, Table 1), like in the model previously developed
(Sato at al., 1994a; Sato at al., 1994b). Following L-DOPA administration, for
DOPAC, the elimination rate constant in the lesioned brain side (0.038 min-1) was
increased about 7-fold compared with the elimination rate constant in the
untreated side (0.0053 min-1). For HVA this disease-induced increase was about a
factor 2.5 (0.011 min-1 for the lesioned versus 0.0044 min-1 for the untreated brain
side). Elimination of DOPAC from the ECF may occur by conjugation, in rats
mostly to sulphates (Swahn and Wiesel, 1976) or by transformation to HVA by
COMT. HVA is formed as metabolite of DOPAC but also directly from dopamine
(Mannisto at al., 1992; Westerink and de Vries, 1985; Wood and Altar, 1988). The
mechanisms of elimination of HVA from the brain are not fully clear. HVA may
leave the brain by passive diffusion (Amin at al., 1992). Also, HVA  effluxes from
the brain via a probenecid-sensitive organic anion transport (OAT3) system,
present at the BBB (Mori at al., 2003). This HVA efflux transport system is likely to
play an important role in controlling the level of HVA in the CNS. The apparent
in vivo efflux rate constant of HVA from the brain was determined by (Mori at al.,
2003) to be 0.017 min-1. Our value for the elimination rate constant of HVA in the
untreated brain side was 0.044 min-1 and is in the same order of magnitude. The
increased values that we found for the elimination rate constants for DOPAC and
HVA could have been the result of upregulation of one of the active elimination
processes. Though expressions of OATs are affected (mainly downregulated) in
certain renal and hepatic diseases (Anzai at al., 2006), to our knowledge, no
studies have been performed indicating changes in OAT functionality at the BBB. 
However, even without the explanation of changes in functionality of the
eliminating processes, the lower baseline values and increased elimination rates
of DOPAC and HVA can be explained. In our study, the rate of formation of
DOPAC and HVA is much lower than their rates of elimination (Table 1). 
The concept of "absorption-rate limited elimination" (Rowland and Tozer, 1995),
that may occur when the absorption rate constant is significantly lower than the
(true) elimination rate constant, might apply to our situation. In "absorption-rate
limited elimination", the absorption process is very slow so that the product of the
absorption rate constant and amount remaining to be absorbed approximately
equals the product of the elimination rate constant and the amount to be
eliminated (ka.Aa ~ kel.Ael). We propose for our results a "formation rate-limited
elimination". Assuming identical distribution volumes for dopamine and its
metabolites, the amounts can be divided by the distribution volume to give
concentrations. As the formation rate constants of DOPAC and HVA are much
lower than their corresponding elimination rate constants, the actual
concentration of dopamine ("remaining to be metabolised") will govern the
formation rate, and therewith the elimination rates of DOPAC and HVA. Then,
kform metabolite * Cdopamine ~ kelim metabolite * Cmetabolite. With unchanged values
for formation of the metabolites (kform metabolite or k46 and k58 for DOPAC and
k47 and k59 for HVA; see table 1), and lower baseline concentrations as measured
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for both DOPAC and HVA, a higher (apparent) elimination rate constant is
observed if dopamine concentrations would be lower in the lesioned brain side.
This is indeed plausible with a diminished amount of dopaminergic neurons. This
indicates that, though we have not been able to measure dopamine directly, the
clearly lower baseline concentrations of DOPAC and HVA found in the lesioned
brain side together with the increased values for the elimination rate constants,
provides insight in changes in dopamine concentrations by the disease process.
We are the first to have developed a population PK model on the kinetics of 
L-DOPA, and its conversion on DOPAC and HVA in both untreated and
(Parkinson's) lesioned brain. This opens up the possibility to further investigate
the potential changes in the PK and conversion of L-DOPA at different stages of
Parkinson's disease. Then, further investigations may focus on a potential
relationship between a gradual decline in %TH staining and DOPAC and HVA
microdialysate concentrations, which would give the opportunity to in vivo
determine the Parkinson's disease state at multiple days as there is no need to
sacrifice the experimental animal. 
In conclusion, our study demonstrates that 2 weeks following a unilateral infusion
of rotenone into the rat brain, there are no changes in the kinetics of L-DOPA in
the lesioned hemisphere of the brain. However, a clear effect of dopamine
depletion on the levels and elimination rates of DOPAC and HVA in brain was
observed. This provides indirect information (confirmed by TH
immunohistochemistry) for decreased dopamine concentrations at the lesioned
brain side in accordance with "formation rate-limited elimination" PK principles.
The models used here may help to unravel the molecular and biochemical
mechanisms beyond the changes in the PK and its relation to the conversion of 
L-DOPA, in different stages of Parkinson's Disease. Further studies in other
Parkinson's disease models that show progressive degeneration over time are
warranted.
The Intracerebral Rotenone Model of Parkinson's Disease in Rats
193
5. Reference List
Abbott NJ, Romero IA (1996). Transporting therapeutics across the blood-brain barrier. Mol. 
Med. Today 2: 106-113.
Alexander GM, Schwartzman RJ, Grothusen JR, Gordon SW (1994). Effect of plasma levels of large
neutral amino acids and degree of parkinsonism on the blood-to-brain transport of levodopa in
naive and MPTP parkinsonian monkeys. Neurology 44: 1491-1499.
Amin F, Davidson M, Davis KL (1992). Homovanillic acid measurement in clinical research: a
review of methodology. Schizophr. Bull. 18: 123-148.
Antkiewicz-Michaluk L, Wardas J, Michaluk J, Romaska I, Bojarski A, Vetulani J (2004). Protective
effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline against dopaminergic neurodegeneration in the
extrapyramidal structures produced by intracerebral injection of rotenone. Int. J.
Neuropsychopharmacol. 7: 155-163.
Anzai N, Kanai Y, Endou H (2006). Organic anion transporter family: current knowledge. 
J. Pharmacol. Sci. 100: 411-426.
Bartels AL, Willemsen AT, Kortekaas R, de Jong BM, de Vries R, de Klerk O, van Oostrom JC,
Portman A, Leenders KL (2008). Decreased blood-brain barrier P-glycoprotein function in the
progression of Parkinson's disease, PSP and MSA. J. Neural Transm. 115: 1001-1009.
Bhidayasiri R, Truong DD (2008). Motor complications in Parkinson disease: clinical
manifestations and management. J. Neurol. Sci. 266: 204-215.
Brannan T, Bhardwaj A, Martinez-Tica J, Weinberger J, Yahr M (1990). Striatal L-dopa metabolism
studied in vivo in rats with nigrostriatal lesions. J. Neural Transm. Park Dis. Dement. Sect. 2: 15-22.
Carvey PM, Zhao CH, Hendey B, Lum H, Trachtenberg J, Desai BS, Snyder J, Zhu YG, Ling ZD
(2005). 6-Hydroxydopamine-induced alterations in blood-brain barrier permeability. 
Eur. J. Neurosci. 22: 1158-1168.
Dauer W, Przedborski S (2003). Parkinson's disease: mechanisms and models. Neuron 39: 889-909.
de Lange EC, de Boer BA, Breimer DD (1999). Microdialysis for pharmacokinetic analysis of drug
transport to the brain. Adv. Drug Deliv. Rev. 36: 211-227.
DeJesus OT, Haaparanta M, Solin O, Nickles RJ (2000). 6-fluoroDOPA metabolism in rat striatum:
time course of extracellular metabolites. Brain Res. 877: 31-36.
del Amo EM, Urtti A, Yliperttula M (2008). Pharmacokinetic role of L-type amino acid transporters
LAT1 and LAT2. Eur. J. Pharm. Sci. 35: 161-174.
Chapter 5
194
Deleu D, Northway MG, Hanssens Y (2002). Clinical pharmacokinetic and pharmacodynamic
properties of drugs used in the treatment of Parkinson's disease. Clin. Pharmacokinet. 41: 261-309.
Doller HJ, Connor JD, Lock DR, Sloviter RS, Dvorchik BH, Vesell ES (1978). Levodopa
pharmacokinetics. Alterations after benserazide, a decarboxylase inhibitor. Drug Metab Dispos. 6:
164-168.
Factor SA (2008). Current status of symptomatic medical therapy in Parkinson's disease.
Neurotherapeutics. 5: 164-180.
Hammarlund-Udenaes M (2000). The use of microdialysis in CNS drug delivery studies.
Pharmacokinetic perspectives and results with analgesics and antiepileptics. Adv. Drug Deliv. Rev.
45: 283-294.
Kortekaas R, Leenders KL, van Oostrom JCH, Vaalburg W, Bart J, Willemsen ATM, Hendrikse NH
(2005). Blood-Brain Barrier dysfunction in Parkinsonian midbrain in vivo. Ann. Neurol. 57: 176-179.
Mannisto PT, Ulmanen I, Lundstrom K, Taskinen J, Tenhunen J, Tilgmann C, Kaakkola S (1992).
Characteristics of catechol O-methyl-transferase (COMT) and properties of selective COMT
inhibitors. Prog. Drug Res. 39: 291-350.
Miwa S, Gillberg PG, Bjurling P, Yumoto N, Odano I, Watanabe Y, Langstrom B (1992).
Assessment of dopamine and its metabolites in the intracellular and extracellular compartments
of the rat striatum after peripheral administration of L-[11C]dopa. Brain Res. 578: 122-128.
Moghaddam B, Bunney BS (1989). Ionic composition of microdialysis perfusing solution alters the
pharmacological responsiveness and basal outflow of striatal dopamine. J. Neurochem. 53: 652-654.
Mori S, Takanaga H, Ohtsuki S, Deguchi T, Kang YS, Hosoya K, Terasaki T (2003). Rat organic
anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the
abluminal membrane of brain capillary endothelial cells. J. Cereb. Blood Flow Metab 23: 432-440.
Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL (1984). The "on-off"
phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N. Engl. J.
Med. 310: 483-488.
Nyholm D (2006). Pharmacokinetic optimisation in the treatment of Parkinson's disease : an
update. Clin. Pharmacokinet. 45: 109-136.
Obeso JA, Rodriguez-Oroz M, Marin C, Alonso F, Zamarbide I, Lanciego JL, Rodriguez-Diaz M
(2004). The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic
innervation and basal ganglia circuits. Neurology 62: S17-S30.
Paxinos G, Watson C, Pennisi M, Topple A (1985). Bregma, lambda and the interaural midpoint in
The Intracerebral Rotenone Model of Parkinson's Disease in Rats
195
stereotaxic surgery with rats of different sex, strain and weight. J. Neurosci. Methods 13: 139-143.
Pifl C, Hornykiewicz O (2006). Dopamine turnover is upregulated in the caudate/putamen of
asymptomatic MPTP-treated rhesus monkeys. Neurochem. Int. 49: 519-524.
Ravenstijn PG, Merlini M, Hameetman M, Murray TK, Ward MA, Lewis H, Ball G, Mottart C, de
Ville dG, Lemarchand T, van Belle K, O'Neill MJ, Danhof M, de Lange EC (2008). The exploration
of rotenone as a toxin for inducing Parkinson's disease in rats, for application in BBB transport and
PK-PD experiments. J. Pharmacol. Toxicol. Methods 57: 114-130.
Rose S, Nomoto M, Kelly E, Kilpatrick G, Jenner P, Marsden CD (1989). Increased caudate
dopamine turnover may contribute to the recovery of motor function in marmosets treated with
the dopaminergic neurotoxin MPTP. Neurosci. Lett. 101: 305-310.
Rowland M & Tozer TN (1995). Extravascular Dose. In:  ed. Balado,D. Clinical Pharmacokinetics-
Concepts and Applications. Williams & Wilkins: Media, PA, pp 34-50.
Sarre S, Herregodts P, Deleu D, Devrieze A, De Klippel N, Ebinger G, Michotte Y (1992).
Biotransformation of L-dopa in striatum and substantia nigra of rats with a unilateral, nigrostriatal
lesion: a microdialysis study. Naunyn Schmiedebergs Arch. Pharmacol. 346: 277-285.
Sato S, Koitabashi T, Koshiro A (1994a). Pharmacokinetic and pharmacodynamic studies of L-dopa
in rats. I. Pharmacokinetic analysis of L-dopa in rat plasma and striatum. Biol. Pharm. Bull. 17: 1616-
1621.
Sato S, Koitabashi T, Koshiro A (1994b). Pharmacokinetic and pharmacodynamic studies of L-
dopa in rats. II. Effect of L-dopa on dopamine and dopamine metabolite concentration in rat
striatum. Biol. Pharm. Bull. 17: 1622-1629.
Savitt JM, Dawson VL, Dawson TM (2006). Diagnosis and treatment of Parkinson disease:
molecules to medicine. J. Clin. Invest 116: 1744-1754.
Schapira AH (2008). Progress in neuroprotection in Parkinson's disease. Eur. J. Neurol. 15 Suppl 1:
5-13.
Swahn CG, Wiesel FA (1976). Determination of conjugated monoamine metabolites in brain tissue.
J. Neural Transm. 39: 281-290.
Westerink BH, de Vries JB (1985). On the origin of dopamine and its metabolite in predominantly
noradrenergic innervated brain areas. Brain Res. 330: 164-166.
Wood PL, Altar CA (1988). Dopamine release in vivo from nigrostriatal, mesolimbic, and










Summary, Conclusions and Perspectives
1. General objective 
The objective of the research described in this thesis was to explore rotenone as a
toxin for inducing Parkinson's disease in rats as a new rat model of this disease,
and to use this rat model in pharmacokinetic(-pharmacodynamic) (PK-PD)
studies on antiparkinson drugs with special reference to blood-brain barrier (BBB)
functionality. 
2. Understanding drug response in Parkinson's disease: the role of
the BBB
In most neuropharmacological studies the effect of drugs in the CNS are still
related to the dose and the mechanisms which may affect the disposition (e.g.
absorption, distribution, metabolism and excretion) and thereby ultimately the
drug response is not considered. Different factors like genetics, species, gender,
age, environmental and pathological conditions can influence the drug response. 
Parkinson's disease is a progressive neurodegerative disease that lacks good
treatment, especially at later stages. Apart from plasma pharmacokinetics,
mechanisms that govern CNS drug distribution and response include the rate and
extent of BBB transport and the kinetics of distribution within the brain including
the brain target distribution. For the development of new drugs as well as for the
optimisation of therapy with the current drugs, the variability of these individual
mechanisms and contribution in terms of rate and extent should be investigated.
Chapter 2 summarised the mechanisms and sources of variation in the response
to drugs used in the treatment of Parkinson's disease. As the BBB is a key player
in the relationship between plasma and brain pharmacokinetics, the influences of
disease states on BBB functionality in the various stages of the disease is important
in order to judge on drug effects. To that end, more integrative research
approaches are needed. This warrants the application of a systems pharmacology
approach in investigations on variability in drug response in Parkinson's disease.
3. Animal models as a tool in systems pharmacology research on
Parkinson's disease treatment
For the development of mechanism-based PK-PD models, animal models are
essential. An animal model for Parkinson's disease displaying the slow
progressive nature of the disease would provide the biological system-specific
parameters needed to determine the neuroprotective properties of new drugs,
preclinically. In Chapter 3, we presented an overview of the currently available
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animal models of Parkinson’s disease, with their main characteristics, followed by
a summary of available behavioural tests and a discussion on the microdialysis
technique for the assessment of BBB functionality. The use of a chronic animal
model for Parkinson's disease is a first step in the characterisation of drug effects
on disease processes and disease progression. A technique such as intracerebral
microdialysis may be applied to determine extracellular, unbound concentrations
of endogenous compounds (e.g. biomarkers for Parkinson's disease or BBB
functionality) as well as of exogenous compounds (e.g. antiparkinson drugs or
marker compounds for specific transport mechanisms of the BBB). Furthermore,
behavioural tests may also be applied as a pharmacodynamic read-out. The data
obtained from these experiments give information on processes on the causal path
between drug administration and response (e.g. target site distribution, target
binding and activation, transduction/homeostatic feedback and diseases
processes/progression). With this, mechanism-based PK-PD models can be
developed which can have properties for extrapolation and prediction in systems
pharmacology research (Danhof et al., 2007). 
4. The exploration of rotenone as a toxin for inducing Parkinson's
disease in rats
In Chapter 4, two methods of inducing Parkinson's disease in rats are introduced
and compared using the neurotoxin rotenone. The administration of low-dose
intravenous or subcutaneous rotenone to rats had previously been shown to
produce a slow, selective degeneration of nigrostriatal dopaminergic neurons
accompanied by the formation of α-synuclein-positive LB-like inclusions as seen
in Parkinson's disease (Betarbet et al., 2000; Sherer et al., 2003). Rotenone's
advantages of being able to create an animal model exhibiting a slow progression
of disease and the formation of LB-like structures outweighed the use of the well-
documented but more acute neurotoxins 6-OHDA and MPTP. Ultimately, this
animal model would be applied as a tool for mechanism-based PK-PD disease
progression models, in which time-dependent changes in the biological system of
diseased animals are taken into account (Post et al., 2005). 
The subcutaneous route was chosen as this was less labor intensive and produced
the same results as administration via jugular vein cannulation (Sherer et al.,
2003). Studies were performed in which we investigated the effect of
subcutaneous rotenone on bodyweight, behaviour and BBB permeability with
sodium fluorescein as a marker and intracerebral microdialysis as a tool to assess
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intracerebral fluorescein concentrations. The intracerebral microdialysis
technique offers the advantage of allowing repeated or continuous sampling in
freely moving animals. Herewith, it provides important information on the BBB
transport and brain distribution. Post-mortem analysis consisted of assessing
nigrostriatal damage based on immunohistological staining with TH as well as
peripheral organ pathology. The results indicated that subcutaneously
administered rotenone failed to produce dopaminergic lesions in the SNc and
striatum and, moreover, led to extensive peripheral organ toxicity. BBB
permeability for fluorescein following subcutaneously administered rotenone
was changed, however due to peripheral toxicity. Other labs have shown similar
results on systemically administered rotenone (Fleming et al., 2004; Hoglinger et
al., 2003; Lapointe et al., 2004; Zhu et al., 2004). 
These results led to the development of the method in which rotenone was
administered directly into the median forebrain bundle (MFB) in the brain to be
able to overcome any peripheral toxicity. Intracerebrally-administered rotenone
(MFB or SNc) is able to decrease striatal and nigral dopamine and its metabolites
(Antkiewicz-Michaluk et al., 2004; Saravanan et al., 2005) and to induce
behavioural changes similar to Parkinson's disease (Sindhu et al., 2006). An
infusion into the MFB was chosen as this might develop a slower, more
progressive degeneration of dopaminergic cells as compared to an intranigral
infusion (Sindhu et al., 2005). To determine the “optimal” dose for inducing
Parkinson's disease in rats, three different doses of rotenone were tested (0.5, 2.0
and 5.0 µg). Here, we monitored bodyweight and performed post-mortem
peripheral organ toxicology to confirm the absence of any influence of the
rotenone peripherally. Additionally, BBB permeability was assessed with sodium
fluorscein as a marker and intracerebral microdialysis. In a separate experiment
rotational behaviour was assessed using amphetamine in animals receiving the
highest rotenone dose (5.0 µg). Post-mortem analysis using TH on the striatum
and SNc was performed. The SNc were analysed for α-synuclein inclusions.
Results showed a progressive lesion of the nigrostrial dopaminergic pathway
with no associated peripheral toxicity. Furthermore, a large increase in
amphetamine induced rotational behaviour was seen and a few rats showed 
α-synuclein immunoreactivity and aggregation. However, no changes in passive
BBB permeability were detected. The results indicated that rotenone infused
intracerebrally (specifically the 5.0 µg-dose) is able to create a progressive rat




5. The intracerebral rotenone model of Parkinson's disease in rats:
altered conversion of L-DOPA into DOPAC and HVA without
changes in BBB transport
In Chapter 5, the relationship between plasma and brainECF kinetics of L-DOPA
and its effect on dopamine metabolites DOPAC and HVA was measured in the
untreated as well as in the brain side 14 days after an injection of rotenone. For this
purpose rotenone (5 µg) was infused unilaterally into the MFB to induce
Parkinson's disease in Lewis rats as presented in chapter 4. The contralateral, non-
infused brain side was used as control. Three groups were used in the experiment,
each receiving a different dose of L-DOPA (10, 25 or 50 mg/kg). Plasma samples
were collected to determine plasma PK of L-DOPA and (dual-probe) intracerebral
microsialysis was used as a tool to measure extracellular concentrations of 
L-DOPA, DOPAC and HVA in the striatum of both the lesioned and
control/untreated brain sides. This enabled us to compare the diseased brain
concentrations to the untreated side. Dopamine could not be detected as the
concentrations were below the limit of quantification. Post-mortem analysis using
TH immunostaining on the striatum was performed. These data were used to
determine "responders" to rotenone, which had a TH staining percentage of 40%
or lower and were considered to be diseased. NONMEM was used to develop a
population based PK model. The results described in this chapter are the first in
which both plasma and brainECF PK of L-DOPA under untreated and diseased
conditions are described by one population PK model. The results indicated that
the disease conditions at 2 weeks post-rotenone-injection in the MFB did not result
in any change in the kinetics of L-DOPA. Merely, a clear effect of disease on the
levels and elimination rates of DOPAC and HVA in brain were found, providing
indirect information on decreased dopamine concentrations at the diseased brain
side based on flip-flop kinetic principles.
6. Discussion and future perspectives
The objective of the research described in this thesis was to explore rotenone as a
toxin for inducing Parkinson's disease in rats as a new rat model of this disease,
and to use this rat model in PK(-PD) studies on antiparkinson drugs with special
reference to BBB functionality in the context of disease. 
The results indicated that subcutaneously administered rotenone failed to
produce dopaminergic lesions and led to extensive peripheral organ toxicity. BBB
permeability for fluorescein following subcutaneously administered rotenone
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was changed, however due to peripheral toxicity. Other labs have shown similar
results on systemically administered rotenone (Fleming et al., 2004; Hoglinger et
al., 2003; Lapointe et al., 2004; Zhu et al., 2004). Rotenone infused intracerebrally
(specifically the 5.0 µg-dose into the MFB) is, however, able to create a progressive
rat model for Parkinson's disease, which could be used in PKPD and other types
of experiments. We showed in a few cases α-synuclein immunoreactivity and
aggregation. These have not been observed in previous experiments using an
intracerebral infusion of rotenone (Alam et al., 2004; Antkiewicz-Michaluk et al.,
2004; Saravanan et al., 2005; Sindhu et al., 2005). Furthermore, the decrease in
striatal TH staining seems to reach a minimal plateau at 28 days post-injection.
Further experiments to follow the progression at longer post-injection intervals
would be required to evaluate if there is disease progression and further 
α-synuclein development beyond 28 days. Many studies have demonstrated
substantial and important age-related changes in neurochemistry and
neurobiology. Data on the decreases and alterations in the dopaminergic
neurotransmitter pathway have been relatively consistent in both animal and
human studies (Adolfsson et al., 1979; Bucht et al., 1981; Wenk et al., 1989). Also,
age seems to increase the sensitivity of dopaminergic neurons to rotenone toxicity
in rats  (Phinney et al., 2006). These findings indicate to further investigate this for
the intracerbrally infused rotenone rats and to study the influence that age might
have on the development of α-synuclein inclusions.
In our intracerebral microdialysis studies using sodium fluorescein as a marker
for BBB permeability, we did not demonstrate any changes in striatal BBB
permeability. We performed our microdialysis study with sodium fluorescein at
one particular time point at a specific location in the brain (striatum), and it
therefore cannot be concluded that no changes in BBB permeability would occur
in other stages of the disease, or at other places within the brain such as the SNc.
Carvey and collegues (Carvey et al., 2005) have found leakage of FITC in the SNc
and striatum which was always patchy in appearance. This suggests that the 
6-OHDA lesion which they applied in their studies, leads to multiple focal
breakdowns in the BBB function. It is worthwhile investigating this phenomenon
in our animal model at different timepoints after the injection of rotenone into the
MFB. The evidence in literature for alterations in BBB functionality in Parkinson's
disease is still growing and shows that BBB research in this disease needs more
future attention. Parkinson's disease patients have shown to have an increase in
vascular density in the SNc, but not the ventral tegmental area (Faucheux et al.,
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1999), and a reduced P-gp function was found using PET to measure brain uptake
of [11C]-verapamil (Bartels et al., 2008; Kortekaas et al., 2005). A rat model using 
6-OHDA has demonstrated that dyskinesias in animals were associated with
increased entry of L-DOPA into the striatum (Carta et al., 2006; Westin et al., 2006)
which was also seen using PET imaging in patients with peak-dose dyskinesias at
1 hour after L-DOPA administration (Fuente-Fernandez et al., 2004). The
dyskinetic 6-OHDA rats also exhibited a significant increase in total blood vessel
length and a visible extravasation of serum albumin in the SNc (Westin et al.,
2006), indicating a role for the BBB in the altered transport of L-DOPA to the brain.
In our studies using the intracerebral rotenone model no change in the plasma
kinetics, nor in the brain distribution kinetics of L-DOPA was seen at 
2 weeks post-rotenone-injection. However, a clear effect of disease on the levels
and elimination rates of DOPAC and HVA in brain were found, providing
indirect information on decreased dopamine concentrations at the diseased brain
side based on flip-flop kinetic principles. The percentage of intact TH staining
found in the rotenone-treated hemisphere compared to the untreated hemisphere
was below 40% in 12 out of 17 rats used in this experiment, and higher than 90%
in the remaining 5 rats. Further experiments might be directed towards
investigating the kinetics of L-DOPA in rats with more advanced lesions.
Bromocriptine, a D2 antagonist used in the treatment of Parkinson's disease, has
shown to be a substrate for P-gp (Vautier et al., 2006). Given the evidence that 
P-gp function might be altered in Parkinson's disease (Bartels et al., 2008;
Kortekaas et al., 2005), it would be worthwhile to investigate possible changes in
the pharmacokinetics (and pharmacodynamics) of bromocriptine in the
intracerebral rotenone rat model. Another D2 receptor agonist used in the
treatment of Parkinson's disease is pramipexole which is a cationic drug which
not only crosses the BBB by diffusion but also via organic cation-sensitive
transporter (Okura et al., 2007). This drug might be an interesting model drug to
investigate Parkinson's disease related changes in this BBB transporter.
7. Conclusion
In the intracerebral rotenone model of Parkinson's disease, studies were
performed at day 14 after injection of rotenone. At this time-point no changes
were found in passive BBB permeability, nor in BBB transport modes of L-DOPA
(LAT transporter & passive permeability). However, a diseased condition was
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present as indicated by the clear effect of rotenone on the levels and elimination
rates of DOPAC and HVA in brain that provided information on decreased
dopamine concentrations at the diseased brain side. 
Altogether it was concluded that the intracerebral infusion of rotenone into the
MFB is able to create a chronic and progressive rat model for Parkinson's disease,
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Doel van dit onderzoek
Het doel van de studies beschreven in dit proefschrift was te onderzoeken of het
gebruik van het neurotoxine rotenon in ratten geschikt was voor het induceren
van een meer chronisch en progessief verloop van de ziekte van Parkinson ten
behoeve van onderzoek naar de relatie tussen farmacokinetiek (PK) en
farmacodynamiek (PD) van geneesmiddelen die worden gebruikt voor de
behandeling van de ziekte van Parkinson. Hierbij werd speciaal de nadruk gelegd
op mogelijke wijzigingen in snelheid en mate van het transport over de bloed-
hersenbarrière (BHB) ten gevolge van de pathologische condities.
De ziekte van Parkinson
De ziekte van Parkinson is een langzaam voortschrijdende ziekte waarbij
dopamine-producerende zenuwcellen in het striatum en de substantia nigra van
de hersenen afsterven (neurodegeneratie). Met de tijd neemt hierdoor de
concentratie van dopamine in de hersenen af, met name in het striatum. Door dit
dopamine-tekort gaan de hersenkernen -die belangrijk zijn voor met name het
uitvoeren van bewegingen- slechter functioneren. In de nog aanwezige
dopaminerge zenuwcellen ontwikkelen zich ophopingen van het eiwit
alfasynucleïne. Dergelijke ophopingen worden Lewy bodies genoemd.
De klinische symptomen die optreden bij de ziekte van Parkinson hebben
voornamelijk betrekking op het bewegingsapparaat (motorisch systeem), te weten
rigiditeit (stijfheid van de ledematen), akinesie (langzaam en weinig bewegen),
rusttremor (trillen bij rust), en gestoorde (voorovergebogen) houding en
houdingsreflexen. Naast deze motorische verschijnselen, kunnen er ook
symptomen van het autonome zenuwstelsel optreden (o.a. overmatige
transpiratie, obstipatie), alsmede psychische verschijnselen (depressie,
vermoeidheid en dementie). 
De behandeling van de ziekte van Parkinson bestaat uit het aanvullen van het
tekort aan dopamine in de hersenen. Dit kan niet door het toedienen van
dopamine zelf, aangezien dopamine de bloed-hersenbarrière (BHB) niet kan
passeren. 
De precursor (uitgangsstof) van dopamine, het L-3,4-dihydroxyphenylalanine 
(L-DOPA), kan wel in de hersenen terecht komen alwaar het door de nog
aanwezige dopaminerge zenuwcellen omgezet wordt in dopamine. Anderszins
kunnen dopamine agonisten de werking van dopamine nabootsten. Echter tot op
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heden is de therapie van L-DOPA in combinatie met een decarboxylase remmer
de meest gebruikte in de behandeling van de ziekte van Parkinson. 
L-DOPA wordt via een actieve transporter over de BHB naar de hersenen
getransporteerd. Zoals eerder gezegd neemt bij het voortschrijden van de ziekte
het aantal zenuwcellen in de substantia nigra steeds verder af. Aangezien de
dopaminerge zenuwcellen verantwoordelijk zijn voor de omzetting van L-DOPA
naar dopamine, onstaat er in een verder gevorded stadium van de ziekte van
Parkinson een probleem met betrekking tot de effectiviteit van de L-DOPA
therapie. Er is gebleken dat de werking van L-DOPA minder constant wordt. Ten
opzichte van het vroege stadium van de ziekte is in het late stadium na toediening
van L-DOPA enerzijds eerst sprake van ongewenste effecten -zoals een teveel aan
onwillekeurige bewegingen (dyskinesieën)-, terwijl anderzijds de werkingsduur
veel korter is of soms zelfs afwezig ("off-verschijnselen"). Om deze ongewenste
effecten te vermijden wordt L-DOPA in latere stadia van de ziekte veelal gegeven
in combinatie met een dopamine agonist of met een catechol-O-methyltransferase
(COMT) remmer of een monoamine-oxidase-B (MAO-B) remmer. Dopamine
agonisten hebben het voordeel dat ze een langere werkingsduur hebben (langere
halfwaardetijd) in vergelijking tot L-DOPA. Remmers van de enzymen COMT en
MAO zorgen ervoor dat L-DOPA minder snel wordt afgebroken waardoor 
L-DOPA langer in effectieve concentraties aanwezig kan zijn. Desalniettemin zal,
in een verder gevorderd stadium van de ziekte, de werking van antiparkinson
geneesmiddelen verminderen en zullen er meer complicaties in de motoriek
optreden. Dit betekent dat er sterke behoefte bestaat aan betere middelen voor de
behandeling van de ziekte van Parkinson. De toekomst van het
geneesmiddelenonderzoek voor de ziekte van Parkinson richt zich dan ook met
name op de ontwikkeling van geneesmiddelen met een beschermende of
herstellende werking op de neurodegeneratie.
De bloed-hersenbarrière
Geneesmiddelen voor de behandeling van de ziekte van Parkinson hebben hun
werking in de hersenen en dienen hiervoor de BHB te passeren. De BHB wordt
gevormd door de wand van de hersencapillairen. Door zogenaamde "tight
junctions" zijn deze hersenendotheelcellen zeer nauw aaneengesloten. De BHB
beschikt over verschillende transportmechanismen. Eén van de
transportmechanismen is passief, door middel van diffusie. Dit kan gebeuren
tussen de cellen door (paracellulair) zowel als door de membranen van de cellen
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heen (transcellulair). Kleine, lipofiele en ongeladen stoffen kunnen via de
transcellulaire route de BHB passeren, terwijl grotere, hydrofiele stoffen dit eerder
via de paracellulaire route doen, die zeer beperkt is door de tight junctions. De
hersenendotheelcellen bevatten ook een aantal specifieke transporter-eiwitten die
actieve influx (bloed naar hersenen) en efflux (hersenen naar bloed) verzorgen. De
influx transporters zorgen voor de opname van stoffen die essentieel zijn voor een
goede werking van de hersenen. Zo zijn er transporters specifiek voor de opname
van eiwitten, peptides, glucose, aminozuren, vitamines en hormonen. Ook
lichaamsvreemde stoffen, waaronder geneesmiddelen, kunnen afhankelijk van
hun fysisch-chemische eigenschappen via deze transporters in de hersenen
opgenomen worden. Zo wordt L-DOPA in de hersenen opgenomen via de grote
aminozuur transporter (LAT1). Efflux transporters zorgen voor het verwijderen
van toxische stoffen en afvalstoffen uit de hersenen en kunnen zo ook diverse
geneesmiddelen uit de hersenen verwijderen. De meest bekende efflux
transporter is het P-glycoproteïne (P-gp). De substraten van het P-gp zullen door
de werking van het P-gp lagere concentraties in de hersenen bereiken. Verder is
er naast de BHB is ook een barrière te vinden tussen het bloed en de
hersenvloeistof (liquor). De BHB wordt echter gezien als de belangrijkste barrière
voor stoffen om de hersenen te bereiken.
2. Mechanismen in geneesmiddelwerking in de ziekte van
Parkinson: BHB in de hoofdrol
Het netto transport van een bepaald geneesmiddel door de BHB, met als resultaat
een bepaalde concentratie van dat geneesmidel in de hersenen, wordt bepaald
door de som van alle BHB transportmechanismen voor deze stof. Veranderingen
in één of meerdere BHB transportmechanismen kunnen de PK van dit
geneesmiddel in de hersenen veranderen, dus ook de werking van het
geneesmiddel. Het functioneren van de BHB kan variëren met verschillende
fysiologische en pathologische omstandigheden of als gevolg van chronisch
geneesmiddel gebruik. Zo is op hogere leeftijd met name de werking van
specifieke transportmechanismen voor o.a. choline, glucose en peptides
verminderd. Ook wordt er gedacht dat neurodegeneratie gerelateerd is aan de
integriteit van de BHB. Zo zijn er aanwijzingen gevonden voor een aangetaste
BHB in hersenbiopten van patienten met de ziekte van Alzheimer, de meest
voorkomende neurodegeneratieve ziekte. Daarnaast is in een kleine groep
patienten met de ziekte van Parkinson met Positron Emissie Tomografie de
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werking van het P-gp in de BHB gemeten die aanwijzingen gaven voor een
verminderde werking van het P-gp. Verder zijn er enkele studies in diermodellen
die duiden op een veranderde functie van de BHB; één daarvan specifiek in het
striatum en de substantia nigra. Aangezien de centrale werking van een
geneesmiddel nauw samenhangt met het concentratie in de hersenen en de BHB
de relatie tussen plasma concentratie en hersenconcentratie bepaalt, zal BHB
transport in verschillende stadia van de ziekte van Parkinson onderdeel moet
uitmaken van studies naar de effectiviteit van antiparkinson middelen. 
In neurofarmacologisch onderzoek wordt de werking van een geneesmiddel
veelal nog slechts gerelateerd aan de dosis. Daarbij wordt voorbijgegaan aan de
invloed van  specifieke mechanismen die de werking van het geneesmiddel in de
hersenen bepalen. Dit zijn met name plasma PK en eiwitbinding, het BHB
transport, de verdeling van de stof binnen de hersenen zelf en naar de plaats van
werking (aangrijpingspunt van het geneesmiddel), alsook de interactie met het
aangrijpingspunt. Deze mechanismen zullen niet in alle omstandigheden een
evengrote bijdrage hebben aan het werkingsprofiel van het geneesmiddel.
Verschillen in factoren zoals genetische achtergrond, soort, geslacht, leeftijd,
omgevingsfactoren en pathologische omstandigheden kunnen de snelheid en de
mate van de individuele mechanismen beïnvloeden en moeten daarom ook in
acht genomen worden bij vergelijk van de werking in verschillende
omstandigheden en zeker waar het voorspellingen van de werking van het
geneesmiddel in de mens zou betreffen. In hoofdstuk 2 is een samenvatting
gegeven van de ziekte van Parkinson en van de geneesmiddelen die gebruikt
worden bij de behandeling van deze ziekte. Verder zijn de mechanismen en
factoren en hun mogelijke invloed op de centrale werking van geneesmiddelen
beschreven. De nadruk is hierbij op de bijdrage van de BHB onder pathologische
omstandigheden gelegd.
3. Diermodellen als gereedschap in onderzoek naar geneesmiddelen
voor de ziekte van Parkinson
De ziekte van Parkinson bestaat uit meerdere componenten die elk veroorzaakt
worden door een samenspel van genetische en niet-genetische factoren. In de
ontwikkeling van nieuwe geneesmiddelen voor de ziekte van Parkinson is het
daarom belangrijk om de invloed van het geneesmiddel op het gehele biologische
systeem te bestuderen (systeemfarmacologie). Diermodellen zijn een essentieel
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onderdeel van systeemfarmacologisch onderzoek, zoals het onderzoek naar de
functionaliteit van de BHB onder verschillende omstandigheden (bijv. ziekte).
Diermodellen vormen een belangrijk onderdeel van geïntegreerde
onderzoeksmethoden die nodig zijn om de individuele componenten volledig te
kunnen begrijpen, inclusief hun eventuele tijdsafhankelijkheid. Informatie
verkregen uit dit onderzoek kan gebruikt worden voor de ontwikkeling van
mechanistische PK-PD modellen. Het doel van het gebruik van mechanistische
PK-PD modellen is het verbeteren van de karakterisatie en de voorspelbaarheid
van processen die betrokken zijn bij de geneesmiddelconcentratie en -werking
onder fysiologische alsook pathologische condities. Een belangrijk onderdeel van
mechanistische PK-PD modellering is het expliciete onderscheid tussen
parameters die specifiek zijn voor het geneesmiddel en parameters die specifiek
zijn voor het biologische systeem (mens, dier). De parameters die specifiek zijn
voor het geneesmiddel kunnen vaak via in vitro experimenten verkregen worden,
terwijl de biologische systeemparameters door middel van in vivo experimenten,
bijvoorbeeld in diermodellen, bepaald moeten worden omdat dit
begrijpelijkerwijs veelal niet in de mens kan gebeuren. 
Diermodellen zijn daarom essentieel in het onderzoek naar de (veranderingen in)
mechanismen die een rol spelen in de relatie tussen PK en PD van een
geneesmiddel, zo ook voor de functionaliteit van de BHB onder verschillende
omstandigheden.
Diermodellen die gebruikt worden in onderzoek naar de ziekte van Parkinson,
kunnen worden onderverdeeld in toxine-geïnduceerde modellen en genetische
modellen. In hoofdstuk 3 zijn deze diermodellen met hun belangrijkste
eigenschappen samengevat. Hierbij zijn de toxine-geïnduceerde modellen verder
uitgelicht. 
De meest toegepaste toxine-geïnduceerde diermodellen voor de ziekte van
Parkinson, maken gebruik van 6-hydroxydopamine (6-OHDA), 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP), paraquat, maneb of rotenon.
Verschillende soorten diermodellen zijn nodig om verschillende
onderzoeksvragen te kunnen beantwoorden. De meeste diermodellen beschreven
in hoofdstuk 3, hebben betrekking op een acute inductie van de ziekte van
Parkinson waarbij de dopamine-producerende zenuwcellen in korte tijd en in
grote mate afsterven. Het neurotoxine rotenon kan als één van de weinigen de
ziekte van Parkinson langzaam induceren, waardoor de voortschrijding van de
ziekte beter nagebootst kan worden. Rotenon heeft als bijkomend voordeel boven
de andere toxine-geïnduceerde diermodellen dat het de vorming van Lewy
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bodies in de substantia nigra tot gevolg kan hebben, vergelijkbaar met wat er
gebeurt bij de ziekte van Parkinson in de mens. Het rotenon diermodel lijkt
daarom geschikt voor gebruik ten behoeve van het ontwikkelen van
mechanistische PK-PD modellen waarin ook de voortschrijding van de ziekte als
factor meegenomen kan worden. Het onderzoek zoals verder beschreven in dit
proefschrift heeft zich daarom gericht op het evalueren van het diermodel voor de
ziekte Parkinson met rotenon. 
Als maat voor het effect van een nieuw geneesmiddel wordt vaak gebruik
gemaakt van de verandering in het gedrag van het diermodel. Voor diermodellen
van de ziekte van Parkinson zijn verschillende gedragsmetingen mogelijk. De
meest voorkomende is het amfetamine-geïnduceerd rotatiegedrag. Andere
methoden meten bijvoorbeeld de voortbeweging of de grijpkracht. Hoofdstuk 3
geeft een samenvatting van de meest gebruikte gedragsmethoden in
diermodellen van de ziekte van Parkinson. Voorts is intracerebrale microdialyse
beschreven als een zeer geschikte techniek voor het bepalen van BHB
functionaliteit. Dit omdat met deze techniek tijdsafhankelijke
concentratiemetingen kunnen worden verricht die nodig zijn voor het bepalen
van de mate en snelheid van mechanismen van BHB transport van een bepaalde
stof (geneesmiddel). 
4. Rotenon als neurotoxine om de ziekte van Parkinson te
induceren in de rat
In de eerste studie beschreven in hoofdstuk 4 werd rotenon via een osmotisch
minipompje subcutaan toegediend aan mannelijke Lewis ratten en het effect op
gewicht en gedrag bepaald terwijl de permeabiliteit van de BHB voor de marker
fluoresceine met behulp van microdialyse werd gemeten. Post-mortem werd de
mate van schade aan de zenuwcellen in het striatum en de substantia nigra
bepaald door een immunokleuring van de hersenen op tyrosine hydroxylase
(TH), als maat voor de dopaminerge cellen. Ook werd de schade aan perifere
organen zoals o.a het hart, de lever, nieren en de maag bepaald. De gegevens van
de rotenon behandelde ratten werden vergeleken met die zonder behandeling
(controle). De resultaten toonden aan dat het subcutaan toegediende rotenon
nauwelijks of geen schade toebracht aan de dopamine-producerende zenuwcellen
in het striatum of substantia nigra, maar wel in grote mate aan de perifere
organen. Tevens bleek er door subcutaan toegediend rotenon verandering in de
BHB permeabiliteit en motoriek te onstaan, echter niet ten gevolge van inductie
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van de ziekte van Parkinson, maar door aspecifieke toxiciteit.  Deze resultaten zijn
later door andere onderzoeksgroepen bevestigd. 
De subcutane toediening van rotenon bleek dus niet geschikt voor het induceren
van de ziekte van Parkinson. Gezocht werd naar een alternatieve manier van
toediening. Er kwamen resulaten beschikbaar van studies waarbij rotenon
intracerebraal in de substantia nigra of de medial forebrain bundle (MFB) werd
geïnjecteerd. Hierbij was een afname te zien in de dopamine concentraties in het
striatum en de substantia nigra. Ook gedrag, specifiek voor de ziekte van
Parkinson werd in deze experimenten waargenomen, maar gegevens van TH
immunokleuring ontbraken. Dit gold als basis voor de tweede set experimenten
beschreven in hoofdstuk 4 waarin rotenon direct en in één hersenhelft plaatselijk
in de MFB van de rat werd toegediend, teneinde perifere toxiciteit te vermijden.
De andere hersenhelft diende als controle. Er werden drie doses rotenon (0.5, 2.0
and 5.0 µg) getest voor het vinden van een 'optimale' dosis voor het induceren van
de ziekte van Parkinson. Het effect van de intracerebrale toediening op gewicht
en perifere orgaan toxicologie werd gemeten voor vergelijking met de resultaten
verkregen na subcutane toediening van rotenon. Verder werd de BHB
permeabiliteit gemeten, alsook het rotatiegedrag van de rat na toediening van
amfetamine. Post-mortem bleek er specifieke schade te zijn ontstaan aan de
dopaminerge zenuwcellen in het striatum en de substantia nigra, zonder enige
aanwijzigingen voor perifere toxicologie. Incidenteel konden in de substantia
nigra alfasynucleïne ophopingen aangetoond worden. Deze bleken echter niet
direct gerelateerd te zijn aan de mate van schade aan de dopaminerge cellen.
Verder nam de schade aan de dopaminerge zenuwcellen toe met de tijd na
toediening van rotenon, met name de 5.0 µg dosis, terwijl de afname in TH-
kleuring bleek een plateau te bereiken op dag 28 na de injectie van rotenon, als
laatste meetpunt. Ook werd een grote toename in het amfetamine geïnduceerd
rotatiegedrag gevonden. Er waren echter geen verschillen gezien in BHB
permeabiliteit. Er werd geconcludeerd dat met het intracerebraal toedienen van
rotenon voorziet in een ratmodel van de ziekte van Parkinson met een progressief
verloop van de ziekte.  
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5. De toepassing van het intracerebrale rotenon rat model: L-DOPA
kinetiek
In hoofdstuk 5 werd in het intracerebrale rattenmodel van de ziekte van
Parkinson (zoals beschreven in hoofdstuk 4) de  kinetiek van L-DOPA in plasma
en in de hersenen onderzocht, alsmede de effecten van L-DOPA op de dopamine
metabolieten 3,4-dihydroxyphenylacetic acid (DOPAC) en homovanillic acid
(HVA) in de extracellulaire vloeistof van de hersenen, op 14 dagen na injectie van
rotenon (5 µg). L-DOPA is de precursor van dopamine dat weer gemetaboliseerd
wordt naar DOPAC of HVA. DOPAC kan buiten de cel worden geconjugeerd
naar een glucuronide of omgezet worden naar HVA. Ongeconjugeerd HVA is
daarmee het belangrijkste eindprodukt van dopamine in de hersenen van
primaten. In de hersenen van ratten is dit DOPAC. In het experiment beschreven
in hoofdstuk 5 werd L-DOPA in 3 verschillende doses intraveneus toegediend (10,
25 of 50 mg/kg). Er werden serieel bloedmonsters afgenomen om de PK van 
L-DOPA in plasma te bepalen. Met behulp van intracerebrale microdialyse
werden L-DOPA, dopamine, DOPAC en HVA in de rotenon-geinjecteerde
hersenhelft en de controle hersenhelft bepaald en vergeleken. Ratten werden op
basis van post mortem TH immunokleuring, ten opzichte van controle
hersenhelft, onderverdeeld in "non-responders" (geen verandering) "responders"
(verlaging, blijkens altijd tot minder dan 40%). Deze gegevens werden allen
gebruikt voor het ontwikkelen van een populatie-PK model met behulp van
NONMEM software. Dit ontwikkelde populatiemodel is de eerste waarbij zowel
de PK van L-DOPA in plasma en in de hersenen in zowel gezonde en zieke
condities, alsook de effecten van L-DOPA op de concentraties van DOPAC en
HVA, worden beschreven. Samengevat geeft het model aan dat de PK van L-
DOPA in plasma en in de hersenen niet wordt beinvloed door de ziekte condities,
terwijl duidelijke verschillen in de eliminatiesnelheidsconstantes van DOPAC en
HVA werden gevonden. Dit kan op basis van kinetische principes worden
teruggevoerd op verlaagde concentraties van dopamine in de zieke hersenhelft. 
6. Discussie en toekomst perspectieven
Het doel van de studies beschreven in dit proefschrift was te onderzoeken of het
gebruik van het neurotoxine rotenon in ratten geschikt was voor het induceren
van een meer chronisch en progessief verloop van de ziekte van Parkinson ten
behoeve van onderzoek naar de relatie tussen farmacokinetiek (PK) en
farmacodynamiek (PD) van geneesmiddelen die worden gebruikt voor de
Nederlandse Samenvatting
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behandeling van de ziekte van Parkinson. Hierbij werd speciaal de nadruk gelegd
op mogelijke wijzigingen in snelheid en mate van een aantal transport-
mechanismen van de bloed-hersenbarrière (BHB) ten gevolge van de
pathologische condities.
De resultaten toonden aan dat het subcutaan toegediende rotenon nauwelijks of
geen schade toebracht aan de dopamine-producerende zenuwcellen, maar wel in
grote mate aan de perifere organen. Tevens bleek er door subcutaan toegediend
rotenon verandering in de BHB permeabiliteit en motoriek te onstaan, echter niet
ten gevolge van inductie van de ziekte van Parkinson, maar door aspecifieke
toxiciteit. Deze resultaten zijn later door andere onderzoeksgroepen bevestigd.
Intracerebraal toegediend rotenon (met name de 5.0 µg-dosis) levert een
progressief rat model voor de ziekte van Parkinson, met een plateau in de afname
in TH kleuring op dag 28 na toediening en met incidenteel alfasynucleïne
ophopingen. Deze alfasynucleïne ophopingen, een kenmerk van de ziekte van
Parkinson bij de mens, waren nog niet eerder aangetoond voor studies met
intercerebraal toegediend rotenon. Verder onderzoek is nodig om te bepalen of er
na een enkele intracerebrale toediening van rotenon, na 28 dagen sprake is van
een verdere progressie van de ziekte, en of er met de tijd meer ophopingen van
alfasynucleïne aanwezig zullen zijn. Daarin zal ook het leeftijdsverschil als
zodanig meegenomen moeten worden. Veel studies hebben namelijk aangetoond
dat er leeftijds-gerelateerde veranderingen zijn in neurochemie en neurobiologie.
Zo zijn er humane- en diergegevens over de veranderingen in de dopaminerge
neurotransmitter pathway. Verder blijkt dat met toenemen van de leeftijd ook de
gevoeligheid van dopamine-producerende zenuwcellen voor rotenon toeneemt
zoals werd aangetoond in de rat.
De experimenten in dit proefschrift voor het bepalen van BHB
transportmechanismen zijn uitgevoerd op 14 dagen na toediening van rotenon en
lieten noch ziekte-geïnduceerde veranderingen in BHB permeabiliteit (passief)
noch verandering in het BHB influx transport van L-DOPA door de LAT1
transporter (actief) zien. Wel werden duidelijke verschillen waargenomen in de
kinetiek van DOPAC en HVA in het striatum van de zieke hersenhelft ten
opzichte van de gezonde. Het is niet uitgesloten dat er op andere locaties in het
brein mogelijk wel veranderingen in BHB functionaliteit ten gevolge van het
ziekteproces optreden. Andere onderzoeksgroepen hebben verhoogde BHB
permeabiliteit aangetoond in het 6-OHDA model voor de ziekte van Parkinson,
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die focaal van aard was. Het is dan ook zinvol om BHB transport op andere
momenten op de tijdschaal van ziekteprogressie het intracerebrale rotenon model
verder te onderzoeken.
Het aantal aanwijzingen in de literatuur dat de functionaliteit van de BHB is
veranderd in de ziekte van Parkinson groeit nog steeds en geeft aan dat
onderzoek naar BHB karateristieken in deze ziekte erg zinvol is. Bromocriptine is
een D2 agonist en geneesmiddel die wordt toegepast bij de behandeling van de
ziekte van Parkinson. Het is ook een substraat voor P-gp en gegeven het feit dat
PET studies hebben aangetoond dat de werking van P-gp in patiënten met
Parkinson verminderd zou zijn, is het erg zinvol om de PK en PD van
bromocriptine in het intracerebrale rotenon rat model te bestuderen. Een tweede
D2 agonist die gebruikt wordt bij de behandeling van de ziekte van Parkinson is
pramipexole. Dit is een geneesmiddel dat zowel via passieve difussie als door een
actieve transporter de BHB passeert. Dit geneesmiddel zou ook een interessante
stof zijn om ziekte-geïnduceerde veranderingen in BHB transport bij de ziekte van
Parkinson te onderzoeken. 
7. Conclusie
Het intracerebraal toedienen van rotenon in de MFB voorziet in een ratmodel van
de ziekte van Parkinson met een progressief verloop. In dit model werd, 14 dagen
na toediening van rotenon, geen veranderingen in BHB permeabiliteit gevonden,
en ook geen veranderingen in het actieve BHB transport van L-DOPA door de
LAT1 transporter. Wel werden duidelijke verschillen waargenomen in de kinetiek
van DOPAC en HVA in het striatum van de zieke hersenhelft ten opzichte van de
gezonde, wat duidt op een vermindering in de dopamine concentratie in de zieke
hersenhelft zoals kenmerkend is voor de ziekte van Parkinson. Er kan worden
geconcludeerd dat het intracerebrale rotenon ratmodel een goed bruikbaar
diermodel is in het systeemfarmacologisch onderzoek naar de factoren die de







Na heel wat jaartjes intensief doorbikkelen is het proefschrift nu toch eindelijk af!
Dit heugelijke feit is mede te danken aan een hele waslijst van personen die in
meer of mindere mate aan de totstandkoming hebben bijgedragen.
Allereerst wil ik de collega's binnen de afdeling Farmacologie noemen. Heel wat
operaties zijn uitgevoerd door Ernst Suidgeest en Susanne Bos. Ook Ineke Postel
heeft bijgesprongen waar dat nodig was. Margret Blom heeft een belangrijke
bijdrage geleverd aan de analyse van plasmamonsters en mij steun verleend bij
het verdrijven van de HPLC geesten. Voor Ernst, Susanne, Ineke en Margret
waren het drukke tijden want ik was zeker niet de enige AIO die bij Farmacologie
onderzoek deed. Ashraf Yassen, Corine Visser, Dorien Groenendaal, Dymphy
Huntjens, Hugo Maas, Lia Liefaard, Marian Geldof en Tamara van Steeg liepen
allemaal ongeveer parallel met mij. Later kwamen daar Gijs Santen en Jasper
Stevens ook nog bij. Kortom een gezellige boel bij elkaar wat zeker heeft
bijgedragen aan de leuke sfeer op de afdeling! Met name zijn de uitjes met de
dames me bijgebleven, o.a. pannenkoeken eten en naar een foute,
nederlandstalige film. Eén keer per jaar zien we elkaar nog, nu met onze kinderen
erbij. Marian, bedankt voor het leren 'hakken' en voor mijn huidige baan. Leuk dat
we elkaar regelmatig op het werk tegenkomen. Lia, bedankt voor de hulp met het
L-dopa model ("ik denk dat NONMEM denkt..."). Corine, bedankt voor de
supersnelle analyse methode voor fluoresceine. Dat heeft heel wat HPLC-
frustratie voorkomen. Tamara bedankt voor je gezelligheid als kamergenoot, de
tijdelijke scoubidou touwtjes-verslaving en de permanente Sims2-verslaving.
Dymphy, jouw malle acties met Knorretje zal ik niet snel vergeten. Ik vind het
leuk dat we weer collega's zijn en hoop in de toekomst nog vaak samen op
skivakantie te gaan. Het afgelopen jaar met jou en Kasper (en Matthijs natuurlijk)
was zeker voor herhaling vatbaar!
Dorien, ik wil je hier natuurlijk even uitlichten. We kennen elkaar al sinds de
eerste dag van BFW en zijn sindsdien beste vriendinnen. Mede dankzij jou ben ik
begonnen als AIO bij Farmacologie. Vanaf het begin zijn we kamergenoten
geweest, eerst met zijn zessen en later met zijn tweeën en ik vond het een zeer
leuke tijd.  Ik ben je zeer erkentelijk voor o.a. je microdialyse-advies en je steun in
barre tijden. Het samen sporten en de gezellige meidenavondjes mis ik wel, nu we
niet meer bij elkaar in de buurt wonen.  
Nawoord
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Miranda, ook wij hebben regelmatig samen gesport. We hebben elkaar leren
kennen toen we allebei nog vrijgezel waren en hebben een leuke vakantie in
Egypte beleefd. Ik denk er nog met veel plezier aan terug. Als mede-import-
brabanders wonen we nu op redelijke afstand van elkaar en gaan we af en toe
naar de sauna. Die ontspanning was (en is) af en toe wel even nodig. 
Dorien en Miranda, ik vind het heel fijn om jullie als paranimfen te hebben. Ik wil
ook jullie (bijna)-echtgenoten Michiel en Cornelis betrekken bij mijn waardering
voor jullie vriendschap.
Eén van de leukste en meest uitdagende taken die ik als AIO had was het
begeleiden van mijn stage-studenten Marolijn Hameetman, Mario Merlini, Terje
Wågan, Sumiati Baatje en Janneke Frederikx. Het heeft me zeer veel voldoening
gegeven om jullie ontwikkeling tijdens de stage te zien. Jullie bijdragen zijn voor
een groot deel terug te vinden in dit proefschrift.
During my studies I was invited to visit and perform some experimental work for
a couple of weeks at the department of drug disposition at Lilly development
Centre in Mont-Saint-Guibert, Belgium and the Neurodegeneration Drug
Hunting Team at Eli Lilly in Windlesham, UK. I have enjoyed my stays at both
Lilly sites and would like to thank Michael O'Neill, Tracey Murray, Mark Ward
and Thomas Lemarchand for their hospitality and kindness. It was a great
learning experience. Michael, Tracey and Mark have also made a significant
contribution to the work presented in this thesis and have stained a numerous
amount of brains. 
Henk-Jan Drenth ben ik zeer erkentelijk voor zijn adviezen en hulp bij het
modeleren. Heel erg fijn dat je tijd voor mij vrij kon maken in je drukke schema
en me uit wilde nodigen bij jou thuis om te overleggen. Dat scheelde me weer een
aantal lange files richting Leiden. 
Mijn huidige collega's van de afdeling Klinische Farmacologie van J&J PRD in
Beerse hebben sinds ik daar werk altijd interesse getoond en steeds gevraagd hoe
het ermee stond. Dit heeft me zeker gestimuleerd en ik ben daar zeer dankbaar
voor.
Ik wil graag mijn vrienden en familie bedanken voor de interesse en steun tijdens
mijn promotietijd. Met name wil ik Gitty, Mijke en Jacq noemen. Ik hoop nog vaak
met zijn vieren te mogen afspreken. Het is me zeer veel waard. 
Lemke, als mijn huisgenoot heb jij mijn promotietijd intensief meebeleefd.
Bedankt dat je er altijd voor me was wanneer het zo nodig was. 
Oma Grimbergen, schoonouders Rob en Christa, Jan, Gideon, Mariska, Paul en
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Oinny ben ik zeer erkentelijk voor hun warme belangstelling en stimulans tijdens
de afgelopen jaren. Ik heb nu gelukkig weer wat meer tijd voor familie.
Zonder de nimmer aflatende steun van mijn ouders was ik niet geworden wie ik
nu ben. Mijn ouders hebben mij naast een nuchtere en positieve kijk op het leven,
ook doorzettingsvermogen en zelfvertrouwen meegegeven. Dat zijn
eigenschappen waar ik nu de vruchten van pluk. Ik ben jullie hiervoor eeuwig
dankbaar.
Als laatste wil ik de meest belangrijke persoon in mijn leven nog noemen, mijn
lieve man Matthijs. Je hebt me niet alleen praktisch gesteund door de layout van
dit proefschrift op je te nemen maar je hebt me ook steeds weer gestimuleerd om
door te gaan als ik het even niet meer zag zitten. Ik ben blij dat ik nu weer meer
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